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1  Introduction 
1.1  Lipoxygenases 
Lipoxygenases (LOs) are dioxygenases that catalyze the conversion of polyunsaturated fatty 
acids, containing a series of cis double bonds, to hydroperoxy fatty acids. They are widely 
expressed in plants, fungi and animals but not in bacteria or yeast. The different enzymes are 
named after the position of the carbon C, which is oxygenated. When necessary the 
stereoconfiguration is specified, e.g. 12R-LO or 12S-LO. Because of the existence of several 
12-lipoxygenases in mammalians, with distinct sequences, catalytic activities and function, 
these are named after the prototypical tissues of their occurrence, e.g. platelet, leukocyte, or 
epidermal 12-LO (Yamamoto et al. 1997).  
Up to date five human LOs are described, the reticulocyte-type 15(S)-LO (Sigal et al. 1988), 
platelet-type 12(S)-LO (Izumi et al. 1990), epidermis-type 12(R)-LO (Boeglin et al. 1998), 
epidermis-type 15(S)-LO (Brash et al. 1997) and 5(S)-LO (Matsumoto et al. 1988). The first 
mammalian LO was identified in 1974 in human platelets by Hamberg et. al. (Hamberg and 
Samuelsson 1974), the 5-LO by Borgeat in 1976 (Borgeat et al. 1976).  
 
1.2  5-Lipoxygenase 
5-Lipoxygenase (5-LO) catalyzes the conversion of arachidonic acid (AA) to 
5(S)-hydroperoxy-6-trans-8,11,14-cis-eicosatetraenoic acid (5-HPETE) and the further 
reaction to the unstable epoxide leukotriene A4 (LTA4), (5(S)-6-oxido-7,9,11-trans-
14-cis-eicosatetraenoic acid (Samuelsson 1983; Ford-Hutchinson 1994; Ford-Hutchinson et 
al. 1994), corresponding to the two distinct enzyme activites – the oxygenase activity and the 
LTA4 synthase activity respectively.  
 
1.2.1  Structure and enzyme activity 
So far no crystal structure of 5-LO exists. Based on the rabbit reticulocyte 15-LO crystal 
structure, as well as in conjunction with primary and secondary structure information, a model 
of 5-LO was predicted. As for all lipoxygenases, the protein consists of a C-terminal catalytic 
domain (aa 115 to 673) and an N-terminal β-barrel domain (aa 1 to 114) (Hammarberg et al. 
2000; Hemak et al. 2002). The C-terminal domain is composed of α-helices and contains the 
catalytic iron, in its inactive ferrous form (Fe
2+). The iron acts as electron acceptor and donor 
during the lipoxygenase reaction mechanism. For catalysis, it needs to be restored into the  Introduction  
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active ferric form by redox reaction with fatty acid hydroperoxides, i.e. 5-HPETE, 12-HPETE 
and 13-hydroperoxyoctadecaenoic acid (Rouzer and Samuelsson 1986; Riendeau et al. 1989; 
Hammarberg et al. 2001). Selenium-dependent glutathione peroxidases (GPx) reduce the 
cellular peroxide content and are therefore potent endogenous suppressors of 5-LO activity 
(Weitzel and Wendel 1993; Werz and Steinhilber 1996). 
The residues essential for iron binding (Zhang et al. 1993; Hammarberg et al. 1995), substrate 
positioning (Gillmor et al. 1997) and nuclear import (Jones et al. 2002; Jones et al. 2003) have 
been identified in the catalytic domain. The catalytic domain represents ∼80% of the 
lipoxygenase mass, but it is the β-barrel region that regulates the action of this domain. 
The β-barrel domain is composed of two 4-stranded antiparallel beta sheets and is one the 
defining members of the PLAT (Polycystin-1, Lipoxygenase, α-Toxin) domain family 
(Bateman and Sandford 1999). This domain shares some common features with C2 domains, 
e.g. calcium-dependent phospholipid binding, but may best be considered a distinct subset of 
the C2 family (Chahinian et al. 2000). Binding of Ca
2+ to the 5-LO β-barrel domain leads to 
phosphatidylcholine (PC) selectivity (Kulkarni et al. 2002) and is essential for nuclear 
membrane translocation (Chen and Funk 2001) and membrane association (due to the higher 
PC content).  
Moreover 5-LO contains a functional Src homology (SH)3-binding motif, a short, proline-rich 
region, suggesting a role for 5-LO in tyrosine kinase signalling (Lepley and Fitzpatrick 1994).  
By means of ATP-affinity column chromatography binding of ATP to the residues of Trp75 
and Trp201 has been shown (Wiseman 1989; Denis et al. 1991). Among LOs only 5-LO can 
bind ATP (Zhang et al. 2000) and is activated by nucleotides (Ochi et al. 1983; Falgueyret et 
al. 1995; Noguchi et al. 1996). 
 
1.2.2  Subcellular distribution of 5-LO 
Depending on the cell type 5-LO in resting cells either localizes in the cytosol or within the 
soluble compartment of the nucleus. Upon cell activation the cytosolic enzyme translocates to 
the ER or the outer nuclear membrane, whereas the nuclear enzyme translocates to the inner 
nuclear envelope (Luo et al. 2003). Import of 5-LO depends on both, the nuclear localization 
sequences and the phosphorylation site Ser271 (Luo et al. 2003), association with the nuclear 
membrane depends on calcium binding to the C2-like domain. 
  Introduction  
3 
1.2.3  Phosphorylation of 5-LO 
Protein phosphorylation is a regulatory mechanism for transduction of extracellular signals 
leading to the activation and redistribution of numerous cellular enzymes and transcription 
factors. Recently p38 MAPK-regulated MKs and ERK1/2 have been reported to 
phosphorylate and activate 5-LO (Werz et al. 2000; Werz et al. 2002). Cell stress induced 
Ca
2+-independent phosphorylation of 5-LO at Ser271 by MK-2/3. ERK2 can phosphorylate 
5-LO at Ser663 in vitro, also independently of calcium. Both pathways have been shown to be 
involved in the translocation of 5-LO to the nucleus (Lepley and Fitzpatrick 1996; Boden et 
al. 2000).  
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Fig. 1 Activation of 5-lipoxygenase 
The figure above is summarizing the activation of 5-LO in a cellular context. Cell stimuli lead 
to elevated intracellular calcium levels and/or stress induced activation of protein kinases. 
Upon calcium binding and/or phosphorylation, as well as conversion of the inactive ferrous 
iron to its active ferric form by fatty acid hydroperoxides, the activated enzyme translocates to 
the nuclear membrane. There 5-LO colocalizes with cPLA2, FLAP and LTC4S. AA is 
released from phospholipids by cPLA2 and presented by FLAP to 5-LO, initiating the 
leukotriene biosynthesis.  
  Introduction  
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1.2.4  Cytosolic phospholiase A2 (cPLA2) 
A critical parameter for 5-LO activity is the availability of substrate. Phospholipase A2 
comprises a superfamily of enzymes that hydrolyse the ester bond of phospholipids at the sn-2 
position (Dennis 1997). Stimulated peritoneal macrophages from cPLA2 knockout mice do 
not produce prostaglandin E2 or leukotriene B4 and C4 (Bonventre et al. 1997; Uozumi et al. 
1997). In leukocytes cytosolic phospholipase A2, a protein of 85 kDa, provides AA for 
leukotriene synthesis, depending on the cell type and stimulus (Leslie 1997). Similar to 5-LO, 
Ca
2+ and/or phosphorylation lead to an activation of cPLA2 (Clark et al. 1991; Lin et al. 1993; 
Kramer et al. 1996). 
 
1.2.5  5-Lipoxygenase-activating protein (FLAP)  
FLAP is an 18 kDa membrane-bound protein that was discovered as a target of the LT 
biosynthesis inhibitor MK886 (Miller et al. 1990). MK886 inhibited LT synthesis in intact 
leukocytes, but not in cell homogenates, thus not inhibiting 5-LO enzyme activity itself. In 
cotransfection studies with 5-LO and FLAP, LT synthesis was dependent on the presence of 
FLAP, 5-LO expression alone did not result in any LT production (Dixon et al. 1990). Also 
FLAP-deficient macrophages from knock-out mice failed to produce any leukotrienes (Byrum 
et al. 1997). It was shown, that FLAP can bind AA and serves as an AA transfer protein 
facilitating the substrate presentation for 5-LO (Mancini et al. 1993). A model was proposed 
where AA-binding FLAP forms a heterodimer with 5-LO (Abramovitz et al. 1993), but direct 
binding to 5-LO was never shown. 
 
1.3  Mediators of the 5-LO pathway 
1.3.1  Leukotrienes 
As lipid mediators, leukotrienes are involved in the signaling between cells, in host defence 
and inflammatory response. 5-LO is basically expressed in inflammatory cells such as 
polymorphonuclear cells, leukocytes, eosinophils, monocytes/macrophages, mast cells, 
dendritic cells, and B-lymphocytes. When overproduced, they also contribute to a variety of 
diseases, including asthma (Drazen et al. 1994), fibrosis (Wilborn et al. 1996), atherosclerosis 
(Spanbroek et al. 2003), allergic hyper-responsiveness (Rachelefsky 1997), ulcerative colitis 
(Rachelefsky 1997), psoriasis (Iversen et al. 1997), rheumatoid arthritis (Griffiths et al. 1995) 
and ischemic reperfusion injury (Noiri et al. 2000).   Introduction  
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After the conversion of AA to 5-HPETE and LTA4, LTA4, depending on the cell type, is 
either converted to LTB4 by LTA4 hydrolase (LTA4H) or conjugated with glutathione by 
LTC4 synthase, forming the cysteinyl leukotriene (CysLT) LTC4. The successive amino 
acid cleavage of LTC4 results in LTD4 and LTE4. Together these cysLTs have been called 
“the slow reacting substance of anaphylaxis” (SRS-A), because of their spasmogenic effects .  
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Fig. 2 The 5-LO pathway 
They lead to smooth muscle contraction (Allen et al. 1992), thus promoting 
bronchoconstriction (Samuelsson 1983). Additionally they promote plasma exudation 
(Dahlen et al. 1981), stimulate mucus secretion (Marom et al. 1982), and recruit eosinophils 
(Michelassi et al. 1982). They are also reported to reduce myocardial contractibility and 
coronoary blood flow (Underwood et al. 1996).  
LTB4 is a potent neutrophil chemoattractant and stimulator of leukocyte adhesion to 
endothelial cells (Samuelsson 1983; Peters-Golden and Brock 2001). In contrast to 5-LO, 
which is only expressed in haematopoetic cells, LTA4H is ubiquitously expressed. During  Introduction  
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inflammation, LTB4 is produced in all kinds of tissue, due to transcellular metabolism of 
LTA4 (Sala et al. 1996).  
Leukotrienes act at distinct GPCRs. The cysteinyl leukotriene receptors  CysLT1 and 
CysLT2 mediate the actions of LTC4 and LTD4. CysLT1 is found on airway smooth muscle 
cells (Lynch et al. 1999) and vascular endothelial cells (Gronert et al. 2001), promoting 
bronchoconstriction. The CysLT2 receptor is detected within pulmonary veins, in spleen, 
Purkinje fibers of the heart and discrete regions of adrenal gland (Heise et al. 2000).  
LTB4 binds with high affinity to the B-LT1 receptor mainly expressed on leukocytes, with 
low affinity to the B-LT2 receptor, which is expressed in wide variety of tissues (Tager and 
Luster 2003). The B-LT1 receptor is reponsible for the chemotactic response to LTB4, 
whereas the function of B-LT2 is still unknown (Yokomizo et al. 2000; Yokomizo et al. 
2001). 
 
1.3.2  Lipoxins 
Besides in the generation of proinflammatory mediators 5-LO is also involved in the 
production of endogenous anti-inflammatory lipid mediators, the lipoxin family (Serhan et al. 
1999). Lipoxins (lipoxygenase interaction products, LXs) are conjugated trihydroxytetraene-
containing eicosanoids (Serhan 2002). They are generated by transcellular biosynthesis during 
cell-cell interaction. In an interplay between activated leukocytes and platelets, leukocyte 
5-LO catalyzes the formation of LTA4 and platelet 12-LO transforms LTA4 to LXA4 and 
LXB4 (Serhan and Sheppard 1990; Serhan and Romano 1995). In epithelial and endothelial 
cells 15-LO generates 15S-HETE and in neutrophils 5-LO proceeds the production to LXs 
(Serhan et al. 1984). The third route in LX production is triggered after aspirin treatment 
(Claria and Serhan 1995). Acetylation of COX2 switches the catalytic activity of COX2 to a 
15-LO, resulting in 15R-HETE, which is further transformed by 5-LO to 15-epi-LXA4 and 
15-epi-LXB4, also called aspirin triggered lipoxins (ATL). The beneficial actions of NSAIDs, 
including prevention of myocardial infarction may be in part due to the biosynthesis of ATL. 
Anti-inflammatory actions of LXs and ATL include inhibition of leukocyte-mediated injury, 
stimulation of macrophages, clearance of apoptotic neutrophils, repression of 
proinflammatory cytokine production, inhibition of cell proliferation and migration and others 
(for detailed review see (McMahon and Godson 2004)). Bioactions of lipoxins are mediated 
either via the GPCR ALXR (Badr et al. 1989; Brady et al. 1990; Maddox et al. 1997; Gronert 
et al. 1998; Bandeira-Melo et al. 2000; McMahon et al. 2000; Gronert et al. 2001; McMahon  Introduction  
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et al. 2002), with LXA4 as specific ligand, or by competitve antagonism at the Cyc-LT1 
receptor (Badr et al. 1989; McMahon et al. 2000; Gronert et al. 2001). 
 
1.4  Pharmacological inhibitors 
Pharmacological intervention on behalf of LTs is possible during either their formation or via 
receptor antagonism to prevent their biological action.  
Although glucocorticoids have been demonstrated to inhibit phospholipases and eicosanoid 
formation in many experimental setups, high dose glucocorticoid therapy did not significantly 
suppress LT formation (Claesson and Dahlen 1999). 
 
1.4.1  5-LO inhibitors 
5-LO inhibitors can be classified into three different groups, namely redox-active 
compounds, iron-ligand inhibitors with weak redox-active properties and non-redox-type 
inhibitors.  
Redox-active inhibitors reduce the catalytic active ferric iron to the inactive ferrous form 
(Fe
2+). This group of inhibitors consists of phenols like nordihydroguaretic acid, caffeic acid, 
or flavonoids and coumarins. Many of these inhibitors show severe side effects like 
methemoglobin formation or are rapidly metabolized (McMillan and Walker 1992; Ford-
Hutchinson et al. 1994). 
The second group of inhibitors, the iron chelating substances, consist of hydroxamic acid 
and N-hydroxy-urea derivatives. Because of the rapid metabolization of the hydroxamate 
group to an inactive carboxylate group, the development of inhibitors was focused on 
N-hydroxy-urea derivates like A-64077 (zileuton). Up to date, zileuton (Zyflo) is the only 
5-LO inhibitor on the market for the treatment of asthma. Only low benefits for the treatment 
of other diseases were observed with zileuton.  
The poor selectivity and low bioavailability of both groups of inhibitors lead to the 
development of non-redox-type inhibitors. These substances contain methoxyalkylthiazol or 
methoxytetrahydropyran structures, competing with AA for the binding site of 5-LO. 
ZD  2138 and ZM  230487 are selective and orally active 5-LO inhibitors (Crawley et al. 
1992). In human leukocytes and whole blood assays LT-biosynthesis was inhibited with IC50 
values of about 20-50  nM (Smith et al. 1995). However, they failed in clinical trials of 
chronic inflammatory diseases (Kusner et al. 1994). Both compounds were less active in cell 
homogenates than in intact cells (Smith et al. 1995). Addition of glutathione or DTT reversed  Introduction  
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the loss of inhibitory activity, indicating that the peroxide level defines the potency of both 
inhibitors (Werz et al. 1998). In other studies with ZM  230487 or the related Merck 
compound L-739,010, the potency of the inhibitors depended on the stimulus and 
phosphorylation status of 5-LO (Fischer et al. 2003).  
These data suggest, that the inhibitory potency of 5-LO inhibitors depends on the 
physiological conditions 5-LO is activated under. In vitro and ex vivo testing of potential 
5-LO inhibitors should therefore include the different activation pathways of 5-LO, by using 
physiological stimuli and priming agents, leading to either calcium or phosphorylation 
dependent 5-LO activation, as well as consider different peroxide levels within the cells. 
 
1.4.2  Dual COX and 5-LO inhibitors 
Both enzymes are co-expressed and up-regulated during inflammation and their products, i.e. 
PGE2 and LTB4 are elevated in inflammed tissues. So there is much reason to develop 
substances inhibiting both enzymes at the same time. Several substances are currently 
evaluated in experimental setups (RWJ-63556, ER-34122) or clinical trials for different 
inflammatory diseases, including S-2474 against arthritis. One very promising substance is 
Licofelone (ML-3000), a pyrrolizidine derivate and an arachidonic acid mimetic, which has 
already been tested in phase III trials with patients with osteoarthritis. No severe side effects, 
like hepatotoxicity were found and the compound demonstrated an excellent gastrointestinal 
profile, better than NSAIDs and equivalent to selective COX2-inhibitors (Wallace et al. 1994; 
Celotti and Durand 2003; Charlier and Michaux 2003).  
Hyperforin is the major lipophilic constiuent of Hypericum perforatum (St. John´s worth). 
The acylphloroglucinol derivate has recently been demonstrated to inhibit 5-LO in human 
PMNL (IC50 1-2 µM in intact cells) and COX1 in platelets (IC50 0.3 or 3 µM dependent on 
the stimulus). Experiments with crude enzymes revealed that hyperforin acts as an direct 
inhibitor of 5-LO in an uncompetitive manner. The mechanism how 5-LO is inhibited is still 
unkonwn. COX2, 12-LO and 15-LO product formation was not influenced  
 
1.4.3  FLAP inhibitors 
So far MK886, BAY-X-1005, MK-0591 have been designed and their properties and potency 
has been characterized (reviewed in (Devillier et al. 1999; Drazen et al. 1999; Werz 2002)). 
Both MK886 and BAY-X-1005 show impaired efficacy in whool blood assays, probably do 
the presence of exogenous AA (Rouzer et al. 1988; Steinhilber et al. 1993; Werz et al. 1997) 
and the high affinity of the inhibitors to plasma proteins (Charleson et al. 1994).   Introduction  
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1.4.4  Receptor antagonists 
The orally active Cyc-LT1 antagonists montelukast (Singulair), pranlukast (Ultair) and 
zafirlukast (Accolate) have been tested in several clinical trials and shown to reduce asthma 
exacerbations and to improve pulmonary function (Nathan and Kemp 2001). 
The LTB4 receptor antagonists CP-105.696 and SC-41930 reduce arthritis index and ankle 
bone destruction in IL-1 accelerated collagen-induced arthrithis and reduce artherosclerosis 
lesion progression in mice (Kuwabara et al. 2000; Aiello et al. 2002). 
 
1.5  5-LO gene and protein expression 
The cDNA for the human 5-lipoxygenase was first cloned by Dixon et al. from DMSO 
differentiated HL-60 cells. The cDNA contained a 673 amino acid long open reading frame, 
encoding for a 78 kDa large protein (Dixon et al. 1988). In parallel, Matsumoto could clone 
the cDNA for 5-LO from a lung and placenta λgt11 cDNA library. He described a 34 bp 
5´-noncoding region and a 442 bp 3´ noncoding region (Matsumoto et al. 1988). 
The human 5-LO gene was first characterized by Funk and Hoshiko (Funk et al. 1989). The 
5-LO gene is unique compared to the other human lipoxygenase genes in several respects, 
including its distinct separate chromosomal location, on chromosome 10q11.2 instead of 
17p13, and its size, 4-7 times larger than the other LO genes (Funk et al. 2002). It consists of 
14 exons separated by 13 introns, spanning around 82  kb. The extent of the 5´- and 
3´-regulatory sequences is unknown.  
 
1.5.1  The 5-LO promoter 
The 5´-flanking region has first been characterized by C. Funk and S. Hoshiko (Funk et al. 
1989; Hoshiko et al. 1990). By nuclease S1 protection and primer extension experiments a 
major TIS in leukocytes at –65 in relation to ATG was identified. Other minor transcription 
initiation sites at –107, -97, -89, -62, -66, -35, and –34 were described by the one or other 
method. Alternative transcripts, 3.1, 4.8, 6.4, and 8.6 kb in length instead of 2.7 kb, have been 
reported in brain tumor cells and DMSO differentiated HL-60 cells (Boado et al. 1992), 
possibly due to aberrant splicing events.  
The sequence comprising about 5900 bp upstream of the ATG displayed promoter activity in 
reporter gene assays in both 5-LO negative and 5-LO positive cell lines, HeLa and HL-60 
cells respectively. The promoter study performed by Hoshiko in HeLa cells also revealed two 
positive regulatory sequences (-5900 to –3700 and –931 to –854) and two negative regulatory  Introduction  
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elements (-3499 to –1557 and –727 to –292). The stretch of –179 to –56 was essential for full 
promoter activity and contained the sequence involved in induction by PMA treatment, as 
well as the 5-tandem consensus Sp1/Egr1 binding site (Sp1 binding to –GGGCGG- and Egr1 
to -GCGGGGGCG-). In gel shifts, Sp1 binding from HeLa cell extracts was shown to the 
DNA stretch –212 to –88 (containing 6 Sp1 consensus binding sites / GC boxes). Different 
bands appeared with a nuclear HL-60 extract. Later it was shown that PMA treatment of 
HUVEC cells triggers Egr1 expression and binding to the 5-tandem Sp1/Egr1 binding site (In 
et al. 1997). 
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-724 CTCCCGCGAC CACTGGCCAT CTCTGGGCCT GGGCGCGGTC TCGGCGCCCG CCTGCCCCCG 
-664 CCAGGAGCCG CAGGTCCAGC CAGTGAAGAA GCCCGCGCTG AAGGAGCCTC TGTGCTCCAG 
-604 AATCCATCCT CAGTATCAGC GCTGGGGTGG CCTCCTCCAG GAAGCCCTTC TGATTCTCTC 
-544 ATGGGTCGCT CTTCCTCTGC AGACTCCCGG AGCACCCCTG CTCCAAGTAC CGCAAGTGGC 
-484 ACTGAGAACT TGGGGAGAGC AGAGGCTGTG CCTAGATTTG TAGGGAGTCC CCGCAGCTCC 
-424 ACCCCAGGGC CTACAGGAGC CTGGCCTTGG CGAAGCCGAG GCAGGCAGGC AGGGCAAAGG
-364 GTGGAAGCAA TTCAGGAGAG AACGAGTGAA CGAATGGATG AGGGGTGGCA GCCGAGGTTG 
-304 CCCCAGTCCC CTGGCTGCAG GAACAGACAC CTCGCTGAGG AGAGACCCAG GAGCGAGGCC 
-244 CCTGCCCCGC CCGAGGCGAG GTCCCGCCCA GTCGGCGCCG CGTGAAGAGT GGGAGAGAAG 
-184 TACTGCGGGG GCGGGGGCGG GGGCGGGGGC GGGGGCGGGG GCAGCCGGGA GCCTGGAGCC 
-124 AGACCGGGGC GGGGCCGGGA CCGGGGCCAG GGACCAGTGG TGGGAGGAGG CTGCGGCGCT
- 64 AGATGCGGAC ACCTGGACCG CCGCGCCGAG GCTCCCGGCG CTCGCTGCTC CCGCGGCCCG 
- 4 CGCCATG
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Fig. 3 Overview of the proximal 5-LO promoter. Indicated are the different transcription factor 
binding sites, CpG islands and reporter gene constructs (N10, N11, N12, N13). The functional 
significance of the putative binding sites for AP2 (Imagawa et al. 1987), CTCF (Filippova et al. 2002), 
NFκB (Lenardo and Baltimore 1989), RBCE (Kim et al. 1992; Chen et al. 1994), ets/PU.1 (Pahl et al. 
1993; Suzuki et al. 1998; Voo and Skalnik 1999) and the TGFβ response element (Marigo et al. 1994) 
is still unknown. Egr1/Sp1 binding has been shown to GC1, GC2, the 5-tandem binding site, GC4 and 
GC5 (In et al. 1997; Silverman et al. 1998; Dishart et al. 2005). The more distal binding sites are of 
interest for future studies. VDR binding was investigated in (Sorg et al. 2006).   Introduction  
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The analyzed promoter sequence contains several consensus binding sites for different 
transcription factors, including Sp1, Sp3, Egr1, Egr2, glucocorticoid receptors, NFκB, GATA, 
myb and AP family members (Hoshiko et al. 1990). For not all of them functionality could be 
shown so far. The c-myb protein downregulates 5-LO gene expression and inhibits 
macrophage differentiation (Habenicht et al. 1989). In vitro binding to the consensus motif in 
the 5-LO promoter at –1840 to –1852 (TAACGG) was demonstrated (Ponton et al. 1997). 
Sequence analysis with databases like TRANSFAC suggest the presence of several putative 
response elements for nuclear receptors, including the VDR, retinoid Z receptor α (RZRα) as 
well as the retinoic acid related orphan receptor α(RORα), TGFβ, Smads, ATF-2, hFast-1, 
Oct-1 and p53. Binding of RORα1 and RZRα to a putative RZR RE at -1521 to -1510 has 
been demonstrated before. The promoter activity as well as 5-LO protein expression in 
B-lymphocytes was repressed by melatonin, a ligand of RZRα (Steinhilber et al. 1995).  
The promoter lacks TATA and CCAAT boxes as well as an Inr element. Conspicuous is the 
high GC content and the high number of Sp1 consensus binding sites (GGGCGG). These are 
characteristics of so-called housekeeping genes, being constitutively expressed with little 
regulation. However 5-LO gene expression takes place primarily in cells of myeloid lineage 
and is regulated on multiple levels.  
 
1.5.2  Mouse 5-LO promoter 
In 2001 the mouse 5-lipoxygenase promoter was cloned and characterized (Silverman et al. 
2002). Though different alignment programs failed to align or to find similarities of the 
human and mouse promoter, a few features of both promoters were almost identical. The first 
292 bp were identified as the core promoter region containing a major TIS at -52 bp and three 
minor start sites, comparable to the human promoter. Both promoters lack the TATA motif, 
TFIIB recognition elements or initiator sequences and are GC-rich. They both contain 
Sp1/Sp3, PU.1/SPI-1 and GATA binding sites in similar promoter regions. The only Sp1 
binding site located at -184 bp to –189 bp seems orthologous to the 5-tandem GC box of the 
human promoter (-145 to-179) and mutation of the site also results in a loss of promoter 
activity in reporter gene assay. Sp1 binding, but not Egr1 binding to this site was shown in gel 
shifts. The lack of any Egr1 binding site and functional response of the promoter to Egr1 
over-expression suggest that Sp1 and Sp3 are more important in the regulation of 
5-lipoxygenase than Egr1. GATA binding was not detectable in gel shifts, but PU.1 binding.  
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1.5.3  Naturally occuring mutations of the 5-LO promoter 
Naturally occurring mutations of the 5-tandem Sp1 binding sites within the human 5-LO 
promoter were identified, such as the deletion of one or two, or addition of one GC box within 
the 5-fold Sp1/Egr1 binding motif (In et al. 1997). In reporter gene assays with transfected 
HeLa cells the promoter activity was reduced independently of the genotype of the mutation, 
whereas in SL2 cells, which do not express Sp1 and Egr1, the activity was proportional to the 
number of Sp1/Egr1 sites (In et al. 1997; Silverman et al. 1998). In gel shift assays, binding of 
both transcription factors to the mutated sites was slightly reduced. Binding of recombinant 
Sp1 and Egr1 to the 5-fold GC  box (-179 to -147 in relation to ATG, also GC0) was 
demonstrated by DNase I footprints (Silverman et al. 1998). In the same experiments Sp1 
could also protect DNA in the regions covering -117 to -109 (GC4) and -224 to -218 bp 
(GC2) covering two other Sp1 consensus binding sites. No other Egr1 binding sites were 
detected in these experiments. In SL2 cells, the over-expression of Sp1 and Egr1 in 
combination with a reporter gene construct covering the 5-LO promoter from -229 bp up to 
the translational start site resulted in an about 30-fold induction of CAT-activity. Expression 
of Egr1 or Sp1 alone lead to a significantly lower promoter induction. Interestingly, Sp1 over-
expression showed a stronger effect on the promoter construct lacking the 5-fold GC box, 
only covering –129 bp up to the translational start site. The role of the GC-boxes was studied 
more closely in 5-LO positive MM6 cells (Dishart et al. 2005). A new Sp1 binding site close 
to the major transcription site was identified. Incubation with the antibiotic mithramycin, 
which binds to GC-rich sequences, reduced 5-LO expression and activity during 
differentiation in MM6 cells with 1,25(OH)2D3 and TGFβ. In DNase  I footprinting Sp1 
binding to the GC-rich parts of the promoter was demonstrated. The levels of Sp1, Sp3 and 
Egr1 did not change upon 1,25(OH)2D3/TGFβ differentiation of the cells, whereas 5-LO 
expression is only found after the differentiation. Together the data suggest that at the early 
time points Sp1/Sp3 and Egr1 are involved in the basal transcriptional regulation of 5-LO, but 
that differentiation with 1,25(OH)2D3/TGFβ also involves another type of mechanism.  
In a study with asthma patients treated with the selective 5-LO inhibitor ABT-761, a zileuton 
derivative, patients carrying a mutation of the 5-tandem site in the 5-LO promoter in both 
alleles showed no response to the anti-asthma treatment. The patients with a 5-fold GC box on 
both alleles showed an average change in the forced expiratory volume in the first second 
(FEV1) of +18.8±3.6%, patients (n=64) carrying both, one mutation and one wild-type site, 
improved by 23.3±6.0% (n=40). The 10 patients with the mutations on both alleles, did not 
benefit from the treatment, indicated by the average change of FEV1 of –1.2±2.9% (Drazen et  Introduction  
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al. 1999). In further studies with Japanese asthma patients the 5-LO promoter mutations did 
not associate either aspirin-induced (AIA) or aspirin-tolerant asthma (ATA) patient groups 
nor with urinary LTE4 and LTC4S activity (Kawagishi et al. 2002). In a Caucasian population 
the 5-LO Sp1 polymorphism was not associated with asthma or asthma-related phenotypes 
either (Sayers et al. 2003). In a recent study performed within Korean population, no 
significant differences in the frequencies of the 5-LO promoter polymorphisms were observed 
between ASA and AIA patients or the control group, but there was a strong association with 
airway hyperresponsiveness in aspirin-intolerant-asthma patients (Kim et al. 2005).  
Recently clinical, population genetic, cell biological and mouse studies indicate the 
participitation of the 5-LO pathway in atherogenesis. In one study 5-LO promoter genotypes 
were linked to atherosclerosis (Dwyer et al. 2004). In the Los Angeles atherosclerosis study 
the Sp1 promoter polymorphism (for carriers of two variant alleles) was associated with 
increased intima-media thickness. Increased intake of n-3 fatty acids could blunt the effect 
whereas increased intake of AA enhanced the atherogenic effect.  
The results from the Los Angeles atherosclerosis study rather suggest an upregulation of 
5-LO expression, than a down-regulation found in the reporter gene assays due to the 
promoter polymorphism. Possible explanations for this paradoxia are versatile. Transfection 
of HeLa and SL2 cells, both not expressing endogenous 5-LO, may not reflect the in vivo 
process of inflammation. Also other enzymes involved in inflammtory processes like 15-LO 
or COX2, may profit from reduced 5-LO expression and have impact in the promotion of 
atherosclerosis (Cyrus et al. 2001; Burleigh et al. 2002). Also the functionality of 5-LO 
promoter genotypes with respect to LT formation in relevant leukocyte populations has not 
been clearly demonstrated in asthma or cardiovascular disease patients.  
Though the 5 LO promoter contains several features of so-called housekeeping genes 5-LO 
expression occurs in a cell specific manner. The expression is mainly limited to cells derived 
from the bone marrow like granulocytes, monocytes, macrophages, mast cells, and B-
lymphocytes (Steinhilber 1999). Besides relevant levels of 5-LO were detected in epidermal 
Langerhans cells (tissue-like macrophages) (Spanbroek et al. 1998) and cultured human skin 
keratinocytes (Janssen-Timmen et al. 1995). 
 
1.5.4  Stimuli of protein expression 
Different inflammatory stimuli increase 5-LO mRNA levels in leukocytes, e.g. transforming 
growth factor-β (TGFβ), granulocyte-monocyte colony-stimulating factor (GM-CSF), 
interleukin-3, oxidized low-densitiy lipoprotein (LDL), phorbol esters (PMA),  Introduction  
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2+-ionophores (Silverman and Drazen 1999). In HL-60 cells, a promyeloic leukemia cell 
line, differentiation with DMSO, retinoic acid (RA) or 1,25(OH)2D3 increased 5-LO levels 
(Bennett et al. 1993; Piechele et al. 1993). In the myeloid cell lines, MM6 and HL-60, 
differentiation of the cells with calcitriol (1,25(OH)2D3) and TGFβ results in a strong 
upregulation of 5-LO gene expression, on the level of mRNA, protein and enzyme activity 
(Brungs et al. 1994; 1995). In HL-60 cells treatment with 24  nM of 1,25(OH)2D3 alone 
increased 5-LO mRNA levels 4-fold, the protein amount about 14-fold, protein activity in 
intact cells 14-fold and in cell homogenates 38-fold. TGFβ (1 ng/ml) alone showed no effect, 
but lead to a further increase of 5-LO mRNA, protein and protein activity when combined 
with 1,25(OH)2D3. 
In MM6 cells, differentiated with 50 nM 1,25(OH)2D3 and 1 ng/ml TGFβ, the effects were 
even stronger. The 5-LO mRNA levels increased up to 64-fold, the protein amount 128-fold 
and the protein activity more than 500-fold. Furthermore, it was demonstrated that the 
upregulation of 5-LO mRNA levels depended on protein synthesis, e.g. of transcription 
factors. More detailed investigations on the mRNA level in MM6 cells demonstrated that 
mRNA half-life was not affected by the combined treatment of 1,25(OH)2D3 and TGFβ. By 
exon/intron specific RT-PCR it was further specified that TGFβ and 1,25(OH)2D3 increase 
primary transcripts about 5-fold and mature 5-LO mRNA 42-fold. Cycloheximid inhibited the 
effect of both agents on the maturation, but only the action of TGFβ on the primary 
transcripts, indicating a 1,25(OH)2D3 impact on the transcriptional level in the presence of 
TGFβ induced proteins. On the post-transcriptional level, including transcript elongation 
and/or maturation cycloheximid blocked the effects of both agents (Harle et al. 1998).  
Most known biological effects of 1,25(OH)2D3 are “genomic” effects, mediated through 
specific and high affinity binding to the nuclear 1,25(OH)2D3 receptor (VDR). Transcriptional 
transactivation involves the binding of the receptor to a response element in proximity to the 
TIS of a responding gene. The 5-LO promoter contains putative VDREs in the proximal 
promoter area, located at -374 to –327 in relation to ATG (Carlberg 1995). Binding of the 
receptor heterodimer VDR-RXR was demonstrated in vitro, in gel shifts and 
DNase  I  footprints, as well as in vivo, in chromatin immunoprecipitation assays (ChIP). 
However the elements showed no functionality in response to 1,25(OH)2D3 in transient 
reporter gene studies (Uhl et al. 2002; Sorg et al. 2006), nor did a stably transfected 5-LO 
promoter reporter gene construct comprising –6,144 to +150 in relation to ATG. This finding 
is supporting the results of nuclear run-off assays, in which 1,25(OH)2D3 did not increase 
transcriptional activity (Harle et al. 1999). In a new approach the complete 5-LO gene was  Introduction  
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screened for putative VDRE. Gel shift studies, reporter gene assays and chromatin 
immunoprecipitation revelead the existance of at least 3 functional VDRE, one located further 
upstream in the promoter (at -2,250), one in intron 4 (at about +42,000) and one in intron 5 (at 
about +50,600), which may cooperatively mediate the 1,25(OH)2D3 response (Seuter et al. 
2006).  
 
1.5.5  DNA methylation and 5-LO 
Expression of several genes with GC-rich promoters has been shown to be regulated by DNA 
methylation. Depending on the GC content GC-rich sequences can be characterized as 
so-called CpG islands, which are of a minimum length of 200  bp, have a minimum 
GC-content of 50% and an observed/expected ratio of GCs greater than 0.6. In housekeeping 
genes CpG islands stay unmethylated, whereas in tissue-specific genes DNA methylation of 
the promoter leads to transcriptional silencing of the gene (Singal and Ginder 1999).  
The 5-LO gene contains at least two CpG islands, covering the proximal promoter area 
-1052  bp to –633  bp and –266  bp to +278  bp in relation to the ATG of 5-LO (compare 
www.ebi.ac.uk/emboss/cpgplot/index.html,  examining the sequence of the homo sapiens 
chromosome 10 contig NT_033985 position 3267921 to 3274901).  
Recently it was demonstrated that 5-LO gene expression in the 5-LO negative cell lines U937 
and HL-60TB is linked to DNA methylation of the proximal 5-LO promoter (Uhl et al. 2002). 
Treatment of the cells with the demethylating agent 5-aza-2`-deoxycytidine upregulated the 
5-LO mRNA levels in both cell lines. Subsequent treatment with 1,25(OH)2D3 and TGFβ also 
resulted in prominent 5-LO protein activity. Bisulfite sequencing of genomic DNA of both 
cell lines revealed that the 5-LO core promoter is heavily methylated in both cell lines, but not 
in the  5-LO positive cell line HL-60. AdC partly demethylated the core promoter, thus the 
degree of methylation/demethylation correlates to the level of gene expression. In reporter 
gene assays in vitro methylation of the most active deletion variant N10, comprising the 5-LO 
core promoter region, almost abolished the promoter activity. These data suggest that DNA 
methylation is at least one possible mechanism in the cell specific expression of 5-LO. 
Apparently the regulation by DNA methylation is unrelated to the regulation by TGFβ and 
1,25(OH)2D3 (Uhl et al. 2002). 
Transcriptional repression by DNA methylation can occur on several levels: i) the binding of 
methylation sensitive transcription factors may be inhibited (Watt and Molloy 1988) and/or ii) 
so-called methyl-CpG DNA binding proteins (Boyes and Bird 1991; Hendrich and Bird 1998) 
recognize the methylated sequences and recruit other corepressors like histone and chromatin  Introduction  
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modifying enzymes, e.g. histone deacetylases (HDAC), transforming the transcriptional 
active chromatin into condensed chromatin (Jones et al. 1998; Nan et al. 1998; Ng et al. 1999; 
Wade et al. 1999; Zhang et al. 1999; Sarraf and Stancheva 2004). Several histone deacetylase 
inhibitors have been identified or synthesized. Trichostatin A (TsA), a hydroxamic acid 
isolated from streptomyces hygroscopius, inhibits HDACs in nanomolar concentrations and 
evokes histone acetylation. After TsA treatment, an upregulation of 5-LO mRNA levels in 
MM6 cells occurs and 5-LO promoter activity is induced in reporter gene assays after 
transient transfection (Klan et al. 2003).  
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Fig. 4 Transcriptional repression by DNA methylation and histone deacetylation. 
TsA also induced promoter activity of in vitro methylated 5-LO reporter gene constructs, but 
it never reached the activity level of the unmethylated and TsA treated constructs, indicating 
that the methylation dominates over the TsA-sensitive histone deacetylation. Other reports 
describe an upregulation of neuronal 5-LO mRNA levels after treatment with valproic acid, 
an other HDAC inhibitor with potential demethylating properties (Phiel et al. 2001; Manev 
and Uz 2002; Detich et al. 2003; Yildirim et al. 2003; Zhang et al. 2004). Together these data 
suggest a link between DNA methylation and chromatin remodeling in the regulation of 5-LO 
transcription (see Fig. 4). 
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1.6  Epigenetic Mechanisms 
In addition to the information encoded by the DNA sequence, so-called epigenetic 
information can be stably inherited through many cell generations.  
 
1.6.1  DNA methylation 
One type of epigenetic information comprises the addition of a methyl group to the 
5´-position of the cytosine ring of CpG dinucleotides, the DNA methylation (Naveh-Many 
and Cedar 1982). About 70% of the CpG dinucleotides are methylated in vertebrates (Ehrlich 
et al. 1982). CpG islands, clusters of CpG dinucleotides, are mainly unmethylated and are 
found in approx. 60% of human promoters (Antequera and Bird 1993). Methylation of 
promoter CpG islands leads to subsequent inactivation of the associated genes. 
 
1.6.1.1  DNA Methyltransferases 
The methylation patterns are introduced by a set of DNA methyltransferases, which are 
subdivided into the two groups of de novo methyltransferases (DNMT3a, DNMT3b) 
introducing cytosine methylation in formerly unmethylated CpGs and the maintenance 
methyltransferase DNMT1, copying an existing methylation pattern during the DNA 
replication from one strand to the other. So far three potential mechanism of triggering de 
novo methylation are understood. First, DNMTs might recognize DNA or chromatin itself, by 
a PWWP domain, a DNA sequence-independent interacting domain (Qiu et al. 2002; 
Shirohzu et al. 2002; Ge et al. 2004). Secondly site-specific transcriptional repressors can 
recruit DNMTs. The myc protein has been described to recruit DNMT3a to the p21 promoter, 
leading to subsequent de novo methylation of the promoter (Fuks et al. 2001; Brenner et al. 
2005). Recently RNAi gene silencing has been linked to DNA methylation. After the 
introduction of double-stranded RNA corresponding to the promoter sequence of a gene, the 
target gene was silenced accompanied by de novo methylation of the promoter sequence 
(Kawasaki and Taira 2004; Morris et al. 2004). Also recruitment of DNMT3A and DNMT3B 
via interaction with the histone methyltransferase SETDB1 (Li et al. 2006) or SUV39H1 
(Fuks et al. 2003) have been described. 
 
1.6.1.2  Methyl-CpG-binding proteins 
The fact that methylated CpG islands are associated with transcriptional repression lead to the  
search for factors being able to read and interpret this epigenetic information. The first protein  Introduction  
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discovered, to bind to methylated DNA and mediating transcriptional repression was MeCP1, 
methyl-CpG-binding protein 1 (Meehan et al. 1989). Later it was shown, that MeCP1 is a 
protein complex, consisting of MBD2 as the methyl-CpG-binding protein and the chromatin 
remodeling complex Mi2-NuRD, which contains the histone deacetylases HDAC1 and 2, 
MBD3, the chromatin remodeller Mi-2, other proteins like RbAp46/48, metastasis-associated 
protein 2, Sin3a and SAP30 and SAP18 (Feng and Zhang 2001). 
MBD (methyl-CpG-binding domain) proteins selectively bind to methylated DNA and recruit 
chromatin remodelling and transcriptional repressor complexes, thereby establishing a 
repressive chromatin state. So far, there are at least five mammalian MBD proteins: MeCP2, 
MBD1, MBD2, and MBD3 for transcriptional repression and MBD4 (also known as MED1) 
primarily for mismatch repair as a thymine glycosylase (Hendrich and Bird 1998). Sequence 
similarity between MBD proteins is limited to the methyl-binding domain itself. Only MBD2 
and MBD3 display about 70 % sequence similarity. This diversity predicts different functions, 
but biochemical analysis could also show different behavior in the ability to bind to 
methylated DNA. Only MeCP2, MBD1, MBD2 and MBD4 bind to methylated DNA. They 
all drive transcriptional repression due to the presence of a transcriptional repressor domain 
(TRD) interacting with other proteins. 
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Fig. 5 Methyl-binding domain proteins. MBD1, 2, 3, 4 and MeCP2 bind to methylated DNA via the 
well conserved methyl-binding-domain (MBD). MBD1 additionally binds to unmethylated DNA via 
one of its zinc-binding domains (CxxC). The transcriptional repression domain (TRD) mediates 
transcriptional silencing due to interaction with corepressors. Because of amino acid changes MBD3 
is unable to bind to methylated DNA and requires interaction with MBD2. MBD4 contains an 
additional glycosylase domain for DNA repair. Kaiso lacks a MBD and binds to unmethylated and 
methylated DNA via the zinc-finger domain (ZF). The POZ domain mediates transcriptional 
repression (Klose and Bird 2006).  Introduction  
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MeCP2 is able to bind to a single symmetrically methylated CpG (Lewis et al. 1992) and 
mutations within the MBD of MeCP2 causes the Rett syndrome (Amir et al. 1999). Recently 
Klose et. al. found a [A/T]≥4 run close to methylated CpG essential for high-affinity binding at 
selected sites and at known MeCP2 target regions in the Bdnf and Dlx6 genes (Klose et al. 
2005). MeCP2 interacts with the transcriptional repressor complex Sin3 containing histone 
deacetylases (HDAC1/2) (Jones et al. 1998; Nan et al. 1998). The recruitment of HDACs by 
MBD proteins links another epigenetic mechanism of transcriptional regulation with DNA 
methylation, namely histone modifications (for details see below). MeCP2 has also been 
shown to associate with histone methyltransferase activity, targeting Lys9 on the histone H3 
tail, a modification linked to repressed chromatin (Lachner and Jenuwein 2002; Fuks et al. 
2003) and Dnmt1 (Kimura and Shiota 2003). In another study MeCP2 alone was capable of 
mediating chromatin compaction independent of HDAC activity and DNA methylation 
(Georgel et al. 2003). Horike et. al. described a silent-chromatin loop formation by MeCP2, 
which was absent in MeCP2-null mice (Horike et al. 2005) and independent of DNA 
methylation. Also binding of MeCP2 to unmethylated DNA in vitro has been described (von 
Kries et al. 1991; Buhrmester et al. 1995), as well as its capability of repressing transcription 
from both methylated and unmethylated DNA (Meehan et al. 1992; Nan et al. 1997; Kaludov 
and Wolffe 2000). Another group discovered a regulating function of MeCP2 in RNA 
splicing (Young et al. 2005), further suggesting functions besides its role in DNA 
methylation. 
MBD1 binds to symmetrically methylated DNA and is able to repress promoter activity even 
from a 3-kb distance (Ng et al. 2000; Fujita et al. 2003). In addition to the TRD, MBD1 
contains up to three zinc-coordinating CXXC domains, depending on the splice variants. The 
third CXXC domain has been shown to bind specifically to non-methylated CpGs and to 
induce DNA methylation independent transcriptional silencing (Fujita et al. 2000; Jorgensen 
et al. 2004). 
Unlike MBD2 and MeCP2, MBD1 does not appear to interact with HDAC1 or HDAC2, since 
coimmunoprecipitation failed to show an interaction (Ng et al. 2000). Still TsA relieved the 
transcriptional repression. Later it was shown, that MBD1 can interact with the histone 
methyltransferase Suv39h1 and the methyl-lysine binding protein HP1 via its methyl-binding 
domain and that Suv39h1 associates with HDAC1/2 (Fujita et al. 2003).  
In a yeast two-hybrid screening interaction between the transcriptional domain of MBD1 and 
MCAF (MBD1-containing chromatin-associated factor), a cofactor of the histone 
methyltransferase SETDB1, was found (Fujita et al. 2003). MCAF itself contains two  Introduction  
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conserved domains, one binding MBD1, another binding the transcription factor Sp1. The 
factor seems to facilitate Sp1-mediated transcription, but when binding to MBD1, it blocks 
transcription. MBD1 recruits SETDB1 through interaction with MCAF1 to form 
HP1-condensed heterochromatin (Ichimura et al. 2005). 
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Fig. 6 Different splicing variants of MBD1. 
During S phase of the cell cycle MBD1 has been demonstrated to form a complex with the 
histone H3 K9 methylase, SETDB1, and the chromatin assembly factor CAFp150 , which in 
turn is associating with the DNA replication machinery (Sarraf and Stancheva 2004). This 
may indicate a special role for MBD1 during the cell cycle in linking DNA methylation to 
histone modification and establishment of gene silencing.  
MBD3 is the smallest member of the MBD family. Mammalian MBD3 has lost its ability to 
bind to methylated DNA, due to a mutation of two highly conserved amino acids (Wade et al. 
1999). It is a component of the Mi2-NuRD complex (Zhang et al. 1999), being part of the 
MeCP1 complex, mentioned above. MBD3 is crucial to normal mammalian development, as 
MBD3 knockout mice fail to develop to term (Hendrich et al. 2001).  
MBD4 can bind to methylated DNA, but first seemed not involved in transcriptional   
repression. Instead it plays a role in the repair of methyl-CpG/TpG mismatches that can arise 
from sponaneous deamination (Hendrich et al. 1999). New reports now suggest repressional 
activity for MBD4 at methylated genes (Kondo et al. 2005). Association of MBD4 with the 
methylated promoters of p16
INK4α and hMLH1 was demonstrated in vivo. The repression is 
HDAC dependent as HDAC1 and Sin3a directly bind to MBD4. 
Splice variants exist for all MBDs. MBD2 occurs as a full-length protein (MBD2a) and as a 
N-terminal truncation, that arises through the usage of an alternative translational start codon. 
The N-terminus of MBD2, lacking in MBD3, contains a repeat of glycine and arginine 
residues, whose function is still unknown. The truncated MBD2b was reported to demethylate  Introduction  
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DNA, but these experiments could not be confirmed by others. MBD2 together with MBD3 is 
part of the MeCP1 complex (Bhattacharya SK 1999). 
MBD2 knock out mice displayed a weak phenotype. Overall methylation and imprinting was 
not effected in these mice. In reporter gene assays with mouse fibroblast cell lines, established 
from wildtype and Mbd2-null mice, significantly repression of the was found with the Mbd2 
deficient cell lines, indicating a possible redundancy between MBD proteins in the repression 
of methylated promoters (Hendrich et al. 2001).  
So far no sequence specificity was found for MBD2, giving raise to the question weather 
MBD2 randomly binds to methylated DNA. Sekimata et al could identify a protein binding to 
MBD2, MIZF (MBD2-interacting zinc finger) with a specific 5 bp recognition sequence for 
DNA, CGGAC (Sekimata et al. 2001; Sekimata and Homma 2004). The same motif was 
found in the retinoblastoma gene, in vivo binding of MIZF to the Rb promoter was shown and 
reduction of the Rb promoter activity in reporter gene assays after cotransfection of MIZF 
(Sekimata and Homma 2004). From their experiments it seems reasonable, that MIZF recruits 
MBD2 and potentially the HDAC containing Mi2-NuRD repressor complex to specific target 
sequences and allows sequence-dependent repression.  
Kaiso is a structurally unrelated protein, which has also been shown to bind methylated 
CGCGs (CGCGCCCAAACG) through its three Kruppel-like C2H2 zinc fingers 
(Prokhortchouk et al. 2001). The protein belongs to the family of POZ (pox virus and zinc 
finger) zinc finger transcription factors, which are implicated in development and cancer 
(reviewed in (Bardwell and Treisman 1994; Albagli et al. 1995)). Most family members act as 
transcriptional repressors and are characterized by an N-terminal protein-protein interaction 
POZ domain and a C-terminal DNA-binding domain, that consists of one or more 
Kruppel-like C2H2 zinc fingers. Kaiso was originally discovered in a yeast two-hybrid 
system with p120 as a bait (Daniel and Reynolds 1999). Up to date Kaiso is the only POZ-ZF 
protein that has been shown to have dual specificity DNA binding. It can bind methylated 
CpG dinucleotides or a specific non-methylated DNA sequence (TCCTGCNA), with the 
minimal core sequence CTGCNA, via its zinc fingers 2 and 3 (Daniel et al. 2002). P120 
intervenes with the sequence specific DNA binding ability of Kaiso (Daniel et al. 2002), . 
Recently Kaiso was identified as a component of the human NCoR corepressor complex 
(Yoon et al. 2003) and repression by Kaiso requires the active NCoR complex, which 
associates HDAC3. Furthermore Kaiso can interact with the human enhancer blocker CTCF, 
decreasing the insulator activity of CTCF (Defossez et al. 2005).   Introduction  
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Besides Kaiso, two so far uncharacterized proteins, ZBTB4 and ZBTB38, containing the 
Kaiso-like zinc fingers, are reported to bind methylated DNA in vitro and in vivo. When 
transfected in mouse cells, they colocalize with foci of heavily methylated satellite DNA. In 
chromatin immunoprecipitation both of these proteins bind to the methylated allele of 
H19/Igf2. They repress the transcription of methylated templates in transfection assays. 
Unlike Kaiso, they can bind single methylated CpGs and are tissue-specifically expressed, 
suggesting non-overlapping functions (Filion et al. 2006). 
 
1.6.2  Histone Code 
The fundamental subunit of chromatin is a nucleosome, consisting of 146  bp of DNA 
wrapped around an octamer of histone proteins, an (H3/H4)2 tetramer assembled with two 
H2A/H2B dimers (Luger 2003). Consecutive nucleosomes form the “beads-on-a-string” fiber 
of 11 nm, which can further be compacted into a 30 nm fiber through the incorporation of 
linker histone H1 protein (Wong et al. 1998; Wolffe 1999).  
The flexible higher order structures of chromatin link to the activation state of chromatin. 
Gene expression occurs at transcriptionally active and structurally accessible states, whereas 
repression is linked to a structurally condensed state. During the last years more and more 
different post-translational modifications of the N-termini of histone proteins have been 
described, among them acetylation of lysines (Grunstein 1997; Sterner and Berger 2000), 
methylation of lysine and arginine residues (Zhang and Reinberg 2001), phosphorylation of 
serine and threonine (Nowak and Corces 2004), ubiquitinylation (Davie and Murphy 1990) 
and sumoylation (Nathan et al. 2003) of lysines, ADP ribosylation (Adamietz and Rudolph 
1984), glycosylation (Liebich et al. 1993), biotinylation (Hymes et al. 1995) and 
carbonylation (Wondrak et al. 2000). These modifications can be highly reversible, such as 
lysine acetylation and serine and threonine phosphorylation, or more stable, such as lysine 
and arginine methylation (Zhang and Reinberg 2001; Lachner and Jenuwein 2002). The 
figure below depicts the variety of modifications of the different residues and the proteins 
with histone-methyltransferase activity (for review see (Margueron et al. 2005)).  
Experimental data suggest, that specific post-translational patterns influence the establishment 
of subsequent modifications on the same histone tail or on neighbouring tails, resulting in 
either an accessible or rather condensed chromatin structure. Following this “histone code” 
hypothesis (Strahl and Allis 2000; Fischle et al. 2003), specific modifications and their 
implications for gene expression have been described. Elevated H3/H4 acetylation levels of a 
gene display transcriptional activity. Furthermore the methylation of H3K4 facilitates  Introduction  
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subsequent acetylation of H3 and H4 by the acetyltransferase p300. Methylation of H3K9 on 
the other hand inhibits acetylation (Wang et al. 2001) and leads to heterochromatin formation 
(Rea et al. 2000; Bannister et al. 2001; Lachner et al. 2001; Nakayama et al. 2001).  
 
 
Fig. 7 Post-translational modifications of histones. Depicted are phosphorylation, methylation, 
acetylation and ubiquitination sites, as well as the so far known histone methyltransferases and their 
target sites [figure from (Margueron et al. 2005)].  
One explanation of how histone acetylation implicates active gene expression is the change of 
histone charges resulting in different interaction with DNA and other nucleosomes, e.g.  Introduction  
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elevated acetylation leads to repulsion of DNA entailing a more open chromatin structure. 
Another model involves the interpretation of the histone modifications by effector molecules. 
The chromodomain protein HP1 (heterochromatin protein) exclusively binds to 
di/trimethylated H3K9 (Jacobs and Khorasanizadeh 2002), polycomb protein specifically to 
trimethylated H3K27 (Cao et al. 2002; Wang et al. 2004). These molecules further spread the 
histone code. HP1, e.g. can recruit SUV39H1, a histone methyltransferase, presumably 
methylating the H3 tail of the adjacent nucleosomes, mediating further HP1 binding and 
spreading of heterochromatin (Aagaard et al. 1999). Acetylated histones recruit positive 
effectors of transcription, e.g. components of the basal transcription machinery, and other 
bromodomain proteins (recognizing acetylated lysine) such as p300 and CBP, two histone 
acetyltransferases, possibly further spreading the acetylation marks and open chromatin 
structure (Ragvin et al. 2004).  
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Fig. 8 Example of interaction of different histone modifications. Methylation of lysine 4 of histone 
protein H3 facilitates subsequent acetylation of K9, 14, 17 and 23 of H3, as well as acetylation of K5, 
8, 12 and 16 of H4. Acetylation leads to transcriptional activation. Methylation of H3K9 on the other 
hand inhibits subsequent methylation and triggers transcriptional repression [figure from (Margueron 
et al. 2005)]. 
It still remains unclear how cells remember their during the differentiation chosen gene 
expression profile and carry on the information to the next generation after cell division. The 
DNA methylation pattern is inherited by the action of DNMT1, recognizing a hemimethylated 
site and methylating the opposite DNA strand in an appropriate manner. During replication  Introduction  
25 
DNA and histones have to be physically separated during the polymerase transit. How the 
distribution of old and new histones to both daughter strands works remains unclear.  
 
1.6.3  The “H3 barcode hypothesis” 
Besides the genetic and histone code, Hake and Allis have recently proposed the “H3 barcode 
hypothesis” (Hake and Allis 2006). The hypothesis is based on the existence of three different  
H3 variants and their possible different biological function. In a study with different 
mammalian cell lines Hake and colleagues could demonstrate that the expression levels of the 
H3 variants varied, independent of cell growth, cell cycle state or chromosomal diploidy, 
suggesting different incorporation patterns during tissue specific differentiation of the cells. 
Additionally the variants carried different post-translational modifications, which are either 
known as marks for transcriptionally active chromatin as for H3.3 (acetlyation of K9, K14, 
K27, K18, K23 and dimethylation of K36, K72) or for silenced chromatin as for H3.2 
(di/trimethylation of K27). H3.1 was enriched in both active and repressive marks (K9 
methylation and K14 acetylation) (Hake et al. 2006).  
 
Fig. 9 Graphical combination of the genetic code, the H3 barcode and the histone code. 
Incorporation of the three different H3 variants separates the genome into active chromatin (H3.3) or 
constitutively repressed (H3.2) or facultative repressed chromatin (H3.1). [figure from (Hake and 
Allis 2006)].  Introduction  
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The hypothesis suggests that the incorporation of different H3 variants separates the 
chromatin into active chromatin (incorporation of H3.3), constitutive (H3.2) or facultative 
(H3.1) heterochromatin domains and serves as a long-term epigenetic memory, whereas post-
translational modifications of histone proteins rather influence the regulation of short-term 
gene expression.  
 
1.7  Histone acetylation/deacetylation 
As described above histone proteins are subject to dynamic and reversible lysine acetylation. 
Histone acetyltransferases (HAT) catalyze the transfer of acetyl groups from acetyl-CoA to 
lysine residues of target proteins, while histone deacetylases (HDACs) remove them. 
Acetylation of histone proteins leads to an open and transcriptionally active chromatin 
structure, whereas deacetylation ends in chromatin compaction. Important positions for 
acetylation are lysine 9 (K9) and K14, K17, K23 of H3, and K5, K8, K12, and K16 of H4.  
The acetylation status of proteins can change protein function, e.g. the DNA binding, 
transcriptional activation and repressor activity of transcription factors, stability, nuclear 
localization and coactivator interaction.  
Beside histone proteins, other targets of HATs/HDACs have been identified, suggesting 
substrate and/or function specificity, e.g. transcription factors such as p53 (Juan et al. 2000), 
GATA-1 EKLF, HNF-4, Sp1 and Sp3 (Doetzlhofer et al. 1999; Ammanamanchi et al. 2003), 
structural proteins such as tubulin (Hubbert et al. 2002; Matsuyama et al. 2002; Palazzo et al. 
2003), Hsp70 (Johnson et al. 2002) and Hsp90 (Kovacs et al. 2005; Murphy et al. 2005). Also 
the basal transcription machinery itself is targeted, deacetylation of TAFI68 by mSir2a 
inhibits PolI-dependent transcription (Muth et al. 2001). 
 
1.7.1  HDACs 
According to their yeast counterparts, HDACs are divided into three different classes. Class I 
contains HDACs 1, 2, 3 and 8, homologs of the yeast protein RPD3. HDAC1, 2, 3 are 
ubiquitously expressed, HDAC8 in cells showing smooth muscle differentiation. Class II 
comprises HDACs 4, 5, 6, 7, 9, 10, which are more similar to the yeast histone deacetylase 
(Hda1), and are tissue-specific expressed. Class  I and class  II HDACs contain the same 
conserved catalytic domain, but class II HDACs are two to three times larger in size than 
class I HDACs. HDAC11 has too low sequence similarity to be classified in either of both 
classes (Gao et al. 2002).   Introduction  
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Class III members are homologs of the silent information regulator (Sir2), also called 
sirtuins. The sirtuin deacetylases contain a 275 aa catalytic domain, which is unrelated to that 
of HDACs. They require NAD as substrate and operate via a different mechanism (Frye 
2000). Nicotinamide is liberated from NAD
+ while the acetyl group of the substrate is 
transferred to cleaved NAD
+, generating O-acetyl-ADP-ribose. This class of deacetylases 
appears not to have histones as their primary substrates and is not inhibited by compounds 
that inhibit class I and class II HDACs. Nicotinamide inhibits SIR2 action (Bitterman et al. 
2002; Anderson et al. 2003). 
HDAC1  binds  HDAC2 to form the catalytic core of the Sin3, Mi-2/NuRD/NRD and 
CoREST complexes, whereas HDAC3 is the catalytic subunit of the NCoR and SMRT 
complexes (Cress and Seto 2000; Ng and Bird 2000; Grozinger and Schreiber 2002). These 
protein complexes are necessary for HDAC activity (Carmen et al. 1999; Hu et al. 2000; Lee 
et al. 2004) and serve as corepressors for several transcriptional repressors (Zhang et al. 1999; 
Guenther et al. 2001). The class II HDACs 4, 5, and 7 cannot be activated by the 
SMRT/NCoR complex. They are not active deacetylases, but recruit the 
HDAC3/SMRT/NCoR complex (Fischle et al. 2001; Fischle et al. 2002).  
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Fig. 10 Structures of class I/II histonedeacetylases. Class I HDACs are homologs of the yeast protein 
Rpd3, class II HDACs are homologs of the Hda1 yeast protein. They all share the same catalytic 
domain, but class II HDACs are 2-3 times larger than class I HDACs. 
HDAC1, 2, and 3 also cooperate with other chromatin and transcriptional regulators, such as 
ATP-dependent chromatin remodelers (Underhill et al. 2000; Battaglioli et al. 2002;  Introduction  
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Kuzmichev et al. 2002), DNA methyltransferases (Fuks et al. 2001; Burgers et al. 2002; Di 
Croce et al. 2002), histone methyltransferases (van der Vlag and Otte 1999; Czermin et al. 
2001; Tie et al. 2001) and topoisomerase II (Tsai et al. 2000; Lupo et al. 2001). Except for 
HDAC3 (Fischle et al. 2001; Fischle et al. 2002; Yang et al. 2002), which contains both a 
nuclear import and export signal, all class I HDACs are exclusively located in the nucleus 
(Johnstone 2002). There is evidence that HDAC8 has also other targets than histone proteins. 
The potent HDAC8 inhibitor SB-379278-A did not affect the cellular histone acetylation 
status or SV40 promoter activity in the human colon carcinoma cell line SW620 (Hu et al. 
2003). Waltregny et al. could also show an exclusive expression of HDAC8 in vivo in cells 
showing smooth muscle differentiation (Waltregny et al. 2004).  
HDAC8 associates with the smooth muscle isoform of α-actin in primary human smooth 
muscle cells. So far it is unclear, if HDAC8 deacetylase activity is involved in the regulation 
of any smooth muscle cytoskeletal protein. Repression of HDAC8 expression however, alters 
the morphology of the cells and reduces smooth muscle contractility (Waltregny et al. 2005). 
Class II HDACs are structurally and functionally different from class I HDACs. They are 
divided into two subclasses, IIa (HDAC4, 5, 7, 9) and IIb (HDAC6, 10, 11). IIa members 
interact with transcription factors including MEF2, BCL6, PLZF and TR2, with 
transcriptional corepressors such as NCoR, SMRT, CtBP and with HP1, the 
methyl-lysine-binding protein (Bertos et al. 2001; Fischle et al. 2001; Khochbin et al. 2001; 
Lemercier et al. 2002; McKinsey et al. 2002). Class II HDACs can shuttle between the 
nucleus and the cytosol.  
Class  IIa HDACs are regarded as regulators of myogenesis. They bind to the myocyte 
enhancer factor-2 (MEF2) and repress specific gene expression in a calcium-dependent 
manner (Miska et al. 1999; Sparrow et al. 1999; Lu et al. 2000; Youn et al. 2000). Similar to 
class IIa HDACs the transcription factor MEF2 is highly expressed in muscle cells, neural 
cells and T-cells. Upon recruitment of class IIa HDACs, gene expression is repressed. 
Activation by calcium signaling leads to a release of HDACs and activation of transcription 
(Grozinger and Schreiber 2000; McKinsey et al. 2000; Youn et al. 2000). There is also 
evidence for an essential role of MEF2 and HDACs in the development and function of the 
heart. The deletion of HDAC9 in mice leads to cardiac hypertrophy (Zhang et al. 2002). A 
mutation of MEF2A has been linked to human coronary artery disease and myocardial 
infarction (Wang et al. 2003). Class IIa HDAC5 and HDAC9 act as repressors of stress-
induced heart hypertrophy (Chang et al. 2004).   Introduction  
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HDAC6 is mainly localized in the cytosol. It contains two catalytic domains, both having 
histone deacetylase activity, but only the C-terminal domain is possessing tubulin deacetylase 
activity (Grozinger et al. 1999; Haggarty et al. 2003). HDAC6 functions as a α-tubulin 
deacetylase and regulates microtubule-dependent cell motility (Hubbert et al. 2002; Haggarty 
et al. 2003; Zhang et al. 2003). Additionally it was discovered, that HDAC6 associates with 
ubiquitinated proteins (Seigneurin-Berny et al. 2001; Hook et al. 2002) and is a component of 
the aggresome, where misfolded proteins are processed (Kawaguchi et al. 2003). The tubulin 
activity of HDAC6 is also involved in the regulation of HIV-1 infection and Env-mediated 
syncytia formation. Overexpression of HDAC6 prevented HIV-1 envelope-dependent cell 
fusion and infection without affecting the expression and distribution of HIV-1 receptors 
(Valenzuela-Fernandez et al. 2005). Another protein regulated by reversible acetylation is 
chaperone Hsp90. Inactivation of HDAC6 results in Hsp90 hyperacetylation and the loss of 
chaperone activity. Hsp90 is necessary for the glucocorticoid receptor (GR) to assume its 
competent ligand binding conformation, and hyperacetylation of the heat shock protein results 
in GR defective ligand binding, nuclear translocation and transcriptional activation (Bali et al. 
2005; Kovacs et al. 2005; Murphy et al. 2005).  
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Fig. 11 Various interactions of HDAC proteins. HDAC1 and HDAC2 are found in the three main 
corepressor complexes Sin3, NuRD and CoREST, which are recruited to promoters or DNA binding 
domains of proteins. HDAC1/2 also interact directly with DNA binding proteins such as YY1, Sp1 and 
others. HDAC3, 4, 5, and 7 associate with the NCo/SMRT corepressor complexes, with the MEF2  Introduction  
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transcription factor family, or the methyl-CpG-binding protein Kaiso. The corepressor complexes 
Sin3, CoRest and Mi-2/NuRD can further associate with MBD proteins, linking again, histone 
deacetylation to DNA methylation. 
 
1.7.2  Regulation of HDAC activity 
As reviewed in (Burke and Baniahmad 2000; Wade 2001; Grozinger and Schreiber 2002; 
Sengupta and Seto 2004) the activity of HDACs is regulated via several mechanism. I) 
HDACs may interact directly with DNA binding proteins, which specifically bind to a certain 
promoter, e.g. HDAC1 and HDAC2 bind to YY1 (Yang et al. 1996), Rb-binding protein 
(Brehm et al. 1998), and Sp1/Sp3 (Sun et al. 2002). II) Instead of direct interaction with a 
DNA binding protein, HDACs can be recruited via protein-protein interaction to a DNA 
binding protein, e.g. as a component of the Sin3a complex. This complex is recruited by 
nuclear hormone receptors in the absence of ligand. Upon ligand binding, the receptor 
changes its confirmation and HATs instead of HDACs form a complex with the receptor. III) 
HDACs and HATs can compete for the same binding site of a transcription factor, e.g. 
HDAC4 and p300 compete for the same binding site of MEF2 (Youn et al. 2000). IV) 
Class  II HDACs 4, 5, and 7 shuttle between the nucleus and the cytosol (Grozinger and 
Schreiber 2000). After phosphorylation at their N-termini, binding to MEF is interrupted and 
the proteins are exported from the nucleus (McKinsey et al. 2000). Subsequent recruitment of 
HATs by MEF leads to acetylation and activation of MEF target promoters (Lu et al. 2000). 
V) Post-translational modifications such as phosphorylation, also play an important role in the 
regulation of HDAC activity. Phosphorylation of HDAC1 by CK2 promotes enzymatic 
activity as well as the ability to form protein complexes (Pflum et al. 2001). Also HDAC2 is 
phosphorylated by CK2 (Tsai and Seto 2002), which is necessary for enzymatic activity and 
complex formation with Sin3a and Mi-2/NuRD/NRD. Furthermore Sun et al. could show the 
association of Sp1/Sp3 with HDAC1 and phosphorylated HDAC2 in human breast cancer 
cells (Sun et al. 2002). Phosphorylation of HDAC8 by PKA reduces deacetylase activity and 
leads to H3/H4 hyperacetylation (Lee et al. 2004). Phosphorylation of HDAC4 and 5 inhibits 
binding to MEF and results in nuclear export (Lu et al. 2000; Lu et al. 2000). Besides 
phosphorylation, sumoylation of HDAC1 (Colombo 2002; David et al. 2002), HDAC4, and 
HDAC6 has been described (Kirsh et al. 2002). Though the studies for HDAC1 are 
contradictory, sumoylation of HDAC4 enhances deacetylase activity. Sumoylation of MEF2 
itself inhibits transcription. HDAC4 potentiates sumoylation of MEF2, but is inhibited by the 
sumoylation of HDAC4 itself (Gregoire and Yang 2005).  Introduction  
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1.7.3  Histone deacetylase inhibitors 
The active site of HDACs I and II consist of a gently curved tubular pocket with a wider 
bottom (Finnin et al. 1999). The removal of the acetyl group occurs via a charge-relay system, 
which requires a Zn
2+ ion, bound to the bottom of the pocket, coordinated by several histidine 
and aspartate residues. HDACi function by replacing the Zn
2+ ion. TsA is the most potent 
reversible HDACi currently known, with an IC50 in the nanomolar range, perfectly fitting to 
the active site (Yoshida et al. 1990). The hydroamic acid functional group coordinates the 
zinc ion, the aliphatic chain makes van der Waals contacts within the channel leading to the 
catalytic center and the cap group has contact with residues on the rim of the pocket. Class I 
and class II HDACs are all equally sensitive to TsA (Marks et al. 2001; Marmorstein 2001; 
Yoshida et al. 2001; Johnstone 2002). Similar to the natural compound TsA, other 
hydroxamic acid group containing substances have been developed, e.g. suberoyl anilide 
hydroxamic acid (SAHA), NVP-LAQ824, PDX101, oxamflatin and others.  
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Fig. 12 Trichostatin  A - Structural properties of HDAC inhibitors. Trichostatin A contains a 
hydroxamic acid functional group, which chelates the zinc ion in the catalytic center of the histone 
deacetylases. The aliphatic chain mimics the lysine and has an optimal length of 5-6 carbons. The cap 
group interacts with the residues surrounding the rim of the catalytic cave. 
A second group of inhibitors comprises short fatty acids, as butyrate, phenylbutyrate and the 
anticonvulsant valproic acid (VPA), which are less efficient inhibitors than TsA with IC50 
values in the millimolar range. Cyclic tetrapeptide antibiotics, including the natural 
compound trapoxin, and benzamides, e.g. MS-275 and Cl-994 (p-N-acetyl dinaline) comprise 
two other groups of inhibitors.  
All HDACs react equally sensitive to the different HDACi. Exceptions are HDAC6, which is 
sensitive to TsA, but not to trapoxin B (Furumai et al. 2001). Class I HDACs are five times 
more efficiently inhibited by VPA, than class II HDACs (Gottlicher et al. 2001). HDAC4 is 
less sensitive to butyrate. The benzamide MS-27-275 preferentially inhibits HDAC1 with an 
IC50 around 0.3 µM, compared to the inhibition of HDAC3 with an IC50 of 8 µM (Hu et al. 
2003). The novel synthetic compounds SK-7041 and SK-7046, with the hydroxamic acid  Introduction  
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group from TsA and a pyridyl ring from the benzamide MS-275, preferentially target HDAC1 
and HDAC2 (Park et al. 2004).  
Unexpectedly HDACi selectively alter the expression of only 2-10% of genes in cultured 
transformed cells (Van Lint et al. 1996; Mariadason et al. 2000; Glaser et al. 2003; Mitsiades 
et al. 2004). In a newer microarray study with SAHA and depsipepetide the expression of a 
higher number of genes, at least 22%, was regulated by both substances within an 16  h 
interval (Peart et al. 2005). Diverse HDACi seem to activate a common set of genes.  
HDACi induce cancer cell cycle arrest, growth inhibition, differentiation, and programmed 
cell death (Johnstone 2002; Marks et al. 2004; Dokmanovic and Marks 2005). For this reason 
different HDACi are in clinical trials for cancer treatment, among them sodium phenyl-
butyrate, SAHA, LAQ824, depsipeptide, MS-275, Cl-944, yroxamide, PXD101 and valproic 
acid (Dokmanovic and Marks 2005; Liu et al. 2006).  
While all class  I and class  II HDACs are equally sensitive to TsA, valproic acid 
preferentially inhibits class I HDACs. HDAC2 is about 5-fold more efficiently inhibited than 
HDAC5 and HDAC6 (Gottlicher et al. 2001), HDAC6 and HDAC10 are not inhibited by 
VPA (IC50 > 20 mM) (Gurvich et al. 2004). In contrast to other HDACi, VPA also induces 
proteasomal degradation of HDAC2 (Kramer et al. 2003). Valproic acid has also been shown 
to induce 5-LO expression in murine hippocampus and in the human neuron-like cell lines 
NT2 and NT2-N (Yildirim et al. 2003; Zhang et al. 2004). 
Nicotinamide (vitamin B3), as an inhibitor of class III deacetylases is often used to treat 
anxiety, osteoarthritis and psychosis and is in clinical trials for treatment of cancer and type I 
diabetes (Luo et al. 2001; Vaziri et al. 2001; Bitterman et al. 2002).  
 
1.8  Gene regulation by Sp1 and Sp3 
1.8.1  Structure of Sp transcription factors Sp1 and Sp3  
Sp proteins form a subgroup of Sp/Kruppel-like factors (KLFs). The family of Sp 
transcription factors comprises by now eight members, Sp1 to Sp8, and is characterized by the 
presence of a particular combination of three conserved Cys2His2 zinc fingers at the 
C-terminus, which form the DNA-binding domain of these factors. Sp1 and Sp3 are the best 
examined family members. Besides the zinc fingers Sp1 and the long isoforms of Sp3 contain 
two well conserved N-terminal transcription activation domains, A and B (Courey and Tjian 
1988; Courey et al. 1989; Pascal and Tjian 1991; Suske 1999). The C domain of Sp1 consists 
of highly charged amino acids. The D domain in Sp1 enables the formation of high order  Introduction  
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complexes and synergistic activation together with the A and B domains and is not found in 
Sp3 (Hagen et al. 1994; Dennig et al. 1996). Whereas Sp1 possesses an N-terminal inhibitory 
domain, the inhibitory domain of Sp3 is close to the zinc finger domain (De Luca et al. 1996; 
Dennig et al. 1996). All Sp proteins contain a N-terminal Sp box, an endoproteolytic cleavage 
site (Su et al. 1999).  
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Fig. 13 Domains of Sp1 and Sp3. (AD) activation domain, (ID) inhibitory domain, (ZF) zinc finger.  
 
1.8.2  DNA affinity 
Sp1 and Sp3 are ubiquitously expressed, Sp4 predominantly in neuronal cells and some 
epithelial cells. Except for Sp2, all family members bind to GC-rich elements such as the 
GC-box (GGGGCGGGG) and the related GT/CACCC-box (GGTGTGGGG), found in 
promoters of housekeeping genes, tissue-specific expressed genes, viral genes and cell cycle 
regulated genes with identical affinity (Hagen et al. 1994; Suske 1999; Black et al. 2001). A 
study demonstrated that Sp1 can also bind to a GC box in a nucleosome, though the binding 
affinity is 10- to 20-fold reduced compared to a naked DNA (Li et al. 1994). 
Sp1 forms a tetramer and then associates with the binding site, thus providing an enlarged 
interface for protein interactions (Mastrangelo et al. 1991). This synergistic transcriptionally 
activation is also seen in promoters with multiple Sp1 binding sites, Sp1 loops intervening 
DNA between distal and proximal promoter sites (Pascal and Tjian 1991; Su et al. 1991). The 
synergistical activation is not exhibited by Sp3 (Yu et al. 2003). Sp3 is unable to form 
oligomers (Mastrangelo et al. 1991; Pascal and Tjian 1991; Yu et al. 2003). On the other 
hand, Sp3 forms more stable complexes at adjacent binding sites than multimeric Sp1-DNA 
complexes and displaces Sp1 from these adjacent binding sites, possibly explaining the 
repressive effects of Sp3 by disturbing Sp1 dependent synergistic transactivation (Yu et al. 
2003). However the p21 promoter contains six Sp1 binding sites and Sp3 activates the 
promoter stronger than Sp1 (Sowa et al. 1999; Gartel et al. 2000).  
Regarding the effects of CpG methylation, the reports are controversial. In some studies DNA 
methylation does not interfere with Sp1 binding (Holler et al. 1988; Clark et al. 1997; Zhu et 
al. 2003), in others CpG methylation reduces Sp1 binding in gel shifts (Clark et al. 1997;  Introduction  
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Mancini et al. 1999). In the p21 promoter methylation of adjacent residues of the GC box 
reduced Sp1 binding stronger than methylation of the central CpG (Clark et al. 1997; Zhu et 
al. 2003). In reporter gene assays with the p16 and SNRPN promoter, Sp1 cotransfection 
induced promoter activity despite in vitro methylation of the promoter constructs (Fujita et al. 
2000). 
 
1.8.3  Transcriptional control by Sp1/Sp3 
Sp1 and Sp3 may act as negative or positive regulators of gene expression. The general 
mechanism for Sp protein dependent transactivation involves DNA-binding and subsequent 
interaction with components of the basal transcription machinery for constitutive expression 
(Pugh and Tjian 1990; Smale et al. 1990; Tanese et al. 1991; Emami et al. 1998). 
Furthermore, the CRSP complex, “cofactors required for Sp1 activation”, a multiunit cofactor 
complex regulates transcription by mediating signals between enhancer-bound factors and the 
core transcriptional machinery (Ryu and Tjian 1999; Ryu et al. 1999; Taatjes et al. 2002). The 
protein complex consists of subunits, which are shared by other mediator complexes, for 
example the DRIP complex (vitamin D interacting proteins) or the analogous TRAP complex 
(thyroid hormone receptor associated proteins) (Rachez and Freedman 2001). Different 
activators seem to induce different conformational changes upon binding to selective subunits 
of the complex thus allowing promoter selectivity (Taatjes et al. 2004). Also the composition 
of the complex defines its actions, for example, the CRSP/Med2 complex was isolated, 
lacking both subunits Med220 and Med70. The complex was able to potentiate transcription 
in response to Sp1, but not to VDR (Taatjes et al. 2004; Taatjes and Tjian 2004).  
 
1.8.3.1  Expression ratio of Sp1/Sp3 
The most simple mechanism of regulation depends on the relative levels of Sp1 and Sp3 
protein expression. In Caco-2 cells for example, the MAO B promoter is regulated by Sp1 and 
Sp3. Sp3 acts as an repressor on the promoter. With differentiation of Caco-2 cells, Sp3 
expression decreases and MAO-B expression increases (Wong et al. 2003). Similarly the 
human secretin promoter is regulated by the Sp1/Sp3 protein ratio. Higher Sp1 levels induced 
transcription whereas higher Sp3 levels repressed the promoter activity (Pang et al. 2004). 
The basal regulation of 15-lipoxygenase is dependent on Sp1 interaction with the promoter, 
whereas Sp3 decreases promoter activity (Tang et al. 2004).  
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1.8.3.2  Interaction with other proteins 
Since Sp proteins can also interact with multiple other DNA-binding proteins and 
coactivators/corepressors the transcriptional control further strongly depends on the promoter 
and cellular context. This is described by the multiple reports regarding the regulation of the 
p21 promoter by Sp1/Sp3/KLF4 DNA binding to the six proximal GC-rich elements and 
different protein interactions in different cell lines [reviewed in (Safe and Kim 2004)]. 
Amongst others activation of p21 expression was induced by p53 in several cell lines (Zhang 
et al. 2000; Koutsodontis et al. 2001), by calcineurin-induced NFAT1 and NFAT2 (Santini et 
al. 2001), by c-jun in HepG2 cells and repressed in human embryonic epithelial 293 cells all 
via distinct GC-sites within the p21 promoter (Kardassis et al. 1999; Wang et al. 2000).  
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Fig. 14 Multiple regulation of Sp mediated transcriptional control. 
Other transcription factors interacting with Sp1 include Ahr, Arnt, GATA-1, GATA-2, 
GATA-3, NF-YA, VHL, MyoD, PML. HTLF, E2F1, YY1, MDM2, c-jun, AP-2, myc, 
NFAT-1, HD protein, cyclin A, Oct-1, TBP, HNF3, HNF4, p53, MEF2C, SMAD2, SMAD3, 
SMDA4, Msx1, several viral proteins, Rb, E1a, p107, ZBP89, DNMT1 (Song et al. 2001; 
Song et al. 2001), histone modifying proteins such as HDAC1 (Doetzlhofer et al. 1999; Kang 
et al. 2005), p300 (Mastrangelo et al. 1991; Jang and Steinert 2002; Huang et al. 2005) and 
nuclear receptors such as ER, AR, PR, RAR, RXR, PPARγ, VDR, the orphan nuclear 
receptors SF-1 (steroidgenic factor-1) and COUP-TFII (chicken ovalbumin upstream 
promoter transcription factor-II [reviewed in (Safe and Kim 2004)].  
Nuclear receptors instead of binding to their response element, can interact with other 
transcription factors, e.g. Sp1 to activate gene expression. 1,25(OH)2D3 upregulates p27 
expression by inducing complex formation of a VDR/Sp1 complex. Sp1 in this case functions 
as an anchor protein for VDR (Huang et al. 2004; Cheng et al. 2006).  Introduction  
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Recently an interaction between the corepressors SMRT, NCoR and BCoR has been 
described between the zinc finger domain and the Sp1 inhibitory domain, giving another 
possible explanation for the repressive effects of Sp1 in some contexts (Lee et al. 2005).  
Multiple reports describe the recruitment of HDAC1 and HDAC2 by Sp1 and/or Sp3 to gene 
promoters. The histone deacetylase inhibitor TsA induces expression of the human telomerase 
reverse transcriptase (hTERT) gene (Hou et al. 2002), the human luteinizing hormone 
receptor gene (Zhang and Dufau 2002; 2003), the TGFβ type II receptor (Huang et al. 2005), 
insulin-like growth factor binding protein-3 gene (Choi et al. 2002) and others. The effect is 
usually reversed by mutation of a specific Sp1 binding site in the proximal promoter area. 
TsA treatment leads to a release of HDAC1 and Sp3 from the Sp1/Sp3/HDAC1/p300 
transcriptional complex from the IGFBP-3 promoter in Hep3B cells and increases Sp1 
binding. TsA also induces acetylation (Huang et al. 2005) or phosphorylation of Sp1 (Choi et 
al. 2002).  
 
1.8.3.3  Sp3 
In vivo four isoforms of Sp3 are expressed that differ in the extent of the N-terminal part, 
deriving from alternative translational start sites and not from splicing events. The two slow 
migrating isoforms form bands around 78/80 kDa, lacking the A domain, the long isoforms 
around 115  kDa. None of the isoforms become glycosylated as Sp1, but all become 
sumoylated at lysine 551 within the inhibitory domain of Sp3. Sumoylation renders all 
isoforms inactive (Ross et al. 2002; Sapetschnig et al. 2002; Spengler et al. 2005). The long 
isoforms act as transcriptional activators whereas the small isoforms are inactive (Sapetschnig 
et al. 2004) and can compete with Sp1 binding or promoter-specific transcription factors, 
thereby repressing transcription (Hagen et al. 1994; Kennett et al. 1997; Kumar and Butler 
1997; Majello et al. 1997; Kennett et al. 2002). However it remains unclear why Sp3 acts as 
an activator/repressor on some promoter settings, but not on others.  
 
1.8.3.4  Posttranslational modifications 
Braun et. al. formerly described the acetylation of the same lysine residue of Sp3 that 
becomes sumoylated (Braun et al. 2001). In vitro CBP and p300, but not PCAF could 
acetylate Sp3. Originally the acetylation event was discussed to be involved in the inhibitory 
function of Sp3, since the lysine residue 553 (KEE motif) is essential for silencing function 
(Braun et al. 2001). However in other reports the acetylation of Sp3 increases the 
transactivation activity. E.g. in the late passage of MCF7 cells, Sp3 acted as an transcriptional  Introduction  
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repressor of the TGFβ receptor expression because of a higher Sp3/Sp1 ratio, whereas 
TsA-induced acetylation of Sp3 recovers TGFβ expression by transactivation of Sp3 
(Ammanamanchi and Brattain 2001; Braun et al. 2001; Ammanamanchi et al. 2003). It is 
possible that acetylation and sumoylation of the same lysine residue regulate Sp3 
transcriptional activity (Ross et al. 2002; Sapetschnig et al. 2002; Sapetschnig et al. 2004; 
Spengler et al. 2005). No phosphorylation of Sp3 has been described so far. 
Phosphorylation of Sp1 can occur at multiple sites by many kinases both in the N- and 
C-terminus. Phosphorylation of Sp1 is induced by various signals including viral infection, 
growth factors, certain drugs, cytokines, mechanical stress, etc (Jackson et al. 1990; Lin et al. 
1997; Chun et al. 1998; Alroy et al. 1999; Black et al. 1999; Ray et al. 1999; Kim and DeLuca 
2002; Pan and Hung 2002; Bonello and Khachigian 2004).  
Phosphorylation by phosphatidylinositol-3-kinase (PI3-K) e.g. increases phosphorylation of 
Sp1 in several prostate cancer cells lines and enhances binding to the promoter of the vascular 
endothelial growth factor (VEGF) (Pore et al. 2004). Phosphorylation by PKA (Lee et al. 
2003), PKC (Rafty and Khachigian 2001), cyclin A-cyclin-dependent kinases (Fojas de Borja 
et al. 2001; Haidweger et al. 2001; Banchio et al. 2004) and mitogen-activated protein kinase 
(Onishi et al. 2001; Milanini-Mongiat et al. 2002) have also been described and linked to 
increased DNA binding and transcription activity of Sp1. As reviewed by Chu et. al 
phosphorylation does not always increase the DNA-binding ability of Sp1 and induced 
transactivation can occur independently of an enhanced DNA-binding affinity (Lin et al. 
1997; Reisinger et al. 2003; Chu and Ferro 2005). Sp1 phosphorylation also increases 
ubiquitinylation and subsequent proteolysis, decreasing Sp1 nulear protein levels (Leggett et 
al. 1995; Mortensen et al. 1997). Since Sp1 can be phosphorylated at various sites or 
combination of sites, phosphorylation leads to a range of changes in protein function, further 
depending on interacting proteins, the promoter and cellular context.  
Similar to Sp3, TsA induced acetylation of Sp1 resulted in increased transcription of the 
TGFβ II receptor (Huang et al. 2005). Trichostatin A treatment altered a multiprotein complex 
consisting of Sp1, NF-Y, HDAC1, p300 and PCAF. Whereas p300 and PCAF recruitment 
was increased, HDAC1 interaction was decreased. The authors could also show, that 
acetylation of Sp1 was dependent on PCAF histone acetyltransferase activity and that PCAF 
can acetylate Sp1 in vivo. Acetylation of Sp1 was also induced after treatment of various 
human cancer cell lines with the DNA topoisomerase II poison TAS-103, but only in p300 
expressing cells. The treatment increased p300 expression and interaction with Sp1, resulting 
in induced promoter activity of the SV40 promoter (Torigoe et al. 2005). In an earlier study it  Introduction  
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was demonstrated that the acetyltransferase region of p300 interacts with the DNA binding 
domain of Sp1 and stimulates DNA binding of Sp1 rather physically than by acetylation 
(Suzuki et al. 2000).  
Concerning serine/threonine O-linked β-N-acetylglucosamine glycosylation, reports describe 
different consequences for Sp1 function. For example, glycosylation protects from subsequent 
degradation after phosphorylation, indicating a reciprocal relationship between 
phosphorylated and glycosylated Sp1 (Han and Kudlow 1997; Wells et al. 2001; Spengler and 
Brattain 2006). The modification intervenes the Sp1 interaction with TATA-binding protein-
associated factor (TAF110) (Roos et al. 1997) and in some contexts inhibits Sp1-dependent 
transactivation (Yang et al. 2001), in others increases Sp1 transactivation (Roos et al. 1997). 
Recently sumoylation of Sp1 has been described and linked to transcriptional repression of 
Sp1. The sumoylation of lysine 16 inhibits the N-terminal cleavage of Sp1 within a negative 
regulatory domain. The authors suggest an inhibiting role of the non-cleaved Sp1 in 
transcription via recruitment of corepressors to the uncleaved binding domain (Spengler and 
Brattain 2006). 
The multiple interactions of Sp1/Sp3 with other DNA binding proteins, 
coactivators/corepressors, DNA and histone modifying proteins, point out, how complex a 
promoter in a specific cell context may be regulated.  Aims  
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2  Aims of the present study 
As outlined in the introduction, the mechanism how 5-LO gene transcription is regulated, is 
not yet fully understood. Besides the prominent upregulation triggered by differentiation of 
cells of myeloid origin by 1,25(OH)2D3 and TGFβ (Brungs et al. 1994; 1995; Harle et al. 
1998; 1999; Uhl et al. 2002; Sorg et al. 2006), which only partly depends on the 
transcriptional level, transcription factors binding to GC-rich sequences including Sp1/Sp3 
and Egr1 (In et al. 1997; Silverman et al. 1998; Dishart et al. 2005), as well as proteins 
involved in the regulation by DNA methylation and histone deacetylation (Uhl et al. 2002; 
Klan et al. 2003), e.g. methyl-CpG-binding proteins and HDACs, are/could be recruited to the 
5-LO promoter under various conditions. 
One aim of this study was to investigate how the histone deacetylase inhibitor TsA induces 
5-LO promoter activity and gene expression. Early studies indicated the presence of relevant 
elements within the core promoter region, possibly Sp1 binding sites (Klan et al. 2003). An 
upregulation of gene expression by histone deacetylase inhibitors suggests the recruitment of 
HDACs, often in combination with HATs, within the proximal promoter area. Treatment with 
HDACi in some cases change the composition of multiprotein-complexes, e.g. consisting of 
Sp1/NF-Y/HDAC1/p300, as shown for the TGFβII receptor (Huang et al. 2005). Also 
posttranslational modifications of transcription factors by HDACs or HATs in response to 
HDACi have been described, e.g. acetylation or phosphorylation of Sp1/Sp3 after TsA 
treatment (Choi et al. 2002; Ammanamanchi et al. 2003; Huang et al. 2005), changing the 
transactivation or binding properties of the transcription factors. 
Since 5-LO expression and DNA methylation of the 5-LO core promoter correlate in 5-LO 
positive and 5-LO negative cell lines (Uhl et al. 2002), proteins involved in the regulation by 
DNA methylation, such as methyl-CpG-binding proteins, should be identified and the 
potential binding sites within the core promoter isolated. In order to investigate the influence 
of DNA methylation on the binding affinity of Sp1, gel shift studies were performed with 
methylated DNA stretches.    Materials and Methods   
40 
3  Materials and Methods 
3.1  Cell lines 
Mono-Mac-6 cells 
Human acute monocytic leukemia cell line; differentiation to macrophages possible; cells 
were kindly provided by H. W. L. Ziegler-Heitbrock, Inst. of Immunology, Univ. of Munich. 
The cells show 5-LO expression after differentiation with TGFβ and 1,25(OH)2D3. 
HeLa cells 
Established from human epitheloid cervix carcinoma; later diagnosis changed to adenoma 
carcinoma; cells were obtained from Dr. W. E Müller, Pharmacological Institute, Biocenter, 
Frankfurt. The cells show no 5-LO expression, there is no effect of TGFβ and 1,25(OH)2D3 
treatment on 5-LO expression. 
 
3.2  Cell culture 
Mono Mac 6 cells were cultured in RPMI-1640 medium supplemented with 2 mM Glutamine, 
1  mM sodium pyruvate, 1  x nonessential amino acids, 10  µg/ml insulin, 1  mM oxalacetic 
acid, 100 units/ml penicillin, 100 µg/ml streptomycin and 10% (v/v) fetal bovine serum. Cells 
were maintained at 37 °C in an humified atmosphere of 5% CO2. Cultures were seeded at 
2 x 10
5 cells/ml. In some experiments TGFβ (2 ng/ml) and 1,25(OH)2D3 (50 nM) were added 
for induction of 5-LO expression and cell differentation. TGFβ1 was purified from outdated 
platelets as described by Werz et. al. (Werz et al. 1996). If indicated, cells were treated 6 h 
with TsA, 330 nM, purchased from Sigma (T8552, solved in ethanol). 
HeLa cells were grown in Dulbecco`s modified Eagle`s medium (DMEM) supplemented with 
10% (v/v) FCS, 100 µg/ml streptomycin and 100 units/ml penicillin. If indicated, cells were 
treated 24 h with TsA, 330 nM, or 24 h with 1 mM valproic acid (Aldrich, Cat.: 22,425-1), or 
with 5 mM nicotinamide (Sigma, solved in DMSO).  
 
3.3  Preparation of whole cell extracts for DNA affinity purification assay 
MM6 cells were seeded at 2  x  10
5  cells/ml. After 4 days the cells were collected by 
centrifugation at 1200 rpm at RT for 3 min. The pellets were rinsed with PBS (pH 7.4) and 
collected in one falcon tube. Following centrifugation the cells were resuspended in 10 ml of 
NETN buffer (50 mM Tris-HCl pH 8.0, 1 mM EDTA, 120 mM NaCl, 0.25% NP-40) and 
lysed for 15 min on ice. After sonication (3 x 5 sec) and cooling on ice for another 30 min the   Materials and Methods   
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cell debris was removed through centrifugation (10,000  rpm at 4  °C for 10  min) and the 
supernatant was stored at -70  °C. Protein content was determined with Bradford assay 
(BioRad Protein Assay). 
HeLa cells were seeded 1-2 x 10
6 cells/180 cm
2, equivalent to splitting the cells 1:10 every 4 
days. After 72 h the cells were harvested. For this the cells were washed twice with PBS 
(pH 7.4) at RT, scraped off in PBS buffer and collected in a falcon tube. After centrifugation 
at 1,200  rpm for 3 min, 1 ml of ice-cold NETN buffer per collected dish was added and the 
cells were lysed for 15  min on ice. The cell debris was removed through centrifugation 
(10,000 rpm at 4 °C for 10 min) and the supernatant was stored at -70 °C. 
 
3.4  Preparation of nuclear and cytosolic cell fractions 
To check for protein expression after transfection, cells were harvested and fractionated into 
nuclear and non-nuclear compartments. Adherent HeLa cells were first washed twice with 
PBS (pH 7.4), then scraped off the cell culture dishes and transferred to falcon tubes. After 
centrifugation at 1200 rpm (200 g) at RT for 5 min the pellet is resuspended in 300 µl of 
NP-40 buffer (10 mM Tris-HCl pH 7.4, 10 mM NaCl, 3  mM MgCl2, 1 mM EDTA, 0.1% 
NP-40) containing protease inhibitors (1  mM PMSF, 1  µg/ml STI, 10  mg/ml Leupeptin), 
lysed on ice for 10 min and subsequently centrifuged at 2700 rpm (800 g) at 4 °C for 10 min. 
The supernatant is the cytosolic fraction and stored at –20 °C. The pellet (nuclear fraction) is 
resuspended in 50 µl of TKM buffer (50 mM Tris-HCl pH 7.4, 250 mM Sucrose, 25 mM 
KCl, 5 mM MgCl2, 1 mM EDTA), sonicated for 3 x 5 sec and stored at –20 °C. For Western 
blot analysis usually the nuclear fraction was prepared. Different probes were normalized to 
the cell number of harvested cells, the volumes were adjusted with MQ to a volume of 20 µl, 
5 µl of 5 x Laemmli buffer (250 mM Tris-HCl pH 6.8, 5 mM EDTA, 50% Glycerol, 10% 
SDS, 0.05% BPB, 10% β-Mercaptoethanol) were added and the samples boiled for 5 min at 
95 °C. 
 
3.5  Preparation of nuclear extracts for gel shift assays and DAPA 
Nuclear extracts were prepared according to Shapiro (Shapiro et al. 1988). Depending on the cell 
type and the growth conditions about 0.2 – 1 x 10
9 cells were harvested by centrifugation at 170 g, 
10 min, 4 °C. Cells were washed twice in cold PBS (pH 7.4). HeLa cells were washed twice with 
ice cold PBS before scraping the cells off the cell culture dishes. The pellet was resuspended in a 
small volume of PBS and centrifuged at 300 g for 10 min, after which the packed cell volume   Materials and Methods   
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(PCV) was measured. The pellet was resuspended in hypotonic buffer (10 mM HEPES, pH 7.9, 
0.75 mM spermidine, 0.15 mM spermine, 0.1 mM EDTA, 0.1 mM EGTA, 1 mM DTT, 10 mM 
KCl and Complete Protease Inhibitor Complex (CPIC, Roche) to 5 times the PCV and allowed to 
swell on ice for 10 min. The cells were pelleted by centrifugation at 300 g for 10 min at 4 °C, and 
resuspended in hypotonic buffer (volume corresponding to 2  x PCV). Cells were broken by 
Dounce homogenization: first tight pestle; then loose pestle after adding 0.1 volume of sucrose 
restore buffer (50 mM HEPES, pH 7.9, 0.75 mM spermidine, 0.15 mM spermine, 10 mM KCl, 
0.2 mM EDTA, 1 mM DTT, CPIC, and sucrose 67.5% (w/v)). The broken cells were quickly 
centrifuged at 10,000 rpm for 1 min. The viscous pellet (containing nuclei) was resuspended in 
2.1  ml nuclear resuspension buffer (20  mM HEPES, pH  7.9, 0.75  mM spermidine, 0.15  mM 
spermine, 0.2 mM EDTA, 2 mM EGTA, 2 mM DTT, 25% glycerol, 0.1 volume saturated (at 4 °C) 
ammonium sulfate and CPIC), shaken for 30  min at 4  °C, during this treatment nuclei are 
disrupted. The resulting solution was cleared by centrifugation for 90  min at 150,000  g, and 
nuclear proteins were precipitated with ammonium sulfate (0.39 g/ml, stirred on ice for 20 min). 
The precipitate was collected by centrifugation at 85,000 g for 20 min. The pellet was resuspended 
in 0.6 ml dialysis buffer (20 mM HEPES, pH 7.9, 20 % glycerol, 100 mM KCl, 0.2 mM EDTA, 
0.2 mM EGTA, 2 mM DTT and CPIC) and dialyzed for 2 times 2 h in >200 volumes of dialysis 
buffer. The final nuclear protein extract was stored at –70 °C. 
 
3.6  SDS-PAGE and Western blot 
If not otherwise indicated 10% polyacrylamide gels were run at 170 V for 60 min. Proteins were 
electroblotted onto Millipore Immobilon-FL PVDF membrane using the BioRad Mini Protean 
system. Membranes were blocked in a mixture of Li-Cor Blocking buffer and PBS (1:1) for 1 h at 
RT and then incubated overnight at 4 °C with primary antibody solution. After washing 4 x 5 min 
in PBS-Tween 0.1%, the membranes were incubated 30 min at RT in secondary antibody and 
subsequently washed another four times for 5 min in PBS-Tween 0.1% and finally 5 min in PBS. 
The membranes were scanned in the Li-Cor Odyssey scanner at 169  µm resolution and high 
quality. 
 
Primary antibodies 
Sp1 (sc-059)  anti-rabbit, anti-goat  1:1000  Santa Cruz / Heidelberg 
Sp3 (sc-644)  anti-rabbit  1:1000  Santa Cruz / Heidelberg 
HDAC2 (sc-7899)  anti-rabbit  1:1000  Santa Cruz / Heidelberg 
HDAC3 (sc-11417)  anti-rabbit  1:1000  Santa Cruz / Heidelberg 
HDAC8 (sc-17778)  anti-rabbit  1:1000  Santa Cruz / Heidelberg   Materials and Methods   
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p300 (sc-32244)  anti-mouse  1:1000  Santa Cruz / Heidelberg 
PCAF (sc-6300)  anti-gaot  1:1000  Santa Cruz / Heidelberg 
MBD1 (sc-25262)  anti-mouse  1:1000  Santa Cruz / Heidelberg 
MBD2 (sc-9397)  anti-goat  1:1000  Santa Cruz / Heidelberg 
MBD3 (sc-9402)  anti-goat  1:1000  Santa Cruz / Heidelberg 
MeCP2 (sc-20700)  anti-rabbit  1:1000  Santa Cruz / Heidelberg 
Anti-acetyl-Lysine (06-933)  anti-rabbit 1:5000  Upstate  /  Hamburg 
Anti-HDAC1 clone 2E10 (05-614) anti-mouse  1:2000  Upstate / Hamburg 
Anti-MBD2/3 (07-199)  anti-rabbit  1:5000  Biomol / Hamburg 
MBD1 (ab3753)  anti-rabbit  1:1000  Abcam / UK 
 
Secondary antibodies 
Donkey anti-rabbit (#611-732127)  IRDye800CW  1:10000  Rockland 
Donkey anti-goat (#A-21084)  Alexa680  1:10000  Molecular Probes 
Goat anti-rabbit (926-32230)  IRDye800CW  1:10000  Odyssey InfraredImaging 
Goat anti-mouse (927-30021M)  Alexa680  1:10000  Odyssey InfraredImaging 
Goat anti-rabbit (926-32221)  IRDye680  1:10000  Odyssey InfraredImaging 
Goat anti-mouse (927-30020R/C)  IRDye800CW  1:10000  Odyssey InfraredImaging 
 
3.7  Plasmids 
3.7.1  5-LO promoter reporter gene vectors 
The cloning of the basic 5-LO promoter luciferase reporter gene constructs N0 to N14 was 
done by Niko Klan and is described in (Klan et al. 2003; Sorg et al. 2006). N0 contains the 
promoter region from +53 bp up to -6079 bp in relation to the major transcription initiation 
site (-12 bp to -6144 bp in relation to the ATG). It was cloned by digesting the plasmid K1 
(containing the fragment -6079 to +409 of the 5-LO gene (provided by Shigeru Hoshiko, 
Japan) first with BstEII, subsequently blunting with T4 DNA polymerase, digesting with KpnI 
and finally ligating the obtained fragment into the promoterless luciferase reporter vector 
pGL3Basic (Promega), which was opened with KpnI and SmaI. 
The plasmids N1-N11 were constructed by digestion of N0, using KpnI in combination with 
either AflII (N1), Van911 (N2), NdeI (N3), PvuII (N5), Eco1471 (N6), EcoRI (N7), EcoRV 
(N8),  PmeI p(N9), PauI (N10) and BstXI (N11). Overhangs were blunted by T4 DNA 
polymerase and the plasmids religated with T4 DNA ligase. 
Constructs N12 to N16 and GC0 were obtained by PCR deletion using N10 as the template. 
The primers used in the PCR reaction are described in Tab. 1. Following 18 temperature   Materials and Methods   
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cycles, the PCR product was treated with DpnI, DNA ends were phosphorylated by T4 
polynucleotide kinase and ligated by T4 DNA ligase. 
Several mutations of transcription factor binding sites and methylation sites were introduced 
by site-directed mutagenesis according to the instructions of the QuikChange II site-directed 
mutagenesis kit of Stratagene. The primers used for the PCR reaction had a minimum length 
of 25 bp, a minimum GC content of 40% and an annealing temperature of at least 78 °C, 
carrying the mutation in the middle of the sequence. Primers, if possible, ended with a G or C 
and were purified by HPLC. For the introduction of a point mutation, the PCR reaction was 
run for 12 cycles, for the mutation of several base pairs, for 16 cycles. The PCR product was 
treated with DpnI to digest template DNA and subsequently transformed to supercompetent 
SURE
 E.coli (Stratagene). The primers used for the different mutations are listed in Tab. 1. 
The following mutations of potential Sp1 binding sites were done by site-directed 
mutagenesis: Mutation of the two proximal GC boxes, GC4 (-113 bp to –118 bp in relation to 
the ATG of 5-LO) and GC box 5 (-78 bp to -83 bp in relation to the ATG of 5-LO) in 
construct N13, the mutation of GC5 in N14, resulting in the reporter gene constructs 
N13GC4, N13GC5, N13GC45 and N14GC5. 
The same single mutations were generated in the larger 5-LO promoter plasmids N10 and 
GC0 (a deletion variant of N10, missing the 5-tandem Sp1 binding site at –147 bp to –176 bp 
in relation to 5-LO), generating the constructs N10GC4, N10GC5, and GC0GC5. 
To produce the plasmids GC0GC4 and GC0GC45 a different cloning strategy was chosen. 
Because of a lack of restriction sites, it was not possible to cut fragments out of the already 
existing mutated plasmids and to religate them into the larger plasmids. For this reason the 
fragments were generated by PCR. Basically, two each other flanking PCR products were 
obtained, one containing the wished mutations of the GC boxes, already introduced in either 
N13GC4 or N13GC45, another containing the adjacent fragment of GC0, needed for the 
ligation into GC0. The plasmid GC0 was opened by the restriction enzymes NotI and NcoI, 
the PCR fragments were digested with either NotI (GC0 as a template) or NcoI 
(N13GC4/N13GC45 as a template), phosphorylated at the blunt ends and ligated both into 
GC0. The primers used for the PCR reaction are shown under “Primers for PCR product 1 
and 2” in Tab. 1 below. 
The triple mutants GC0GC145 and GC0GC245 were obtained using the same strategy, using 
GC0GC1 or GC0GC2 and N13GC45 as templates. GC0GC1245 was generated using 
N10GC12 and N13GC45 as templates.   Materials and Methods   
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Mutations of the more distal binding sites of Sp1, including the sites from -238 bp to -233 bp 
(GC box 1),  -216 bp  to  -221 bp  (GC box 2),  -721 bp  to  -726 bp  (GC box 7),  -766 bp  to 
-771  bp (GC  box  6), were introduced into N10 and GC0 using site-directed mutagenesis, 
resulting in the constructs N10GC1, N10GC2, N10GC6, N10GC7 and GC0GC1, GC0GC2. 
Mutations of the two potential Sp1 binding sites GC8 (-887 bp to -892 bp in relation to ATG) 
and GC9 (-1002 bp to -1007 bp) within the reporter gene construct N9 were also introduced 
by site-directed mutagenesis generating the reporter gene constructs N9GC8 with an 
additional BamHI site, N9GC9 with an additional NcoI site and N9GC89 respectively. To 
further introduce the five-fold mutation of GC1, GC2, GC4, GC5 and the deletion of GC0 
into these constructs the BstXI/BglII fragment from construct GC0GC1245 was inserted, 
replacing the natural BstXI/BglII fragments from the plasmids via restriction digest, leading to 
the constructs N9GC01245, N9GC8GC01245, N9GC8GC01245 and N9GC89GC01245. 
The most distal Sp1 binding site (GC box 10, from -1002 bp to -1007 bp) was mutated in N8 
via site-directed mutagenesis resulting in construct N8GC10. 
To investigate the influence of the methylation sites within the proximal promoter area, 
mutations of these sites were introduced into construct N13. Construct N13MutMethIII was 
achieved via site-directed mutagenesis, N13MutMethI and N13MutMethII via two flanking 
PCR products which were cloned into the NotI/NcoI opened plasmid N13. 
Additionally CpG sites within the inverted repeat structure of the proximal 5-LO promoter 
were mutated to check for methylation effects in the secondary DNA structure (Hoshiko et al. 
1990). These mutations were both introduced via site-directed mutagenesis into N13, 
resulting in the reporter gene constructs N13MutInvRep1 and N13MutInvRep2. Primers used 
for the methylation relevant mutations are stated in the table below. 
 
3.7.2  Expression plasmids 
The expression plasmids pETM1, pETM3, pETM4 for the methyl-CpG-binding proteins 
Mbd1 (AF072240, coding for the murine isoform Mbd1a), Mbd2 (AF072243, using the 
second ATG coding for the murine isoform Mbd2b) and Mbd3 (AF072248) of murine origin 
and pCMV-HA-MeCP2 of rat origin (NM_022673) were kindly provided by Adrian Bird, 
University of Edinburgh, UK. H.  Leonhardt, from the Max Delbruck center in Berlin, 
Germany, kindly send us the expression plasmid of mouse Dnmt1, pEMT. From M. Szyf, 
McGill University, Montreal we have received pHis-dMTase (human MBD2b) and from 
F.  Li, University of Giessen, Germany, the plasmids pcDNA3.1HisDnmt3a and 
pcDNA3.1HisDnmt3b1, containing the murine coding sequences.   Materials and Methods   
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Plasmid  Forward primer for PCR deletion  Reversed primer for PCR deletion 
N12 
N13 
N14 
N15 
N16 
GC0 
CGCGTGAAGAGTGGGAGAGAAGTACTGCGG 
CAGCCGGGAGCCTGGAGCCAGACC 
AGGGACCAGTGGTGGGAGGAGGCT 
GCTAGATGCGGACACCTGGACCGC 
GGCTCCCGGCGCTCGCTGCTC 
CAGCCGGGAGCCTGGAGCCAGACC 
TATCGATAGAGAAATGTTCTGGCA 
See N12 
See N12. 
See N12 
See N12 
CCGCAGTACTTCTCTCCCACTCTTCACGCG 
Plasmid  Forw. primer for site-directed mutagenesis  Rev. primer for site-directed mutagenesis 
N13GC4 
N13GC5 
N13GC45 
N14GC5 
N10GC1 
N10GC2 
N10GC12 
N10GC4 
N10GC5 
N10GC6 
N10GC7 
GC0GC1 
GC0GC2 
GC0GC5 
N9GC8 
N9GC9 
N9GC89 
N8GC10 
N13MutInvRep1 
N13MutInvRep2 
N13MutMethIII 
AGCCAGACCGGCCCGGGGCCGGG 
GGACCAGTGTGCCAGGAGGCTGCGGC 
see N13GC5; N13GC4 as template 
see N13GC5 
GCCCCTGCCCCGGGCGAGGCGAG 
GAGGCGAGGTCCCGGGCAGTCGGCG 
see N10GC2; N10GC1 as template 
see N13GC4 
see N13GC5 
CGACCCGTGACCCCTGGCCTGAGGTAGACAGCCC 
CGTCCCGCCTGCCCGGGGCGACCACTGGC 
see N10GC1 
see N10GC2 
see N13GC5 
GAGGCGGGCGCCAGGAGTGGATCCGAACCTGGG 
CCCAGCCGCGGGAAGCCATGGAGGAGCGCGC 
see N9GC8 
GACTTCACATCCCCGGGATCCCACGCACGGTGAGC 
CTCTATCG ATACAGCTGGGAGCCTGGAGCC 
CGAGGCTCCCGACCCTCGCTGCTC 
CAGACTGGGGCGGGGCTGGGACCTGGGCCAG 
CCCGGCCCCGGGCCGGTCTGGCT 
GCCGCAGCCTCCTGGCACCACTGGTCC 
see N13GC5; N13GC4 as template 
see N13GC5 
CTCGCCTCGCCCGGGGCAGGGGC 
CGCCGACTGCCCGGGACCTCGCCTC 
see N10GC2; N10GC1 as template 
see N13GC4 
see N13GC5 
GGGCTGTCTACCTCAGGCCAGGGGTCACGGGTCG 
GCCAGTGGTCGCCCCGGGCAGGCGGGACG 
see N10GC1 
see N10GC2 
see N13GC5 
CCCAGGTTCGGATCCACTCCTGGCGCCCGCCTC 
GCGCGCTCCTCCATGGCTTCCCGCGGCTGGG 
see N9GC8 
GCTCACCGTGCGTGGGATCCCGGGGATGTGAAGTC 
GGCTCCAGGCTCCCAGCTGTATCGATAGAG 
GAGCAGCGAGGGTCGGGAGCCTCG 
CTGGCCCAGGTCCCAGCCCCGCCCCAGTCTG 
Plasmid Primer  for  flanking  PCR product 1   Primer for flanking PCR product 2  
GC0GC4 
 
 
GC0GC45 
 
 
GC0GC12 
 
 
GC0GC145 
 
 
GC0GC245 
 
 
GC0GC1245 
 
 
N13MutMethII 
Template: GC0 
for TCGGTGCGGGCCTCTTCGCTATTACGCCAG 
rev CCGCAGTACTTCTCTCCCACTCTTCACGCG 
Template: GC0 
see GC0GC4 
see GC0GC4 
Template: N10GC12 
see GC0GC4 
see GC0GC4 
Template: GC0GC1 
see GC0GC4 
see GC0GC4 
Template: GC0GC2 
see GC0GC4 
see GC0GC4 
Template N10GC12 
see GC0GC4 
see GC0GC4 
Template N13 
Template: N13GC4 
for CAGCCGGGAGCCTGGAGCCAGACCG 
rev CCAGGAACCAGGGCGTATCT 
Template: N13GC45 
see GC0GC4 
see GC0GC4 
Template: N13 
see GC0GC4 
see GC0GC4 
Template: N13GC45 
see GC0GC4 
see GC0GC4 
Template: N13GC45 
see GC0GC4 
see GC0GC4 
Template N10GC12 
see GC0GC4 
see GC0GC4 
Template N13   Materials and Methods   
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N13MutMethI 
 
 
for TCGGTGCGGGCCTCTTCGCTATTACGCCAG 
rev ACCACAGCCTCCTCCCACCACTGGTC 
Template N13 
for TCGGTGCGGGCCTCTTCGCTATTACGCCAG 
rev CAGCAGTCCAGGTGTCCACATCTAG 
for GCTAGATGCGGACACCTGGACCGCC 
rev GCCAACCGAACGGACATTTC 
Template N13 
for TGCTGAGGCTCCCGGCGCTTGCTGCTCC 
rev CCAGGAACCAGGGCGTATCT 
  Forward primer for oligo insertion  Reversed primer for oligo insertion 
pSG5mcsNEU  AATTCCCATGGCATGCGGATCCGGTACCACT 
AGTCCCGGGA 
GATCTCCCGGGACTAGTGGTACCGGATCCGCA 
TGCCATGGG 
  Forward primer for PCR amplification  Reversed primer for PCR amplification 
pSG5HDAC1 
pSG5Hdac2m 
pSG5HDAC2h 
pSG5HDAC3 
pSG5HDAC8 
pSG5Mbd1m 
 
pSG5Mbd2m 
pSG5Mbd3m 
pSG5Dnmt1m 
pSG5DNMT3b1 
TCCCCCGGGATGGCGCAGACGGCAGGGCAC 
TCCCCCGGGATGGCGTACAGTCAAGGAGGCGG 
TCCCCCGGGATGGCGTACATGCAAGGAGGCGC 
CGGGATCCCCATGGCCAAGACCGTGGCC 
CGGAATTCATGGAGGAGCCGGAGGAACCG 
TCCGGAATTCATGGCTGAGTCCTGGCAGGACT 
 
TCCGGAATTCGCCATGGACTGCCCGGCCCTCCC 
TCCGGAATTCATGGAGCGGAAGAGGTGGGAGTGCC 
AGGAATGGCAGACTCAAATAGATCCCCAAGATC 
TCCGGAATTCCAGGAAACAATGAAGGGAGACAGCAG
GGAAGATCTTCAGGCCAACTTGACCTCCTCCTTG 
GAAGATCTTCAGGGGTTGCTGAGCTGTTCTG 
GAAGATCTTCAGGGGTTGCTGAGCTGTTCTG 
GGACTAGTCCACTCTTAAATCTCCACATCGCTTTCC 
CCCAAGCTTCTAGACCACATGCTTCAGATTCCCTTTG 
TGGAAGATCTCTCTCCTACAAAACTTCTTCTTTCAAC 
TGC 
TGGAAGATCTTGCACTGCACCGGAAGGGCCCTGC 
TGGAAGATCTCTACACTCGCTCTGGCTCCGGCTCTTC 
CTAGTCCTTGGTAGCAGCCTCCTCTTTTGC 
GCGGATCCCTATTCACAGGCAAAGTAGTCCTTCAACG 
Tab. 1 Primers used for cloning. All oligonucleotides were synthesized by Sigma-Genosys 
(Steinheim). 
 
Further on, different plasmids expressing histone deacetylases (human HDAC1, HDAC3 
[pcDNAFlagHDAC3], HDAC8, as well as mouse Hdac2 [pME18S-HDAC2] ) were kindly 
provided by E. Seto, from the H. Lee Moffit Cancer Center, University of South Florida, 
USA. pEVR2/CMV-Sp1, pRC/CMV-Sp3 and pRC/CMV-Sp4 were a gift of by G. Suske, 
University of Marburg, Germany. 
For co-expression studies together with 5-LO promoter reporter gene constructs it was 
reasonable to use expression plasmids with the same vector background. For this reason the 
expression plasmids were cloned into the high copy expression vector pSG5 from Stratagene, 
containing a SV40 promoter. First the multiple cloning site of the pSG5 vector was extended. 
For this the pSG5VDR plasmid ( a gift of C.  Carlberg, University of Kuopio, Finland, 
containing the vitamin D receptor coding sequence) was opened with EcoRI and BglII and a 
double stranded oligo filling up the EcoRI and BglII site, and additionally containing 
restriction sites for NcoI, BamHI, KpnI, SpeI, and SmaI was ligated into the backbone of the 
plasmid.    Materials and Methods   
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Fig. 15 Extention of the multiple cloning site of pSG5mcsNEU 
PCR fragments covering the coding sequences of human HDAC1 (Acc. No. NM_004964), 
HDAC3 (Acc.  No.  NM_003883) and HDAC8 (Acc. No. NM_018486)  were  respectively 
inserted via the restriction sites SmaI/BglII,  BamHI/SpeI and EcoRI/HindIII into 
pSG5mcsNeu. Human HDAC2 (Acc. No. NM_001527) was cloned from HeLa cDNA using 
SmaI and BglII for inserting the PCR fragment into pSG5mcsNeu.  
The coding sequence of Dnmt1 (Acc. No. AF175432) was amplified by PCR and introduced 
via the SmaI site into the pSG5mcsNEU. Dnmt3b1 (Acc. No. AF068626) were subcloned via 
PCR amplification into pSG5mcsNeu using EcoRI and BamHI sites. Murine Dnmt3a 
(Acc. No. AF068625) was excised from pSX173 with XbaI and BamHI and ligated to the 
pSG5mcs opened with SpeI and BamHI. 
The coding sequences of the murine methyl-CpG-binding proteins were also introduced into 
pSG5mcsNeu using PCR amplification and the restriction sites of EcoRI and BglII in the mcs. 
The HA-tagged MeCP2 cds (Acc. No. NM_022673) was excised from pCMV-HA-MeCP2 
with  EcoRI and ligated into the EcoRI opened pSG5mcsNeu vector, resulting in 
pSG5mcsMeCP2. 
Plasmid sequences were confirmed by DNA sequencing. Restrictions enzymes were 
purchased from either MBI Fermentas, New England Biolabs or Promega, Pfu DNA 
Polymerase from Promega, T4 DNA Ligase from NEB and T4 Polynukleotide Kinase from 
MBI Fermentas. 
 
3.8  Preparation of plasmid DNA 
Larger amounts of plasmid DNA, especially for transfections, were prepared using the 
Nucleobond AX 2000
-System (Macherey-Nagel). According to the manufacturer 500 ml of 
bacterial culture is harvested. After lysing the cells by a NaOH/SDS solution, chromosomal 
DNA and proteins are precipitated with a potassium acetate solution and the plasmid DNA is 
further purified via a silica based anion exchange chromatography. 
   Materials and Methods   
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3.9  In vitro methylation  
Plasmid DNA or PCR products were incubated over night at 37 °C with HpaII methylase., 
M. HhaI, M. SssI or the combination of M. HpaII and M. HhaI at 0.8 unit/µg pDNA in either 
50 mM Tris-HCl, 5 mM 2-Mercaptoethanol, 10 mM EDTA, pH 7.5, for the methylation with 
M. HpaII or M. HhaI, or 10 mM Tris-HCl, 50 mM NaCl, 10 mM MgCl2, 1 mM DTT, pH 7.9, 
for the methylation with M. SssI each supplemented with 800 µM of S-adenosylmethionine. 
Complete methylation was confirmed by either HhaI, HpaII of BstUI restriction digest of the 
plasmids. For transfections the methylated pDNA was purified by phenol-chloroform 
extraction, PCR products by NucleoSpin® Extract columns (Macherey-Nagel). HpaII 
methylase was purchased from MBI Fermentas, HhaI M. and SssI M. from New England 
Biolabs. 
 
3.9.1  Phenol-Chloroform extraction 
The methylation reaction is supplemented with 50 µl of 3 M sodium acetate and adjusted with 
MQ to a total volume of 500 µl. An equal volume of phenol (pH 7.6-8.0, equilibrated with TE 
buffer), chloroform and isoamylcalcohol (25:24:1) is added. The mixture is vortexed for 
1 min and centrifuged for 5 min at 12,000 g. The upper, aqueous phase is transferred to a 
fresh tube and an equal volume of chloroform and isoamyl alcohol (24:1) is added. The 
mixture is vortexed for 30 sec and centrifuged at 12,000 g for 2 min. The upper phase is 
transferred to a fresh tube again, the same volume of ice-cold isopropyl alcohol is added to 
precipitate the DNA. For complete precipitation the samples are incubated at –20 °C for 1 h 
and centrifuged at 4 °C for 45 min at 12,000 g. The pellet is rinsed with ice-cold ethanol 
(70%) and dried in the laminar flow. Finally the pellet is solved in 50 µl sterile MQ. 
 
3.10 Transfection methods 
3.10.1  Lipofection of HeLa cells 
Before transfection, cells were plated into a 24-well tissue culture plate at a density of 4 x 10
4 
cells per well for 24 h, so that 60-80% of the cells were confluent at the time of transfection. 
Plasmid DNA of the luciferase reporter gene construct (0.4  µg) and internal standard 
pCMVSEAP (0.02  µg) were diluted into 50  µl of serum free DMEM and incubated with 
Plus reagent (Invitrogen) for 15 min. Precomplexed plasmid DNA was mixed with 25 µl of 
1:50 in serum free DMEM diluted Lipofectin reagent (Invitrogen) and incubated for 30 min   Materials and Methods   
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at room temperature. Meanwhile the medium of the cells was replaced by 200 µl of fresh 
serum free medium and the DNA-PLUS-Lipofectin reagent complex was added to the cells 
and incubated for 3 or 5 h at 37 °C in 5% CO2. Then 1 ml of medium containing 15% (v/v) 
FCS was added. 24  h after transfection the medium was removed, replaced by 100  µl of 
DMEM medium and luciferase activity was determined. 
 
3.10.2  Calcium phosphate transfection method for HeLa cells 
For reporter gene assays cells were, 24 h prior to transfection, plated into a 24-well tissue 
culture plate at a densitiy of 4 x 10
4  cells per well, so that 60-80% of the cells were confluent 
at the time of transfection. For the transfection 0.8 µg plasmid DNA of the luciferase reporter 
gene construct, and 0.02 µg of internal standard pCMVSEAP were used per well. For the 
preparation of the precipitate 20 µg of the reporter gene plasmid and 0.5 µg of pCMVSEAP 
were diluted in 450 µl of sterile MQ and mixed with 50 µl of 2.5 M CaCl2 solution. The 
mixture is then added dropwise (within 1 min) to 500 µl of HeBS buffer pH 7.08 (50 mM 
HEPES, 28 mM NaCl, 1.5 mM Na2HPO4) while bubbling air into the suspension in order to 
mix instantly DNA and phosphate buffer. After another min of incubation time 40 µl of the 
calcium phosphate-DNA precipitation per well are added to the cells. The medium was 
changed 16 h after transfection. Usually 24 h later the cells were harvested. The medium was 
again changed, 100 µl of fresh medium were added and luciferase activity was determined. If 
at all, cells were incubated directly after changing the medium.  
 
3.10.3  Electroporation of MM6 cells 
According to Niko Klan (Klan and Steinhilber 2003), 48 h to 72 h before transfection, cells 
were split to 2 x 10
5 cells/ml and cultured at 37 °C in an humified atmosphere of 5% CO2. At 
the time of transfection, cells were harvested by centrifugation at 1200 rpm for 5 min at RT 
and washed twice with RPMI-1640, containing neither FCS nor other additives. Then cells 
were resuspended at a density of 40  x  10
6 cells/ml in RPMI-1640 medium without any 
additives. 0.3 ml of cell suspension were placed into a 0.4 cm electroporation cuvette. 40 µg 
of plasmid DNA (reporter gene construct) and 1 µg of internal standard (pCMVSEAP) were 
dissolved in water to a final volume of 30 µl and added to the cell suspension. Cells and 
plasmids were preincubated for 5 min at RT before electroporation at 975 µF and 200 V in the 
Biorad Gene Pulser  II. Immediately after the pulse, the cuvettes were placed on ice for 
20 min. Finally the transfected cells were transferred to 10 ml of cell culture medium. Cells 
were harvested 6 h later, since the Luciferase signal peaked at 6 h after transfection.   Materials and Methods   
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3.11 Reporter gene assays 
To determine the activity of the different 5-LO promoter constructs under various conditions 
cell lysates were assayed for luciferase activity by measuring light emission in a Microlumat 
Plus LB96V EG&G Berthold Luminometer. The light emission was integrated for 5 sec when 
measuring the luciferase signal whereas the signal of the internal standard (SEAP activity) 
was only integrated for one sec. Considering different transfection efficiencies the luciferase 
activity was normalized to the SEAP activity.  
 
3.11.1  Luciferase assay 
MM6 cells were harvested 6 hours after transfection, emptying the cell culture flasks into 
10 ml falcon tubes, centrifuging the cells for 2 min at 1200 rpm at RT. Due to increased cell 
death after the stressing electroporation procedure highest luciferase signals are achieved after 
6 h after transfection and are decreasing when cells are collected at later times. 33 µl of the 
medium is saved for the SEAP assay, the rest of the medium is decanted and the falcons are 
put upside down on a cellulose to dry the pellets. Cells are resuspended in 100 µl of PBS and 
lysed in 100  µl of lysis buffer of the Steady- or Bright-Glow luciferase assay system 
(Promega) containing the luciferase substrate luciferin, which is converted by 
Firefly-luciferase to oxyluciferin under the emission of light. The lysated cells are transferred 
to a white 96 well plate, which is measured in the luminometer. 
HeLa cells are harvested, if not otherwise indicated, 24  h after removing the Calcium 
phosphate precipitation and changing the medium. 33 µl of medium are saved for the SEAP 
assay. Then, the medium is replaced by 100 µl of fresh HeLa medium, 100 µl of lysis buffer 
are added and the procedure is followed as described above for the MM6 cells. 
 
3.11.2  SEAP (Secreted Placental Alkaline Phosphatase) assay  
The activity of the internal standard was determined using the Phospha-Light
TM system kit 
from Applied Biosystems. According to the manufacturers recommendations 33  µl of the 
medium of the transfected cells are mixed with 100 µl of dilution buffer and incubated at 
65 °C for 30 min to heat inactivate endogenous alkaline phosphatases. To measure the activity 
of the transfected SEAP, 50 µl of the conditioned medium are transferred to a 96 well plate, 
preincubated for 5 min at RT with 50 µl assay buffer (containing inhibitors for endogenous 
alkaline phosphatases) and finally incubated for 20  min with 50  µl of  reaction buffer   Materials and Methods   
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containing the Tropix CSPD
® chemoluminescent substrate for the secreted alkaline 
phosphatase. Light emission is measured and the signal is integrated for one sec. 
 
3.12 Gel shifts 
All oligonucleotides were synthesized by Sigma-Genosys (Steinheim). For methylation 
studies, either the inner CpG dinucleotide was methylated at the 5´-position of the cytosine or 
CpG dinucleotides surrounding the Sp1 binding sites were methylated . Oligos were dissolved 
in sterile MQ at 100  µM concentrations. For annealing, 1  µl the forward and 1  µl of the 
complementary reversed strand oligo were mixed in 98 µl MQ and heated up to 95 °C for 
5 min, then the probes were cooled down at 0.02 °C/sec to room temperature. 
3.5  µl of the double-stranded oligonucleotides were labeled at the 5´-ends using 
T4 polynucleotide kinase in 20 µl of reaction volume containing 10 µCi of [γ-
32P]-ATP (GE 
Healthcare). After stopping the reaction with 29 µl of TE buffer pH 8.0, 1 µl of EDTA pH 8.0 
(0.5  M) and heat inactivation at 68  °C the radio-labeled double-stranded oligonucleotides 
were purified through G-25 microspin columns (GE-Healthcare), and stored at –20  °C. 
1-10 µg of nuclear extract, and/or Sp1 protein (150-300 ng, Promega) were preincubated in 
binding buffer (50  mM Tris-HCl, 2.5  mM DTT, 250  mM NaCl, 5  mM MgCl2, 2.5  mM 
EDTA, 20% glycerol) for 10 min at RT before the labeled oligonucleotide probe (40,000 cpm 
to 150,000 cpm; as indicated in the figures) was added to a total reaction volume of 20 µl. For 
competition studies, a 100-fold molar excess of unlabeled oligonucleotide was added to the 
reaction mixture prior to the addition of radio-labeled probe. EMSA reactions were resolved 
on 4-20% pre-run (200 V for 60 min in an ice bath) nondenaturing polyacrylamide TBE gels 
(BioRad premade) which were electrophoresed at 100 V for 110 min in an ice bath. Gels were 
dried under vacuum before exposure, or exposed directly to Fuji Super RX film at –20 °C or 
to a FLA 3000 imaging plate at RT for the indicated exposure times. 
 
Forward strands of EMSA probes 5´ to 3´   
CTGCGGGGGCGGGGGCGGGGGCGGGGGCGGGGGCGGGGGCAG  5 x GC box 
CTGCGGGGGOGGGGGOGGGGGOGGGGGOGGGGGOGGGGGCAG 5 x GC box methylated  
CAGACCGGGGCGGGGCCGGGACCGGGGC  Consensus Sp1 site / GC box 4 
CAGACOGGGGCGGGGCOGGGACOGGGGC  Consensus Sp1 site / GC box 4 methylated around 
the Sp1 binding motif 
CAGACCGGGGOGGGGCCGGGACCGGGGC  Consensus Sp1 site / GC box 4 methylated within 
the Sp1 binding motif   Materials and Methods   
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GACCGGGGCCAGGGACCAGTGGTGGGAGGAGGCTGCGGCGC  Non-consensus Sp1 site / GC box 5 41 bp 
GACOGGGGCCAGGGACCAGTGGTGGGAGGAGGCTGOGGOGC  Non-consensus Sp1 site / GC  box  5 41  bp 
methylated around the Sp1 binding motif 
AGTGGTGGGAGGAGGCTGCGGCGCT  Non-consensus Sp1 site / GC box 5 20 bp 
GATCGAACTGACCGCCCGCGGCCCGT  Ap2 binding site as unspecific competitor 
ATTCGATCGGGGCGGGGCGAGC  classical Sp1 binding motif as specific competitor  
Tab. 2 Forward strands of EMSA probes 5´ to 3´ 
 
3.13 DNA affinity purification assays (DAPA) 
This assay is based on the immobilization of protein-DNA complexes via binding of a 
biotinylated oligonuceotide to a streptavidin matrix. Oligonucleotides, only the forward strand 
was biotinylated at the 5´-end, were synthesized by Sigma-Genosys (Steinheim). Sense and 
antisense oligonucleotides were dissolved in 10-fold annealing buffer (0.5 M NaCl, 0.2 M 
Tris-HCl pH 8.0) to an end concentration of 50 µM, heated for 5 min at 95°C and annealed by 
decreasing the temperature down to RT in steps of 0.02°C/sec.  
200 µl of whole cell extract were incubated with 200 µl of binding buffer H (100 mM KCl, 
20 mM HEPES [pH 7.8], 20% glycerol, 1 mM DTT, 0.1% NP40) and 2 µl of the biotinylated 
double-stranded oligo mixture for one hour on ice. After adding 50  µl of equilibrated 
streptavidin-coupled agarose beads (Sigma, S1638) incubation was continued for 30 min at 
4 °C on a spinning wheel. The beads were washed four times with 500 µl of binding buffer by 
swaying the tubes 6-8 times and finally boiled with 20 µl of MQ and 5 µl of 5 x Laemmli 
sample buffer (250 mM Tris-HCl pH 6.8, 5 mM EDTA, 50% Glycerol, 10% SDS, 0.05% 
BPB, 10% β-Mercaptoethanol). The proteins were separated via SDS-PAGE.  
 
Forward strands of DAPA probes 5´ to 3´   
CTGCGGGGGCGGGGGCGGGGGCGGGGGCGGGGGCGGGGGCAG  5 x GC box 
CAGACCGGGGCGGGGCCGGGACCGGGGC  Consensus Sp1 site / GC box 4 
CAGACCATCTGCAGCCCGGGACCGGGGC  Consensus Sp1 site / GC box 4 mutated 
GACCGGGGCCAGGGACCAGTGGTGGGAGGAGGCTGCGGCGC  Non-consensus Sp1 site / GC box 5  
GACCGGGGCCAGGGACCAGTGGTGATCTGCAGCTGCGGCGC  Non-consensus Sp1 site / GC box 5 mutated 
Tab. 3 Forward strands of DAPA probes 
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3.14 Chromatin immunoprecipitation assay (ChIP) 
ChIP assays were performed as described by Väisänen (Vaisanen et al. 2005). In brief, 
nuclear proteins were crosslinked to genomic DNA by adding formaldehyde directly to the 
medium to a final concentration of 1% (v/v), for 10 min at 37°C. Cross-linking was stopped 
by adding glycine to a final concentration of 0.125 M and incubating at room temperature for 
five minutes on a rocking platform. The medium was removed and the cells were washed 
twice with ice-cold PBS (140  mM NaCl, 2.7  mM KCl, 1.5  mM KH2PO4, 8.1  mM 
Na2HPO4⋅2H2O). 
After lysis in Pipes buffer (5 mM Pipes (pH 8.0), 85 mM KCL, 0.5% NP-40 plus protease 
inhibitors) and SDS buffer (1% SDS, 10 mM EDTA, 50 mM Tris-HCl (pH 8.1) plus protease 
inhibitors) cells were sonicated to DNA fragments of 300-1000 bp in length. The cellular 
debris was removed by centrifugation and the lysates were diluted 1:10 (v/v) in ChIP dilution 
buffer (16.7 mM Tris-HCl (pH 8.1), 0,01% (w/v) SDS, 1.1% (v/v), Triton X-100, 1.2 mM 
EDTA, 16.7 mM NaCl, protease inhibitors). 
To remove unspecific background, the chromatin suspensions were incubated with a salmon 
sperm DNA / protein A agarose slurry (Upstate Biotechnology, Lake Placid, NY, USA) at 
4°C for 30 min with agitation. The samples were centrifuged and the recovered chromatin 
solutions were incubated over night at 4°C with 5 µl of the indicated antibodies. The immuno-
complexes were collected with 60 µl of protein A agarose slurry at 4°C for two hours with 
rotation. The beads were pelleted by centrifugation at 4°C for one minute at 100g and washed 
sequentially for five minutes by rotation with 1 ml of the following buffers: low-salt wash 
buffer (20  mM Tris-HCl (pH  8.1), 0.1% SDS, 1% Triton  X-100, 2  mM EDTA, 150  mM 
NaCl), high-salt wash buffer (20 mM Tris-HCl (pH8.1), 0.1% SDS. 1% Triton X-100, 2 mM 
EDTA, 500 mM NaCl) and LiCl wash buffer (10  mM Tris-HCl (pH  8.1), 0.25  mM LiCl, 
1% (v/v) Nonidet P-40, 1% (w/v) sodium deoxycholate, 1 mM EDTA). Before elution the 
beads were washed twice with TE-buffer (10  mM Tris-HCl, 1  mM EDTA, pH  8.0) The 
immuno-complexes were then eluted by adding 250 µl of elution buffer (1% SDS, 100 mM 
NaHCO3) and incubated at room temperature for 15 min with rotation. After centrifugation, 
the supernatant was collected and the elution was repeated. The supernatants were combined 
and the cross-linking was reversed by adding NaCl to final concentration of 200 mM and 
incubating at 65°C overnight. The remaining proteins were digested by adding proteinase K 
(final concentration 40 µg/ml) and incubation at 45°C for one hour. The DNA was recovered 
by extraction with phenol/chloroform/isoamyl alcohol (25:24:1, by volume) and precipitated   Materials and Methods   
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with 0.1 volume of 3 M sodium acetate (pH 5.2) and two volumes of ethanol using glycogen 
as a carrier.  
Subsequently, the immuno-precipitated genomic DNA was used as a template for PCR. 10 ng 
of each immunoprecipitated DNA was used as template for the PCR reactions with the 
following profile: preincubation at 94°C for 5  min, 40  cycles denaturation at 95°C for 
30 seconds, annealing at primer-specific temperature for 30 seconds and elongation at 72°C 
for 30 seconds, with one final incubation at 72°C for ten minutes. The PCR products, loaded 
with SybrGreen, were separated by electrophoresis through 2.0% agarose and the gel images 
scanned on a Fuji FLA3000 reader. Antibodies for Sp1, [(H-225) sc-14027], Sp3 [(D-20) 
sc-644] and RNA polymerase  II [polII (n-20) sc-899] were purchased from Santa Cruz 
Biotechnology, Heidelberg. Antibody for acetylated histone H4 from Upstate, Lake Placid, 
H4 #06-866. PCR reactions were run in an IQ-cycler, Biorad, Hercules (USA). 
 
PCR primer sequences   Location within the 5-LO promoter  
(in relation to 5-LO TIS) 
5´-CACAAACCCAAGACAGTATGAGGAGATG-3´ 
5´-CACGGGTCGGCTCTCTGAATCG-3´ 
-1049 to -714 
5´-CGATTCAGAGAGCCGACCCGTG-3´ 
5´-CTTCCACCCTTTGCCCTGCCTG-3´ 
-735 to -292 
5´-GCAGGCAGGCAGGGCAAAGGGTGGAAG-3´ 
5´-AGCAGCGAGCGCCGGGAG-3´ 
-318 to +52 
5´-AGGAACAGACACCTCGCTGAGGAG-3´ 
5´-GAGGCTGAGGTAGATGTAGTCGTCAGTG-3´ 
-219 to +143 
Tab. 4 PCR primer sequences for ChIP and their location within the 5-LO promoter 
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4  Results 
4.1  Regulation of 5-LO gene expression by histone deacetylation 
4.1.1  5-LO promoter activity is induced by the histone deacetylase inhibitor TsA 
In  Mono Mac 6  (MM6)  cells 5-lipoxygenase mRNA levels are induced 10.6-fold after 
treatment with the histone deacetylase inhibitor trichostatin A (TsA). In reporter gene assays 
we could also show that TsA induces 5-LO promoter activity, both in HeLa and in MM6 
cells, independent of transforming growth factor (TGFβ) and 1,25-dihydroxyvitamin D3 
(1,25(OH)2D3) (Klan et al. 2003). Since the activity of the core promoter fragment N10, 
comprising the region -843 bp to -12 bp (in relation to the 5-LO ATG), was strongly induced 
by TsA, successive deletion variants, of the 5-LO promoter, N11 to N16, were transfected 
into HeLa cells and stimulated with TsA for 24 h, in order to identify the region entailing 
HDAC activity. 
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Fig. 16 Schematic overview of the 5-LO promoter and reporter gene deletion variants. The largest 
reporter gene construct N0 comprises the sequence -6144 bp to –12 bp of the 5-LO promoter sequence 
in relation to the ATG of 5-LO. The most active promoter construct is the plasmid N10, containing 
eight consensus Sp1 binding sites and three non-consensus binding sites. N10∆GC is a special 
deletion variant of N10, lacking the central Sp1 binding sites. Further depicted are successive deletion 
variants of the promoter construct N10, differing in size and GC  box content. N15, the smallest 
construct depicted, just covers the major transcription initiation site (TIS). 
N11 is still containing the sequences –294 bp to –12 bp, N12 –206 bp to –12 bp, N13 –143 bp 
to –12 bp, N14 –96 bp to –12, N15 –67 bp to –12 bp (just comprising the major transcription 
initiation site), and N16, lacking the TIS, only comprising the sequence from –35 bp to –12 bp  Results  
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(all in relation to the 5-LO ATG). N10∆GC (also N10dGC) is a deletion variant of N10 
lacking the sequences –258  bp to –96  bp, including the central Sp1/Egr1 binding sites 
(compare the chart of Fig. 16). The reporter gene data show an induction of the larger 
promoter constructs N10, N11, N12 and N13, whereas the smaller constructs, N14 to N16, do 
not respond to the histone deacetylase inhibitor treatment (see Fig. 17).  
Fig. 17 Induction of 5-LO promoter activity of successive deletion variants by TsA in reporter 
assays in HeLa cells. The cells were seeded in 24 well plates and transfected with 0.8 µg of the 
promoter luciferase reporter gene constructs together with receptor expression vectors pSG5hRXR 
and pSG5hVDR (0.1 µg each) and 0.02 µg of pCMVSEAP per well by calcium phosphate method. The 
medium was changed 16 h after transfection and the cells were incubated either with solvent or with 
TsA (330 nM) for 24 h. Then luciferase activity was determined. Each experiment was performed in 
triplicates. Results are presented as mean + SE of three independent experiments after normalization 
for transfection effeciency by cotransfection of pCMVSEAP. A: Relative activity in untreated cells B: 
Inductions by TsA, expressed with respect to the untreated and transfected cells. 
It is possible, that the loss of induction by TsA is due to the loss of promoter function, since 
the shorter reporter gene constructs only have weak promoter activity. Nevertheless, construct 
N14 is still 5-fold more active than the promoterless construct pGl3Basic.  
 
4.1.2  Mutations of Sp1 binding sites relieve the response to TsA 
Besides in length, the deletion variants also differ in their content of Sp1 binding sites. In 
silico analysis of of the 5-LO promoter reveals eight different consensus binding sites within 
the proximal promoter area of –294 bp. Sp1 binding to and transactivation of the proximal 
promoter area has been shown in DNase I footprints and gel shift assays for the stretches 
-179 bp to -147 bp (containing the 5xGC box), -224 bp to -218 bp (GC2),  -118 bp to -109 bp 
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(GC4) and -85  bp and -66  bp (GC5) as well as in reporter gene assays (In et al. 1997; 
Silverman et al. 1998; Dishart et al. 2005).  
In different genes, e.g. p21, TGFβ type II receptor, induction of promoter activity by TsA has 
been linked to Sp1 binding sites within the promoter sequence (Sowa et al. 1997; 
Ammanamanchi and Brattain 2001; Ammanamanchi et al. 2003). Reporter gene assays with 
the 5-LO constructs suggest, that the response to TsA is dependent on an element still present 
in construct N13, comprising  -143 bp to –12 bp in relation to the 5-LO ATG, but not in the 
shorter construct N14, comprising only –96 bp to –12 bp. For this reason mutations of the two 
Sp1 binding sites, GC box 4 (still present in N13, but not in N14) and GC box 5 (still present 
in N14), have been introduced via site-directed mutagenesis into the minimal promoter 
constructs N13 and N14. The resulting plasmids N13GC4 (GC box 4 is mutated), N13GC5 
(mutated GC  box  5), the double mutated construct N13GC45 and N14GC5 have been 
transfected into HeLa cells and their activity as well as their response to TsA have been 
measured (see Fig. 18).  
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Fig. 18 Point mutations of Sp1 binding sites relieve response of 5-LO promoter constructs to the 
histone deacetylase inhibitor TsA in HeLa cells. The cells were transfected by the calcium phosphate 
precipitation method with the wild–type or mutated reporter gene constructs (0.8 µg of reporter gene 
construct, 0.02 µg of pCMVSEAP per well). The medium was changed 16 h after transfection and the 
cells were incubated either with solvent or TsA (330  nM) for 24  h. Then, luciferase activity was 
determined. Each experiment was performed in triplicates. Results are presented as mean + SE of six 
independent experiments after normalization for transfection effeciency. Inductions are expressed with 
respect to the untreated cells. 
Trichostatin A induces the promoter activity of plasmid N10 up to 34.8-fold. Construct GC0, 
lacking the 5-fold GC box, is slightly less induced, 28.0-fold, and the shorter deletion variant 
N13, also lacking the tandemized GC box, in these experiments is strongly induced up to  Results  
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61.0-fold. The mutation of GC box 4 in N13GC4 attenuates the response to TsA comparable 
to the level of the shorter construct N14, lacking GC box 4 at all (inductions 2.8-fold and 
3.9-fold respectively). Mutation of GC box 5 also strongly decreases the activating effect of 
TsA, but not to the same extent (8.9-fold induction of N13GC5). Looking at the activity of the 
constructs itself (without TsA treatment, see Fig. 19) mutation of GC box 4 almost reduces 
the promoter activity to the level of the promoterless pGl3Basic construct. Mutation of GC5 
enhances promoter activity 2.1-fold, the double mutation results in a loss of promoter activity. 
When the cells are treated with TsA, mutation of GC box 4 in N13 again abolishes promoter 
activity, mutation of GC5 also reduces promoter activity (3.2-fold).  
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Fig. 19 Relative activity of the GC box-mutated constructs N13 and N14 in HeLa cells. The cells 
were transfected by the calcium phosphate precipitation method with the wild–type or point mutated 
reporter gene constructs (0.8 µg of reporter gene construct, 0.02 µg of pCMVSEAP per well). The 
medium was changed 16 h after transfection and the cells were incubated either with solvent or with 
TsA (330 nM) for 24 h. Then luciferase activity was determined. Each experiment was performed in 
triplicates. Results are presented as mean + SE of six independent experiments after normalization for 
transfection effeciency. Inductions are expressed with respect to the untreated cells. 
From these data we conclude, that the proximal Sp1 binding sites GC4 and GC5 recruit 
HDAC activity. In the minimal promoter construct N13, GC box 4 is an activating element, 
whereas GC box 5 has repressing features. It seems, that in HeLa cells an transcriptional 
activator preferably binds to GC box 4, whereas some repressor is recruited to GC box 5. 
After the treatment with the histone deacetylase inhibitor TsA the formerly repressive 
function of GC box 5 is reversed into an activating function.  Results  
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4.1.3  Response to TsA in a larger promoter context  
The same mutations of the Sp1 binding sites GC4 and GC5 were cloned into the larger and 
most active 5-LO promoter construct N10, to investigate the relevance and functionality of 
these sites in a larger promoter context. In addition to GC4, GC5, and the 5-fold GC box, N10 
contains several more putative Sp1 binding sites (compare Fig. 3 page 9). The consensus 
motifs GC1 (-133 to -139 bp) and GC2 (-116 to -139 in relation to 5-LO ATG), still present in 
the CpG island comprising the core promoter region, and two non-consensus motifs in the 
distal CpG island, GC6 (-770 to -765) and GC7 (-720 to -725) were also introduced into N10, 
resulting in the constructs N10GC6, N10GC7, N10GC1 and N10GC2. GC0 lacks the 5-fold 
GC box. Sp1 binding to element GC2 had been demonstrated before in DNase I footprints 
(Silverman et al. 1998). 
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Fig. 20 Mutation of Sp1 binding sites in the reporter gene construct N10 and their response to TsA. 
HeLa cells were transfected by the calcium phosphate precipitation method with the wild–type or 
mutated reporter gene constructs (0.8 µg of reporter gene construct, 0.02 µg of pCMVSEAP per well). 
The medium was changed 16 h after transfection and the cells were incubated either with solvent or 
TsA (330 nM) for 24 h. Then luciferase activity was determined. Each experiment was performed in 
triplicates. Results are presented as mean + SE of five independent experiments after normalization 
for transfection effeciency. Inductions are expressed with respect to the untreated cells. 
The mutation of the different GC boxes within the larger promoter context of construct N10 
showed weaker influence on the response to TsA than in the minimal promoter plasmid N13 
(see Fig. 20). The mutations of GC7 and GC1 do not efficiently influence the promoter 
response to TsA. Mutation of the distal non-consensus sites GC6 and especially of the 
proximal site GC5 even increase the effect of TsA. Only the deletion of the 5-tandem GC box 
and mutation of GC box 4 decrease the response to the histone deacetylase inhibitor (42% and  Results  
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11% respectively). In the larger promoter context the impact of discrete Sp1 binding sites is 
less pronounced than in the minimal promoter context of N13. 
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Fig. 21 Relative activity of the GC  box-mutated constructs cloned from N10. HeLa cells were 
transfected by the calcium phosphate precipitation method with the wild–type or mutated reporter 
gene constructs (0.8 µg of reporter gene construct, 0.02 µg of pCMVSEAP per well). The medium was 
changed 16 h after transfection and the cells were incubated either with solvent or TsA (330 nM) for 
24 h. Then luciferase activity was determined. Each experiment was performed in triplicates. Results 
are presented as mean +  SE of five independent experiments after normalization for transfection 
effeciency.  
The relative activity of the mutated constructs is only reduced, when GC4, GC5 and GC1 are 
mutated (44%, 54%, 40% respectively; with TsA treatment 35%, 56%, 31%, 46% (GC0) 
repectively). Also in the larger promoter context GC box 4 is necessary for the full promoter 
activity. In contrast to the data with the mutated sites in N13, in N10 also GC box 5 and 
GC box 1 are important for full promoter activity. 
 
4.1.4  Investigations on the role of particular Sp1 binding sites 
In order to examine the interdependence of discrete Sp1 binding sites, the particular mutations 
were combined in the reporter gene construct GC0, already lacking the 5-tandem GC box. 
The combination of different mutations in the complete construct N10 was impossible to 
accomplish, due to the presence of the 5-fold GC box, the resulting high GC content and the 
lack of restriction sites. 
The generated constructs were termed according to the mutations carrying, e.g. GC0GC4 is 
equivalent to construct GC0 with an additional mutation in GC  box  4. GC0GC12 is 
equivalent to GC0, holding extra mutations in the binding sites GC 1 and GC 2. The plasmids  Results  
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were transfected into HeLa cells and the promoter activity was determined in the luciferase 
assay (see Fig. 22).  
In these experiments the deletion of the 5-fold GC box significantly decreased the promoter 
activity, which was not the case in an other series of experiments. Mutations of any other Sp1 
binding site further reduced the promoter activity, especially the mutation of GC4. The 
combination of two and more mutated binding site resulted finally in a complete loss of 
promoter activity (compare GC0GC1245). 
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Fig. 22 Mutation of Sp1 binding sites in the reporter gene construct GC0, relative activity and 
response to TsA. HeLa cells were transfected by the calcium phosphate precipitation method with the 
wild–type or mutated reporter gene constructs (0.8  µg of reporter gene construct, 0.02  µg of 
pCMVSEAP per well). The medium was changed 16 h after transfection and the cells were incubated 
either with solvent or TsA (330  nM) for 24  h. Then luciferase activity was determined. Each 
experiment was performed in triplicates. Results are presented as mean + SE of three independent 
experiments after normalization for transfection effeciency. Inductions are expressed with respect to 
the untreated cells. A: x-fold induction by TsA, B and C RLUs without and with TsA treatment 
respectively.  Results  
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The response to trichostatin A was reduced strongest when GC4 was additionally mutated. 
The combined mutations of GC4 and GC5 further decreased the effect of TsA, any extra 
mutation eliminates the effect.  
Together these results underline the importance of GC box 4 for the full promoter activity of 
5-LO in HeLa cells in the minimal construct N13 and in the larger promoter constructs N10 
and GC0, as well as the relevance of this site in respect to the recruitment of histone 
deacetylase activity. The results also suggest an additive effect of the particular sites in the 
promoter activation, independent of any stimulus. 
 
4.1.5  Reporter gene assays with mutated constructs in MM6 cells  
The same experiments were performed in the 5-LO expressing cell line Mono  Mac  6, to 
investigate the influence of the cellular context on the promoter activity and the response to 
the histone deacetylase inhibitor TsA. Mutation of the GC  boxes GC1, GC2 and GC5 in 
construct N10 do not influence the response of the 5-LO promoter to TsA. Mutation of GC4 
strongly reduces the induction by TsA, so does the deletion of the tandem GC box, but to a 
lesser extent (58% versus 32%). These data are in accordance with the results achieved in 
HeLa cells (compare Fig. 23 with Fig. 20). 
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Fig. 23 Induction of 5-LO promoter constructs by histone deacetylase inhibitor trichostatin A in 
MM6 cells. 72 h before transfection cells were seeded at 2 x 10
5 cells/ml. For the electroporation 
procedure the cells were suspended at a density of 40 x 10
6 cells/ml in RPMI-1640 medium without 
any additives. 0.3 ml of the cells suspension were placed into a 0.4 cm electroporation cuvette. 40 µg 
of reporter gene plasmid and 1 µg of internal standard pCMVSEAP were dissolved in MQ and added 
to the suspension. Electroporation was performed in a Biorad Gene Pulser at 975 µF and 200 V. The 
transfected cells were transferred to 10 ml of cell culture medium and incubated with 330 nM TsA.  Results  
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After 6  h, the cells were harvested and luciferase activity was determined. Each experiment was 
performed in triplicates. Results are presented as mean + SE of 2-4 independent experiments after 
normalization for transfection efficiency. Inductions are expressed with respect to the transfected but 
untreated cells. 
Looking at the minimal promoter constructs, in MM6 cells, TsA induces the shortest construct 
N14 to the same extent as construct N13 (see Fig. 23). This finding is in contrast to HeLa 
cells, in which N13 is 15.6  x higher induced than N14 (compare Fig. 20). The higher 
induction in HeLa cells is probably caused by the different incubation times used for the two 
cell lines. Mono Mac 6 cells could only be incubated with TsA for 6  h (due to the low 
survival rate of the cells after the electroporation procedure and the fast decay of luciferase 
activity), whereas HeLa cells were incubated for 24  h before the promoter activity was 
determined. As in HeLa cells, the mutation of GC4 in construct N13 attenuates the TsA 
response, but in contrast to, the mutation of GC5 does not alter the TsA response. 
Interestingly the same mutation in N14 leads to a loss of induction by TsA. Also in contrast to 
the results obtained in HeLa cells, both GC boxes are required for full promoter activity in 
N13, irrespective to the treatment with the histone deacetylase inhibitor (see Fig. 24). 
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Fig. 24 Relative promoter activity of mutated construct N13 in MM6 cells. The electroporation 
procedure was performed as described in Fig. 23. Each experiment was performed in triplicates. 
Results are presented as mean + SE of 3 independent experiments after normalization for transfection 
effeciency.  
 
Within the larger promoter context of construct N10 the mutation of GC box 4 does not result 
in a decrease of promoter activity. Only after treatment with TsA the activity is significantly 
reduced, when GC box 4 is mutated.  Results  
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Fig. 25 Relative promoter activity of mutated construct N10 in MM6 cells. The electroporation 
procedure was performed as described in Fig. 23. Each experiment was performed in triplicates. 
Results are presented as mean +  SE of 2-4 independent experiments after normalization for 
transfection effeciency.  
 
These results suggest a similar role for GC box 4 in both cell lines. Possibly other factors are 
recruited to the non-consensus site GC5, whose presence in MM6 cells is also necessary for 
full promoter activity. 
 
4.1.6  Activity and TsA response of more distal promoter parts 
Reporter gene assays with successive deletion variants of the 5-LO promoter revealed 
positively and negatively regulated DNA stretches (Hoshiko et al. 1990; Sorg et al. 2006). In 
HeLa cells as in MM6 cells, N10 displays the highest promoter activity. The promoter activity 
of construct N9 (the next larger reporter gene construct, extended by 135 bp, see Fig. 26) is 
already decreased by 50% compared to the activity of N10. This part of the 5-LO promoter 
sequence is part of a second CpG island, including two more potential Sp1 binding sites, GC8 
and GC9. Activity and response of the plasmids N7, N8 and N9 to the histone deacetylase 
inhibitor TsA were determined in reporter gene studies. These experiments were only 
performed in HeLa cells.  Results  
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Fig. 26 Schematic overview of the reporter gene constructs N7, N8 and N9. Covered by these 
plasmids are more distal promoter parts. In the distal end of N10 starts a second CpG  island, 
containing additional Sp1 binding sites. CpG islands are characterized by an above average 
GC content, a minimum length of 200 bp and an observed/expected presence of CpG greater than 0.6. 
The distal extension of the promoter plasmids reduces promoter activity (see Fig. 27). N9 
already looses 50% of the promoter activity of N10. N8 and N7 display comparable promoter 
acitivity to N9, indicating the presence of repressive elements within the promoter extension 
of N9, comprising an additional sequence of 135 bp compared to N10. Additional treatment 
of the less active promoter plasmids with TsA results in an increase of promoter activtiy, and 
suggests recruitment of HDAC activity in this promoter region. However their promoter 
activity does not reach the level of N10 (data not shown). 
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Fig. 27 Relative activtiy and response to TsA of the reporter gene constructs N7, N8 and N9. HeLa 
cells were transfected by the calcium phosphate precipitation method (0.8  µg of reporter gene 
construct, 0.02 µg of pCMVSEAP per well). The medium was changed 16 h after transfection and the 
cells were incubated either with solvent or TsA (330  nM) for 24  h. Then luciferase activity was 
determined. Each experiment was performed in triplicates. Results are presented as mean + SE of  Results  
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three independent experiments after normalization for transfection effeciency. Inductions are 
expressed with respect to the transfected but untreated cells. 
To examine the influence of the two potential GC boxes in construct N9, both sites were 
mutated to inhibit transcription factor binding. Both mutations resulted in a decrease of 
promoter activity, indicating their activating character (see Fig. 28).  
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Fig. 28 Mutation of Sp1 binding sites in the reporter gene construct N9 reduces promoter activtiy 
and enhances the response to TsA. HeLa cells were transfected by the calcium phosphate 
precipitation method (0.8  µg of reporter gene construct, 0.02  µg of pCMVSEAP per well). The 
medium was changed 16 h after transfection and the cells were incubated either with solvent or TsA 
(330  nM) for 24  h. Then luciferase activity was determined. Each experiment was performed in 
triplicates. Results are presented as mean + SE of three independent experiments after normalization 
for transfection effeciency. Inductions are expressed with respect to the transfected but untreated cells. 
 
Additional deletion of the 5-fold GC box and the other proximal Sp1 binding sites GC1, GC2, 
GC4 and GC5 in construct N9GC01245, reduced promoter activity almost to the level of the 
promoterless plasmid pGl3Basic. (N9GC01245: 25 RLUs, pGl3Basic: 6 RLUs; N9: 188 
RLUs). The single mutations of GC8 and GC9 rather increased the promoter response to TsA, 
whereas the mutation of the proximal sites (GC0GC1245) abolished the induction by TsA. 
These results underline the importance of the proximal GC  boxes for basal and induced 
promoter activity. The elements GC8 and GC9 do not seem to be responsible for the 
repressive effects of construct N9, nor do they seem to recruit HDAC activity. 
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4.1.7  Time dependent induction of promoter activity after TsA treatment 
HeLa cells were transfected with the highly inducible reporter gene plasmids N10 and N13, as 
well as with the promoterless luciferase construct pGl3Basic and the SV40 promoter 
containing plasmid pGl3Prom as a positive control. After the removal of the calcium 
phosphate precipitate, the cells were incubated with or without 330 nM trichostatin A for 
either 4 h, 8 h, 12 h of 24 h. Then the promoter activity was determined.  
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Fig. 29 Time dependent induction of promoter activity in reporter assays after TsA treatment. HeLa 
cells were transfected by the calcium phosphate precipitation method (0.8  µg of reporter gene 
construct, 0.02 µg of pCMVSEAP per well). The medium was changed 16 h after transfection and the 
cells were incubated either with solvent (A) or TsA (330 nM) for 4 h, 8 h, 12 h or 24 h (B). Then 
luciferase activity was determined. Each experiment was performed in triplicates. Results are 
presented as mean +  SE of three independent experiments after normalization for transfection 
effeciency. Inductions are expressed in respect to untreated cells (C).  Results  
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Without TsA treatment promoter activity is steadily decreasing. When the cells were 
incubated with TsA the basal level of activity is highly increased already after 4 h, then the 
activity starts to decay. After 24 h, construct N10 and pGl3Prom, containing multiple Sp1 
binding sites (8 versus 6) gain back their full activity, but not the minimal construct N13. 
These data indicate an early activation of the 5-LO promoter and prolonged transcriptional 
activity after HDACi treatment. 
 
4.1.8  Effects of valproic acid and nicotinamide on 5-LO promoter activity 
As outlined in the introduction, three different families of histone deacetylases are 
distinguished. Class I HDACs consist of HDAC1, 2, 3 and 8; whereas class II consists of 
HDAC4, 5, 6, 7, 9, 10 and 11. Members of a third class, also called sirtuins, are structurally 
unrelated to the human class I and class II HDACs and consist of homologues of the highly 
conserved yeast Sir2 protein, NAD
+-dependent deacetylases. Nicotinamide, a product of the 
Sir2 deacetylation reaction, is an inhibitor of Sir2 activity, both in vivo and in vitro.  
The activity of class I and class II HDACs is inhibited, amongst others, by hydroxamic and 
short-chain fatty acids. The hydroxamic acid trichostatin A inhibits class I  and  class II 
HDACs, whereas the short-chain fatty acid valproic acid preferentially inhibits class I HDACs 
(Gottlicher et al. 2001; Gurvich et al. 2004).  
In order to identify the histone deacetylases involved in the regulation of the 5-LO promoter, 
the three inhibitors were tested in reporter gene assay (see Fig. 30 A). The 5-LO promoter 
construct N10 was transfected into HeLa cells and either incubated together with 330 nM 
TsA, 1 mM VPA (IC50 in HeLa cells ∼1 mM, data not shown) or 5 mM Nicotinamide for 
24 h.  
TsA activated the 5-LO promoter strongest, 14-fold after 24 h, followed by valproic acid, 
8-fold. Nicotinamide showed no effect (1.5-fold). Since VPA also significantly induces 5-LO 
promoter activity, the recruitment of class I HDACs seems evident, whereas the recruitment 
of sirtuins is beyond question. In the next experiment, the effect of VPA on the different 
deletion variants and mutants of construct N13 were tested.  Results  
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Fig. 30 Effect of different histone deacetylase inhibitors on 5-LO promoter activity. HeLa cells were 
transfected by the calcium phosphate precipitation method (0.8 µg of reporter gene construct N10, 
0.02 µg of pCMVSEAP per well). The medium was changed 16 h after transfection and the cells were 
incubated either with DMSO, TsA (330 nM), NA (5 mM) or VPA (1 mM) for 24 h. Then luciferase 
activity was determined. Each experiment was performed in triplicates. Results are presented as mean 
+ SE of 3-4 independent experiments after normalization for transfection effeciency. Inductions are 
expressed in respect to untreated cells. A: Reporter gene construct N10 was transfected into HeLa 
cells and incubated with the different HDAC inhibitors. B: The indicated plasmids were transfected 
and cells were incubated with 1 mM VPA. 
The single mutation of GC box 4 in N13GC4 and the mutation of both GC boxes reduced the 
activation by valproic acid down to the level of the promoterless plasmid pGl3Basic, 
comparable to the former experiments in HeLa cells (see Fig. 18). The mutation of GC5 had 
no infuence on basal of induced promoter activity (data not shown). 
 
4.1.9  Protein expression of Sp1 and Sp3 in HeLa and MM6 cells 
Whole cellular protein extracts of TsA treated and untreated HeLa and MM6 cells were 
prepared and examined by Western blot analysis, as described in “Materials and Methods” 3.3 
and 3.6. The protein expression of both transcription factors was unchanged after HDACi 
treatment in both cell lines. 
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Fig. 31 Endogenous protein expression of Sp1 and Sp3 in HeLa and MM6 cells. The cells were 
treated with or without 330 nM TsA for 24h before cell harvest. The preparation of the cell extracts is 
described in 3.3. The protein content was determined with Bradford assay and same amounts of 
treated and untreated extracts (10 µg) were loaded for SDS-PAGE and Western blot analysis (see 
3.6). Antibodies: anti-rabbit anti-Sp1 and anti-rabbit anti-Sp3. 
 
4.1.10  Coexpression studies with Sp1 and Sp3 in reporter gene assay 
Since the activating effect of the histone deacetylase inhibitors is related to the presence of 
two Sp1 binding sites, GC4 and GC5, binding of Sp1 and Sp3 to the different mutants of the 
5-LO promoter reporter gene construct N13 was tested. For this, expression plasmids for 
human Sp1 and Sp3 were cotransfected together with the promoter plasmids into HeLa cells 
and the promoter activity was determined. We expected a further increase of promoter activity 
at least by Sp1 since activation by this transcription factor has been shown before in SL2 
cells, which lack endogenous Sp1 or Sp3 expression.  
In HeLa cells, the cotransfection of Sp1 or Sp3 alone did not change promoter activity, which 
may be due to the high endogenous expression levels of both proteins. On the other hand 
promoter activity of construct N13 was induced after the cotransfection, when the cells were 
additionally treated with the histone deacetylase inhibitor trichostatin A, suggesting that TsA 
somehow enhances the binding or the transactivation by Sp1 and to a lesser degree by Sp3. In 
these experiments both proteins act as activators on the 5-LO gene expressionl. Sp3 in these 
experiments does not compete with Sp1 binding.  Results  
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Fig. 32 Cotransfection of Sp1 and Sp3 to 5-LO promoter constructs. HeLa cells were transfected by 
the calcium phosphate precipitation method with 0.8 µg of the indicated promoter plasmids and 0.1 µg 
of either the empty pCMV construct or the expression plasmids pCMVSp1 or/and pCMVSp3. The 
medium was changed 16 h after transfection and the cells were incubated either with solvent or TsA 
(330  nM) for 24  h. Then luciferase activity was determined. Each experiment was performed in 
triplicates. Results are presented as mean + SE of 3 independent experiments after normalization for 
transfection effeciency by cotransfection of pCMVSEAP.  
The promoter activity of the mutant N13GC4 is strongest induced after Sp1 cotransfection 
when the cells are treated with TsA, 11.7-fold, followed by N13GC5, 4.5-fold, and N14, 
3.9-fold. The effects on N13 and N10 are much weaker, 3.0-fold and 1.4-fold induction by 
Sp1 cotransfection respectively. Protein overexpression was checked in Western blot analysis 
(data not shown).  
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Fig. 33 x-fold induction by Sp1/Sp3 cotransfection. Experiments were performed as described above 
in Fig. 32.  Results  
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4.1.11  Effect of TsA on DNA binding affinity of Sp1 and Sp3 
Since the endogenous expression levels of the transcription factors Sp1 and Sp3 were not 
influenced by the treatment with the histone deacetylase inhibitor TsA, it was of interest to 
examine their binding affinities in response to TsA. A DNA affinity purification assay was 
established and binding of Sp1 and Sp3 to the proximal GC  boxes including the 5-fold 
tandemized GC box, the consensus site GC4 and the non-consensus site GC5 was analyzed. 
Specific protein binding to the probes was checked by mutating the GC  boxes and by 
incubating the cell extract only with beads (without a DNA probe).  
 
Forward strands of DAPA probes 5´ to 3´   
CTGCGGGGGCGGGGGCGGGGGCGGGGGCGGGGGCGGGGGCAG  5 x GC box  5xGC 
CAGACCGGGGCGGGGCCGGGACCGGGGC  Consensus Sp1 site / GC box 4  GC4 
CAGACCATCTGCAGCCCGGGACCGGGGC  Consensus Sp1 site / GC box 4 mutated  GC4M
GACCGGGGCCAGGGACCAGTGGTGGGAGGAGGCTGCGGCGC  Non-consensus Sp1 site / GC box 5   GC5 
GACCGGGGCCAGGGACCAGTGGTGATCTGCAGCTGCGGCGC  Non-consensus Sp1 site / GC box 5 
mutated 
GC5M
Tab. 5 DNA probes used in DNA affinity purification assay. Five different probes were investigated 
covering the proximal Sp1 binding sites of the 5-LO promoter. Depicted are the forward strands of the 
probes; 5xGC, covering the 5-fold GC  box, GC4, covering the consensus binding site, GC4M, 
covering the mutated GC box 4, GC5 and GC5M, covering the non-consensus binding site either with 
the wild-type or mutated sequence. 
 
2 µl of biotinylated DNA probes were incubated with 200 µl of whole cellular extract in 
200 µl of binding buffer H (100 mM KCl, 20 mM HEPES [pH 7.8] 20% glycerol, 1 mM 
DTT, 0.1% NP40) on ice for 1 h. Then 50 µl of streptavidin-coupled agarose beads (Sigma) 
were added to the mixture and incubated on a spinning wheel for another 30 min at 4°C. After 
washing the beads four times with 500 µl of binding buffer H the probes were boiled with 
20 µl of MQ and 5 µl of 5x laemmli sample buffer (250 mM Tris-HCl pH 6.8, 5 mM EDTA, 
50% Glycerol, 10% SDS, 0.05% BPB, 10% β-mercaptoethanol). The supernatant containing 
the proteins were separated by SDS-PAGE. The use of nuclear extracts instead of the 
whole-cell extracts resulted in unspecific protein binding. 
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Fig. 34 Principle of DNA affinity purification assay. Biotinylated DNA probes, either 
oligonucleotides or PCR fragments, are incubated with cellular extract. Depending on the protocol 
whole-cell extracts or nuclear cell extracts can be utilized. DNA binding proteins theoretically recruit  
cofactors. When these DNA-protein complexes have formed, the binding reaction is incubated with the 
streptavidin-coupled matrix, e.g. with agarose beads. This step is followed by washing steps with 
binding buffer, in order to reduce unspecific protein binding. To improve the specificity of protein 
binding, different salt concentrations, tensides or competitor DNA, such as salmon sperm DNA or 
synthetic polymers like poly(dA-dT)•poly(dA-dT), can be added to the binding reaction itself or to the 
washing steps. The proteins specifically binding can either be eluted from the beads, also using 
different salt concentrations or the complete mixture can be boiled with leammli buffer. The captured 
proteins are separated and identified by SDS-PAGE. 
 
The binding affinity of Sp1 in this assay neither with HeLa cell extract nor with MM6 cell 
extract seemed to be changed after the treatment with the histone deacetylase inhibitor (see 
Fig. 35). In HeLa cells the binding of Sp1 to the non-consensus binding site is less prominent 
than to the other sites, but independently of trichostatin A treatment. The DNA affinity of Sp3 
was also unchanged after HDACi treatment and did not differ between the probes (see Fig. 
36). 
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Fig. 35 DNA affinity purification assay with HeLa and MM6 cell extracts for Sp1. 200 µl  of 
whole-cell extract were incubated with 200  µl of binding buffer H and 2  µl of double-stranded 
biotinylated oligonucleotides for one hour on ice. The cell extracts were gained as described in 
“Materials and Methods”. The cells were either treated with TsA (330 nM) for 24h or with solvent. 
After adding 50 µl of equilibrated streptavidin-coupled agarose beads, the incubation was continued 
on a spinning wheel for 30 min at 4°C. The beads were washed four times with 500 µl of binding 
buffer and after taking off the supernatant the samples were boiled with 25 µl of 1x Laemmli sample 
buffer for 5 min at 95 °C. The DNA-binding proteins were separated by SDS-PAGE and analyzed by 
Western blot for the presence of Sp1. One representative example of at least two independent 
experiments is shown. 5xGC: 5-fold GC box as DNA probe; GC4: GC box 4 as probe; GC4M: DNA 
probe covering the mutated Sp1 binding site GC4; GC5 and GC5M respectively. M: All Blue Protein 
Marker (Biorad); ZE: sample of whole-cell extract, used in the DAPA; NE: nuclear extract; B: beads 
only. 
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Fig. 36 DAPA with HeLa and MM6 cell extracts for Sp3. The assay procedure is described in Fig. 
35. The DNA-binding proteins from the supernatant were separated by SDS-PAGE and analyzed by 
Western blot for the presence of Sp3. One representative example of at least two independent 
experiments is shown. 5xGC: 5fold GC box as DNA probe; GC4: GC box 4 as probe; GC4M: DNA 
probe covering the mutated Sp1 binding site GC4; GC5 and GC5M respectively. M: All Blue Protein 
Marker (Biorad); ZE: sample of whole-cell extract, used in the DAPA; NE: nuclear extract; B: beads 
only. 
 
4.1.12  In vivo binding of Sp1 and Sp3 to the 5-LO promoter in MM6 cells  
In chromatin immunoprecipitation (ChIP) assays the effect of TsA on the histone acetylation 
status of the 5-LO promoter and the in vivo binding of RNA polymerase II, Sp1 and Sp3 cells 
was examined in MM6 cells. These data were kindly provided by Dr. Sabine Seuter. Since the 
promoter activity in the reporter gene assays highly depends upon the proximal GC-rich 
sequences containing most Sp1 binding sites, ChIP analysis focused on the first 1000 bp just 
upstream of the TIS. 
ChIP assays were performed as described by Väisänen (Vaisanen et al. 2005). In brief, 
nuclear proteins were crosslinked to genomic DNA by adding formaldehyde directly to the 
medium (1%, 10 min at 37°C). After lysation in Pipes buffer (5 mM Pipes pH 8.0, 85 mM 
KCL, 0.5% NP-40 plus protease inhibitors) and SDS buffer (1% SDS, 10 mM EDTA, 50 mM 
Tris-HCl, pH  8.1 plus protease inhibitors) cells were sonicated to DNA fragments of 
300-1000 bp in length. The chromatin was then diluted in ChIP dilution buffer. After 
incubating the chromatin resuspensions with a salmon sperm DNA / protein A agarose slurry 
to remove unspecific background the recovered chromatin solutions were incubated over 
night at 4°C with the indicated antibodies. The immuno-complexes were collected with  Results  
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protein A agarose slurry. The beads were pelleted, washed with increasing salt concentrations 
and finally the immuno-complexes were eluted. The crosslink was reversed and the remaining 
proteins digested by adding proteinase K.  
Genomic DNA fragments were recovered using phenol-chloroform extraction. Subsequently 
the immuno-precipitated genomic DNA was used as a template for PCR. The amount of 
generated PCR product reflects the abundance of DNA binding proteins. The PCR products, 
loaded with SybrGreen, were separated by electrophoresis through 2.0% agarose and the gel 
images scanned on a Fuji FLA3000 reader (for a more detailed description of the procedure 
and the primer sequences used for the PCR reaction see 3.14 in “Meterials and Methods”). 
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Fig. 37 Chromatin immunoprecipitation assay of the 5-LO promoter in MM6 cells. A: Depicted are 
the gel scans of the obtained PCR products covering the proximal promoter region after 
immunoprecipitation with the antibodies against RNA polymerase II, the transcription factors Sp1 and 
Sp3 as well as with an antibody against acetylated histone H4 protein, giving information about the 
activation status of the promoter. As controls, PCRs were run with DNA from recovered chromatin 
directly after reversing the cross-linking (input bands), after precipitation with IgG (IgG bands), and 
after immunoprecipitation without any antibody (no ab bands) to exclude unspecific bands. B: The 
four regions examined in the ChIP are equivalent to the GC rich proximal promoter area, containing  Results  
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several Sp1/Sp3 binding sites. Please note, that the numbering is in relation to the major TIS (=+1) of 
the 5-LO promoter and not in relation to ATG. 
 
The high acetylation status of histone H4 (acetylation of K5, K8, K12, K16), without any TsA 
treatment indicates an open and transcriptional active chromatin structure of the 5-LO gene 
promoter area. Nevertheless the 5-LO mRNA expression level in MM6 cells without any 
treatment is very low (Klan et al. 2003). RNA polymerase II binding within the examined area 
increases clearly already after 6 h of TsA treatment and exists without any treatment only in 
the area surrounding the TIS (-318 to +52 bp). Sp1 binding seems to decrease in the two distal 
promoter parts, whereas the binding in the proximal areas increases with time. Sp3 behaves 
similarly, within the most distal area the protein slightly looses its affinity, whereas in all 
other regions the binding is strongly enhanced. 
From these in vivo data we can conclude that in MM6 cells, TsA treatment does not increase 
the acetylation status of the 5-LO promoter and the relaxation state of chromatin, but clearly 
enhances Sp1 and Sp3 binding, especially within the area surrounding the TIS, including the 
proximal GC boxes 1, 2, 4, 5 and the tandemized box. Due to the high GC content of the 
proximal 5-LO promoter, it was not possible to investigate binding to more precise regions or 
even discrete Sp1 binding sites. Nevertheless, the data also show in vivo binding of Sp1 and 
Sp3 to the more distal promoter parts including the putative binding sites GC6, GC7, GC8, 
GC9 and others. 
 
4.1.13  Cotransfection of expression plasmids of class I HDACs 
In coimmunoprecipitation studies complex forming between Sp1 and HDAC1 and HDAC2 
has been shown in different cell lines, e.g. in the pancreatic cancer cell lines BxPC-3, MIA 
PaCa-2 cells (Zhao et al. 2003), and in UK Pan-1 cells (Huang et al. 2005). The same 
publications also suggest a disruption of this complex after treatment with the histone 
deacetylase inhibitor TsA. Preliminary data by C. Katryniok proofed the recruitment of 
HDAC1 and HDAC2 by Sp1 both in HeLa and in MM6 cells, but TsA treatment does not 
alter the complex formation. She also investigated, a possible interaction between Sp3, 
HDAC1 and HDAC2 in HeLa and in MM6 cells. In both cell lines HDAC1 
coimmunoprecipitated with HDAC2, but none of both proteins with Sp3. 
An other approach to verify the recruitment of preferentially class I HDACs are coexpression 
studies with 5-LO reporter gene constructs. Expression plasmids containing the human 
HDAC1, HDAC2, HDAC3, HDAC8 were cotransfected with the promoter plasmid N13,  Results  
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containing the TsA responding Sp1 binding sites GC4 and GC5, into HeLa cells. To assure 
sufficient amounts of Sp1 protein in the cells, the expression plasmid for human Sp1 was 
additionally transfected. In HeLa cells, HDAC1, 2 and 3 are expressed endogenously, 
whereas HDAC8 is not (data not shown). Protein expression after transfection was checked 
by Western blot analysis (data not shown). 
Fig. 38 Cotransfection of HDACs: Relative activity of N13. Hela cells were transfected by the 
calcium phosphate precipitation method with 0.8 µg of reporter gene construct N13, with 0.1 µg of 
pEVR2/CMV-Sp1 or empty pCMV and with 0.1  µg of expression plasmids for the human class I 
histone deacetylases or the empty control plasmid pSG5. 16  h after transfection the medium was 
changed and the cells were treated with solvent of trichostatin A (330 nM) for 24 h. Then luciferase 
activity was determined. Results are presented as mean +  SE of 3 independent experiments after 
normalization for transfection effeciency.  
In untreated cells the additional cotransfection of the histone deacetylases interestingly 
resulted in an increase of promoter activity and not as assumed in a reduction. This effect was 
independent of Sp1 cotransfection. When the cells were treated with the histone deacetylase 
inhibitor the activating effect of the cotransfection was relieved and as shown before the 
transactivation by Sp1 was induced. These data do not provide any evidence that class I 
HDACs are directly recruited to the proximal 5-LO promoter.  
 
4.1.14  DNA affinity purification assay: Possible recruitment of HDACs and HATs 
An other experimental approach to investigate the recruitment of HDACs to the 5-LO 
promoter was achieved by DNA affinity purification assays. The same assay conditions used 
to show specific Sp1 and Sp3 binding were applied and the recruitment to oligonucleotides 
covering GC  box  4 and GC  box  5, or containing the mutated Sp1 binding sites was 
investigated. Additional to the recruitment of HDACs, the potential binding of histone 
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acetyltransferases (HATs) was investigated. Interaction between Sp1 and p300 has been 
described in Hep3B cells at the IGFBP-3 promoter (Choi et al. 2002), between Sp1, p300 and 
PCAF in Mia, PaCa-2 and UK Pan-1 cells (Huang et al. 2005).  p
NE
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Fig. 39 DNA affinity purification assay with HeLa cell extracts. 200 µl of whole-cell extract were 
incubated with 200 µl of binding buffer H and 2 µl of double-stranded biotinylated oligonucleotides 
for one hour on ice. The cell extracts were gained as described in 3.3 in “Materials and Methods”. 
The cells were either treated with TsA (330  nM) for 24  h or with solvent. After adding 50  µl of 
equilibrated streptavidin-coupled agarose beads, the incubation was continued on a spinning wheel 
for 30 min at 4 °C. The beads were washed four times with 500 µl of binding buffer and after taking of 
the supernatant boiled with 25 µl of 1x Laemmli sample buffer for 5 min at 95 °C. The DNA-binding 
proteins and potential coactivators or corepressors from the supernatant were separated by 
SDS-PAGE and analyzed by Western blot with the indicated antibodies. One representative example 
of at least two independent experiments is shown. GC4: GC box 4 as probe; GC4M: DNA probe 
covering the mutated Sp1 binding site GC4; GC5 and GC5M respectively. M: All Blue Protein Marker 
(Biorad;) NE: nuclear cell extract. Antibodies: anti-mouse anti-HDAC1 clone 2E10, anti-rabbit 
anti-HDAC2, anti-rabbit anti-HDAC3, anti-mouse anti-HDAC8; anti-mouse anti-p300, anti-goat 
anti-PCAF.  
Under the specific binding conditions applied in this assay, originally chosen to proof Sp1 and 
Sp3 binding, neither p300 nor the histone acetyltransferase PCAF was recruited to the  Results  
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different oligonucleotides. Also the identification of HDAC1, HDAC3 and HDAC8 failed in 
this assay. The only evidence for other protein binding eventually by Sp1 or Sp3 could be 
presented for HDAC2. However, recruitment of HDAC2 appeared not to be specific, since it 
was found binding to the wild-type probes as well as to the mutated probes and even only to 
the agarose beads. It seems that the binding conditions for each protein have to be adjusted to 
proof specific DNA binding or recruitment by DNA-binding proteins. 
 
4.1.15  Investigations on the acetylation status of Sp1 and Sp3 
Inhibition of histone deacetylases shifts the balance from histone deacetylase acitvity towards 
higher histone acetyltransferase activity. Histone acetyltransferases, such as CBP/p300, 
PCAF, GCN5, do not only acetylate histone proteins, but also transcription factors, including 
p53, GATA-1, YY1, STAT3 NF-κB and others [reviewed in (Glozak et al. 2005)]. The 
acetylation of Sp1 eventually results in an increased DNA binding affinity as well as in a 
higher transactivation activity [reviewed in (Li et al. 2004)]. The acetylation of Sp3 renders 
the transcription factor a transcriptional activator in the regulation of TGFβ type II receptor 
(Ammanamanchi and Brattain 2001; Ammanamanchi et al. 2003). In the assumption, Sp1/Sp3 
might be acetylated upon TsA treatment, I applied the DNA affinity purification assay to 
investigate the acetylation status of Sp1 and Sp3 after binding to the 5-LO promoter probes. 
In the Western blot analysis of the fished proteins, I first detected the transcription factor 
binding, then incubated the extensively washed membrane with the anti-acetyl-lysine 
antibody and the equivalent second antibody.  
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Fig. 40 DNA affinity purification assay for Sp3 with MM6 cell extract. 200 µl of whole-cell extract 
were incubated with 200  µl of binding buffer H and 2  µl of double-stranded biotinylated 
oligonucleotides for one hour on ice. The cell extracts were gained as described in “Materials and 
Methods”. The cells were either treated with TsA (330 nM) for 24 h or with solvent. After adding 50 µl 
of equilibrated streptavidin-coupled agarose beads, the incubation was continued on a spinning wheel  Results  
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for 30 min at 4 °C. The beads were washed four times with 500 µl of binding buffer and after taking 
off the supernatant the samples were boiled with 25 µl of 1x Laemmli sample buffer for 5 min at 95 °C. 
The DNA-binding proteins were separated by SDS-PAGE and analyzed by Western blot for the 
presence of Sp3 (anti-rabbit, sc-644, Santa Cruz). Then, the membrane was incubated with 
anti-acetyl-lysine antibody (anti-rabbit anti-acetyl-lysine #06-933, Upstate) to check for acetylated 
protein binding. 5xGC: 5-fold GC box as DNA probe; GC4: GC box 4 as probe; GC4M: DNA probe 
covering the mutated Sp1 binding site GC4; GC5 and GC5M respectively. M: All Blue Protein Marker 
(Biorad); ZE: sample of whole-cell extract, used in the DAPA; NE: nuclear extract; B: beads only. 
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Fig. 41 DNA affinity purification assay for Sp3 and acetylated Sp3 protein with HeLa cell extract. 
DAPA and Western blot analysis were performed as described in Fig. 40. 
 
As in the experiments before, in HeLa and in MM6 cells, trichostatin A did not influence the 
binding of Sp3 to the different GC boxes of the proximal 5-LO promoter. The incubation with 
the anti-acetyl-lysine antibody did not change the signals of the Sp3 bands from the pulldown, 
but intensified a band overlapping the migration band of the smaller isoforms from the cell 
extracts itself. However, this finding was independent of TsA treatment of the cell extracts. 
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Fig. 42 DNA purification affinity assay for Sp1 with MM6 cell extract. DAPA and Western blot 
analysis were performed as described in Fig. 40. Antibodies: anti-rabbit anti-Sp1, sc-059 (Santa 
Cruz); anti-rabbit anti-acetyl-lysine, #06-933 (Upstate).  Results  
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The same experiment was repeated and instead of Sp3, Sp1 was detected. Sp1 binding was 
not influenced by TsA. After incubating the membrane with the anti-acetyl-lysine antibody, 
additional bands appeared in lanes of the cell extracts, as well as in the lanes of the pulled 
samples. Nevertheless, these bands did not overlap with Sp1 and did also appear in the 
negative control (beads only), therefore resulting from some unspecific protein binding to the 
agarose beads.   Results  
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4.2  Regulation of the 5-lipoxygenase promoter by DNA methylation 
The expression of 5-lipoxygenase in myeloid cell lines is regulated by DNA methylation, as 
was shown by Uhl and Klan et al. (2002). In the 5-LO negative cell lines U937 and HL-60TB 
the 5-LO promoter was heavily methylated within the proximal promoter region, whereas it 
was completely unmethylated in the 5-LO positive cell line HL-60. Treatement of U937 and 
HL-60TB cells with the DNA methylase inhibitor AdC (5-aza-2`-deoxycytidine) could induce 
5-LO expression and led to a demethylation of the promoter as shown by bisulfite sequencing. 
Both in HeLa (5-LO negative) and in MM6 cells (5-LO positive), reporter gene constructs of 
the 5-LO core promoter showed strong activity, which was almost abolished after in vitro 
methylation with SssI methylase, recognizing and methylating all CpG dinucleotides. 
 
4.2.1  DNA methylation reduces promoter activity in reporter gene studies 
In order to localize relevant methylation or transcription factor binding sites within the core 
region of the 5-LO promoter which could be involved in the repression of promoter activity 
by DNA methylation, reporter gene constructs differing in length and CpG dinucleotide 
content were in vitro methylated, purified by phenol-chloroform extraction and transfected 
into HeLa cells. Besides SssI methylase recognizing all potential CpG dinucleotides, 
M. HpaII and M.  HhaI were used for methylation (as well as their combination), only 
partially methylating the promoter because of their more specific recognition sites,  -CCGG- 
and –CGCG-, respectively. 8 h after the calcium phosphate transfection, the medium was 
changed, cells were incubated with either ethanol or trichostatin A (330 nM) for 24 h and 
reporter gene activity was determined. 
As in former experiments, in vitro methylation led to a strong reduction of 5-LO promoter 
activity. Methylation with SssI methylase reduces promoter activity to the level of the 
promoterless reporter gene plasmid pGl3Basic. Also M. HpaII and M. HhaI inhibit promoter 
activity, though to a lesser extent. Besides pGl3Basic as negative control, pGl3Prom was used 
as positive control. The reporter gene plasmid contains pGl3Basic as backbone (as the 5-LO 
constructs) and the SV40 (simian virus) promoter instead of the 5-LO promoter. Since this 
promoter lacks HpaII and HhaI methylation sites, one should expect no alterations in 
promoter activity after methylation with M.  HpaII and M.  HhaI. Nevertheless, HpaII 
methylation leads to a significant decrease of promoter activity of pGl3Prom (16.7–fold), 
indicating, that methylation of the plasmid backbone can influence promoter activity too, 
possibly via action of methyl-CpG-binding proteins from more distal plasmid parts.   Results  
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Methylation of all CpG dinucleotides by SssI methylase showed the strongest repression of 
promoter activity, 50.8-fold for the largest construct N10, comprising –778 bp to +53 bp in  
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Fig. 43 DNA methylation reduces promoter activity in reporter gene assays. After in vitro 
methylation with HpaII, HhaI or SssI methylase, plasmids were transfected into HeLa cells by the 
calcium phosphate method. Medium was changed 8 h after transfection, Reporter gene activity was 
measured 24 h later. Each experiment was performed in triplicates. Results are presented as mean 
+  SE of three independent experiments after normalization for transfection effeciency by 
cotransfection of pCMVSEAP. Reductions are expressed with respect to unmethylated plasmids. 
 
relation to the major TIS, 63.3-fold, 41.6-fold, 35.1-fold, 21–fold for N11, N12, N13 and N14 
respectively, and only 4-fold and 2.2-fold for the minimal promoter constructs N15 and N16. 
The smaller the deletion variants are, the smaller is the loss of promoter activity caused by the 
different methylation patterns (N14 to N16). This may be due to the basically lower promoter 
activity of the shorter constructs, the adjusting ratio of the number of methylation sites for the 
different methylases or may indicate the special relevance of the methylation sites within the 
proximal promoter area.  
 
Plasmid Promoter 
HpaII M. sites / 
x-fold reduction 
HhaI M. sites / 
x-fold reduction 
SssI M. sites /  
x-fold reduction 
N10  -843 bp to –12 bp       6 / 11.6*  10 / 5.2*      64 / 50.8* 
N11  -294 bp to –12 bp    5 / 8.5*  4 / 6.1      31 / 63.3* 
N12  -206 bp to –12 bp       5 / 11.2**       3 / 10.8**       21 / 41.6** 
N13  -143 bp to –12 bp   5 / 9.1*   3 / 23.4     15 / 35.1*  Results  
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N14  -96 bp to –12 bp  1 / 9.4   3 / 20.7   10 / 21.0 
N15  -67 bp to –12 bp  1 / 3.2  2 / 2.7  8 / 4.0 
N16  -34 bp to –12 bp  1 / 2.1  1 / 1.8  3 / 2.2 
pGl3Prom  SV40     0 / 16.7*  0 / 5.5   10 / 58.5* 
 
Tab. 6 Depicted are the number of methylation sites and the x-fold reduction caused by the specific 
methylation patterns. The data were achieved in the same experiments as in Fig 43. Reductions are 
expressed with respect to unmethylated plasmids. *, P<0.05 **, P<0.01, by paired two-sided 
Student´s t test. The positions of the promoter sequences included in the different plasmids are in 
relation to the 5-LO ATG. 
 
4.2.2  Reduction of promoter activity correlates with methylated CpG sites 
In the larger luciferase reporter gene constructs (N10, N11, N12, and N13) the decrease in 
promoter activity is dependent on the number of methylated CpGs within the promoter region. 
Fig. 44 is showing the correlation between the number of methylation sites and the reduction 
by DNA methylation. Clearly the reduction in promoter activity is increasing with the number 
of methylation sites. 
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Fig. 44 The reduction in promoter activity of the larger promoter constructs N10, N11, N12 and 
N13 correlates with the number of methylation sites. Data were achieved in the same experiments as 
in Fig.43. Plotted are x-fold reductions in relation to the number of methylation sites. The linear 
regression line was drawn through the origin. 
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4.2.3  TsA induces 5-LO promoter activity dependent on the degree of methylation 
In vivo, so-called methyl-CpG-binding proteins can bind to methylated DNA sequences and 
either directly or indirectly recruit histone deacetylases. As mentioned before, endogenous 
5-LO gene expression in MM6 cells is induced after TsA treatment (Klan et al. 2003). So far 
no studies concerning the methylation status of the 5-LO promoter in MM6 cells exist. Since 
treatment with 1,25(OH)2D3 and TGFβ strongly induces the protein expression in MM6 cells, 
but not in U937 or HL-60-TB cells (in both cells lines the promoter is methylated), we assume 
that the promoter is not methylated in MM6 cells. In order to investigate, if DNA methylation 
promotes recruitment of HDACs to the 5-LO promoter, HeLa cells were additionally 
stimulated with TsA when transfected with the methylated promoter constructs.  
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Fig. 45 TsA induces promoter activity of unmethylated and partially methylated reporter gene 
constructs. After in vitro methylation with HpaII, HhaI or SssI methylase, plasmids were transfected 
into HeLa cells by the calcium phosphate method. Medium was changed 8 h after transfection, cells 
were incubted with TsA 330 nM for 24 h. Each experiment was performed in triplicates. Results are 
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presented as mean +  SE of at three independent experiments after normalization for transfection 
effeciency by cotransfection of pCMVSEAP. Inductions by TsA are expressed with respect to untreated 
cells (A,B). C: relative promoter activites after TsA treatment. 
Promoter activity of the larger unmethylated promoter constructs N10 to N13 is increased 
after treatment with TsA, whereas the small constructs N14, N15 and N16 are not affected. 
This finding locates the effect of TsA to the more distal promoter area upstream of N14. 
Complete DNA methylation is abolishing promoter activity as well as any induction by TsA. 
Either TsA treatment alone is not sufficient to reactivate the promoter or the regulation is 
independent of any HDAC recruitment at this state of methylation.  
Partial methylation of the promoter fragments by M. HpaII and M. HhaI on the other hand 
stimulates activation by the histone deacetylase inhibitor, indicating a recruitment of HDACs 
to the promoter and the potential of activation of the promoter. Still, the methylated constructs 
never reach the original promoter activity of the unmethylated constructs.  
 
4.2.4  Cotransfection of different methyl-CpG-binding proteins  
Methylated DNA is recognized by methyl-CpG-binding proteins (MBD proteins). In order to 
identify MBD proteins binding to the 5-LO promoter, we intensified reporter gene assays. In 
cotransfection studies with methylated promoter plasmids and expression plasmids for murine 
Mbd1, Mbd2, Mbd3 and rat MeCP2, we expected the methyl-CpG-binding proteins to further 
reduce promoter activity, either by competing with other transcription factors or by 
recruitment of corepressors, including HDACs. The coding sequences of the different MBDs 
were cloned into pSG5, to ensure the same expression levels of the different proteins (for 
details see “Materials and Methods”, 3.7.2). Protein expression was controlled by Western 
blot analysis. We could not detect endogenous MBD1 or MeCP2 in HeLa cells. 
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Fig. 46 Protein overexpression of methyl-CpG-binding proteins in HeLa cells. 24 h  before 
transfection, HeLa cells were seeded in 14.5 cm ∅  dishes, so that 60-80% of the cells were confluent  Results  
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at the time of transfection. Cells were either transfected with 50 µg of pSG5mock per dish or with 
25 µg or 50 µg of expression plasmid pSG5Mbd1, pSG5Mbd2, pSG5Mbd3 or pSG5MeCP2 by calcium 
phosphate transfection. 16 h after transfection the medium was changed, 24 h later the cells were 
harvested and fractionated into the cytosolic and nuclear compartments, as described in “Materials 
and Methods”, 3.4. For SDS-PAGE and Western blot analysis the different probes were normalized to 
the cell number of harvested cells. The nuclear fractions were blotted. 
In the reporter gene assays with methylated construct N10, only the cotransfection with Mbd1 
leads to a further reduction in promoter activity. The effect is strongest after HpaII 
methylation, but also exists after methylation with M. HhaI and M. SssI, see Fig. 47. The 
same is true for construct N13, indicating a possible binding site within this proximal 
promoter region.
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Fig. 47 Relative Activíty of methylated reporter gene constructs N10 and N13 cotransfected with 
methyl-CpG-binding proteins. After in vitro methylation of the reporter gene plasmids and 
purification with phenol-chloroform extraction, the constructs were transfected into HeLa cells by 
calcium phosphate method. The cells were seeded in 24 well plates and transfected with 0.8 µg of the  Results  
90 
methylated reporter gene plasmids with 0.02 µg of pCMVSEAP and 0.1 µg of the expression plasmids. 
Medium was changed 8 h after transfection, cells were incubted with solvent or TsA, 330 nM, for 24 h. 
Each experiment was performed in triplicates. Results are presented as mean +  SE of three 
independent experiments after normalization for transfection effeciency by cotransfection of 
pCMVSEAP. This time, luciferase activity was determined using the Bright Glow Luciferase Assay 
System (Promega), ensuring higher activities (about 10-fold) of the methylated constructs, due to the 
different buffer conditions during the luciferase assay. Also RLUs had to be normalized to pGl3Basic 
because the cotransfection caused backbone effects on pGl3Basic. 
Additional treatment of the cells with TsA does not relieve the reduction in promoter activity 
caused by Mbd1. This finding is according to (Fujita et al. 2003), suggesting an alternative 
pathway in the repression by Mbd1 independent of HDACs. Interestingly, when the cells are 
treated with the histone deacetylase inhibitor TsA Mbd2 decreases the promoter activity. 
 
4.2.5  Mutation of methylation sites within the proximal promoter of 5-LO 
Observations so far suggest the presence of relevant methylation sites and a possible 
recruitment of Mbd1 to the proximal promoter area covered in the reporter gene construct 
N13.  
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Fig. 48 Schematic overview of the proximal 5-LO promoter covered by the reporter gene constructs 
N13 and N14. Depicted are the different methylation sites for M. SssI, M. HpaII and M. HhaI, the 
inverted repeats and the Sp1 binding sites. 
To identify the potential binding site for Mbd1, different methylation sites within N13 were 
mutated to inhibit methylation and binding of Mbd1. Construct N13 lacks the 5-fold GC box,  Results  
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but still contains the two Sp1 binding sites, GC  box  4 and GC  box  5. Additionally, two 
inverted repeats are present in this proximal promoter area, whose functions are still unclear. 
The HpaII methylation sites were of special interest, since Mbd1 cotransfection showed its 
strongest effects when the reporter gene constructs were methylated with M. HpaII (mutations 
in N13Rep1, N13Rep2 and N13MMIII). In gel shift assays, methylation of the HpaII sites 
around GC box 4 diminished Sp1 binding (see Fig. 54), but binding of other nuclear, so far 
unknown proteins was enhanced (mutated in N13MutMethIII). Methylation of the HhaI site 
between GC  box  5 rather increased Sp1 binding, no additional protein binding was seen 
(mutated in N13MutMethII). The relevance of the sites surrounding the TIS or within the 
inverted repeats shall be investigated by the mutations in N13MutMethI, N13InvRep1 and 
N13InvRep2. 
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Fig. 49 Mutations of the different methylation sites within N13. In N13MutInvRep1 and 
N13MutInvRep2 methylation sites within the sequences of the inverted repeast were point mutated. In 
the constructs N13MutMethI – III methylation sites of larger stretches of the promoter were mutated, 
including the HpaII sites surrounding GC box 4, the methylation sites surrounding GC box 5 and the 
methylation sites surrounding the transcription start site.  Results  
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Since the mutations could also affect basal promoter activity, by disabling transcription factor 
binding, changes in promoter activity of the unmethylated constructs have to be considered. 
The point mutation of the HpaII methylation site within the inverted repeat  1 sequence 
significantly reduces the promoter activity, as well as the mutation of the sites beside 
GC box 5 in N13MutMethII (N13MMII). The other mutations do not significantly change 
promoter activity. Also, the different mutations show no significant changes in response to 
TsA treatment, underlining the dependency of the TsA effect on only GC box 4. 
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Fig. 50 Relative Activity of the mutated, but unmethylated N13 constructs. HeLa cells were seeded in 
24 well plates and transfected with 0.8 µg of the purified plasmids with 0.02 µg of pCMVSEAP by 
calcium phosphate method. The medium was changed 8 h after transfection. Cells were incubated with 
TsA (330 nM) or ethanol. 24 h later, the reporter gene activity was determined. Each experiment was 
performed in triplicates. Results are presented as mean + SE of three independent experiments after  
normalization for transfection effeciency by pCMVSEAP. *, P<0.05 **, P<0.01, by paired two-sided 
Student´s t test.  Results  
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Fig. 51 X-fold reduction by DNA methylation of the different mutated N13 constructs. After in vitro 
methylation with M. HpaII, M. HhaI or M. SssI the plasmids were purified using phenol-chloroform 
extraction. HeLa cells were seeded in 24  well plates and transfected with 0.8  µg of the purified 
plasmids with 0.02 µg of pCMVSEAP by calcium phosphate method. The medium was changed 8 h 
after transfection. Cells were incubated with TsA (330 nM) or ethanol. 24 h later, the reporter gene 
activity was determined. Each experiment was performed in triplicates. Results are presented as mean 
+ SE of three independent experiments after normalization for transfection effeciency by pCMVSEAP. 
*, P<0.05 **, P<0.01, by paired two-sided Student´s t test. 
 
Methylation of the plasmids itself reduces promoter activity. In respect to the different 
mutations, reduction of promoter activity by HhaI methylation does only significantly differ 
between the constructs N13 and N13MutMethIII (N13MMIII). 
Also the mutations in N13Rep1 and N13MutMethII (N13MMII) are releasing the repressive 
effects of DNA methylation by M. HpaII, and in N13Rep2, carrying a mutation of the HpaII 
site upstream of the TIS, HpaII methylation even further reduces promoter activity. Only the 
mutations in N13MMII do significantly decrease the reduction by SssI methylation compared 
to N13.  
The additional cotransfection of the expression plasmid of the murine CpG-binding protein 
Mbd1 leads to a further decrease in promoter activity of the unmethylated and methylated 
constructs. Mbd1 strongly effects HpaII methylated constructs, though SssI methylation and 
coexpression of Mbd1 together have the biggest impact on promoter activity. In comparison 
to N13, Mbd1 significantly reduces promoter activtiy of N14 (**) when the plasmids were 
methylated with M. HpaII (*, P<0.05 **, P<0.01, by paired two-sided Student´s t test), but 
not of the other constructs.  Results  
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Fig. 52 X-fold reduction by Mbd1 cotransfection. Mbd1 alone reduces promoter activity of 
unmethylated and methylated mutated N13 constructs. Mbd1 enhances promoter repression by 
DNA methylation. After in vitro methylation with M. HpaII, M. HhaI or M. SssI the plasmids were 
purified using phenol-chloroform extraction. HeLa cells were seeded in 24 well plates and transfected 
with 0.8  µg of the purified plasmids with 0.02  µg of pCMVSEAP and 0.1  µg of pSG5mock or 
pSG5Mbd1 by the calcium phosphate method. The medium was changed 8 h after transfection. 24 h 
later, the reporter gene activity was determined. Each experiment was performed in triplicates. 
Results are presented as mean +  SE of three independent experiments after normalization for 
transfection effeciency by pCMVSEAP.  
 
4.2.6  Influence of DNA methylation on in vitro Sp1 binding 
Within the proximal 5-LO promoter area three different Sp1 binding sites exist. For all of 
them, in vitro binding of Sp1 has been shown before (In et al. 1997; Silverman et al. 1998; 
Dishart et al. 2005). Mutation or deletion of theses sites results in a loss of promoter activity 
in reporter gene assays (see Fig. 22). As outlined in the introduction (see page 33) different 
studies have shown interference between DNA methylation and Sp1 binding. In some cases 
the binding of Sp1 to methylated Sp1 binding sites was reduced, in others methylation of 
adjacent sites diminished binding of the transcription factor, or methylation showed no 
influence at all.  
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Fig. 53 Overview of the proximal 5-LO promoter sequence and oligonucleotides used as probes in 
gel shift assays. To test the influence of DNA methylation on Sp1 binding within the 5-LO promoter 
context, three different oligonucleotides were designed, covering the three proximal Sp1 binding sites: 
the 5 x GC oligo, the consensus oligo and the non-consensus oligo, indicated by the grey boxes. Parts 
of the consensus and non-consensus oligos are overlapping. In the 5 x GC oligo, all five GC boxes 
were methylated. Methylation of the consensus oligo is possible at three M. HpaII methylation sites 
surrounding GC box 4 and within the binding site itself. The non-consensus oligo was methylated at 
both ends, equivalent to a methylation by M. HpaII and M. HhaI. 
 
In order to investigate the influence of DNA methylation on Sp1 binding sites of the 5-LO 
promoter, oligonucleotides covering the different sites were ordered and binding to the 
unmodified or methylated probes was tested in gel shift assays. Either the CpG dinucleotides 
of the core binding site/s itself were methylated or the CpGs surrounding the GC boxes were 
methylated. Following this guideline, the 5 x GC oligo was either synthesized completely 
unmethylated, or all five CpG dinucletides within the five Sp1 core motifs were methylated at 
the 5´ position of the cytosines. Fig. 53 and Tab. 7 below depict the location of the probes 
within the 5-LO promoter and the relevant sequences modified by DNA methylation. 
 
Forward strand of double-stranded probes 5´ to 3´   
CTGCGGGGGCGGGGGCGGGGGCGGGGGCGGGGGCGGGGGCAG  5 x GC oligo, covering 5 x GC box, unmethylated 
CTGCGGGGGOGGGGGOGGGGGOGGGGGOGGGGGOGGGGGCAG 5 x GC SssI M. oligo, all Sp1 sites methylated  
CAGACCGGGGCGGGGCCGGGACCGGGGC  Consensus oligo, covering GC box 4 
CAGACOGGGGCGGGGCOGGGACOGGGGC  Consensus HpaII M., methylated around  Results  
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GC box 4 (three HpaII M. sites) 
CAGACCGGGGOGGGGCCGGGACCGGGGC  Consensus SssI M., methylated within the Sp1 
binding motif itself 
GACCGGGGCCAGGGACCAGTGGTGGGAGGAGGCTGCGGCGC  Non-consensus oligo, Sp1 site / GC box 5, 41 bp 
GACOGGGGCCAGGGACCAGTGGTGGGAGGAGGCTGOGGOGC  Non-consensus H/H, Sp1 site / GC box 5, 41 bp, 
methylated around the Sp1 binding motif (HpaII 
and HhaI M. site) 
AGTGGTGGGAGGAGGCTGCGGCGCT  Non-consensus 20 bp, Sp1 site / GC box 5, 
Missing the HpaII M. site 
GATCGAACTGACCGCCCGCGGCCCGT  Unspecific competitor, Ap2 binding site 
ATTCGATCGGGGCGGGGCGAGC  Specific competitor, classical Sp1 binding motif  
Tab. 7 Sequences of the forward strands of the equivalent gel shift probes. “O” represents a 
methylated cytosine of a CpG dinucleotide. 
The consensus oligo was tested either completely unmodified, methylated within the GC box 
(GC box 4 in reporter gene assays), or with the three HpaII M. sites surrounding the GC box. 
In case of the last Sp1 binding site (GC box 5 in reporter gene assays) a methylation of the 
transcription factor binding site itself is not possible, since the sequence covers a 
non-consensus binding motif -GGGAGG-. Nevertheless the methylation of the residues 
within the HpaII M. and HhaI M. sites surrounding the binding site was possible. As an 
additional control, a shorter version of the non-consensus oligo was used, only 20 bp long, 
missing the HpaII M. site. 
After annealing the single-stranded primers (for details see “Materials and Methods”, 
page  52), oligonucleotides were labeled at the 5´-ends using T4 polynucleotide kinase. 
Radiolabelled double-stranded oligos then were purified with Microspin G-25 columns 
(Amersham Biosciences) and stored at –20 °C. 1.25 µg to 10 µg of nuclear extract and/or Sp1 
protein (150-300  ng) was incubated with labelled oligonucleotide probe in binding buffer 
(50 mM Tris-HCl, pH 7.5, 5 mM MgCl2, 2.5 mM EDTA, 2.5 mM DTT, 250 mM NaCl, 20% 
glycerol) and 0.5 µg poly(dAdT)•poly(dAdT) for 30 min at RT in a total reaction volume of 
20  µl. For competition studies a 25-, 50- or 100-fold molar excess of unlabelled Sp1 
consensus oligonucleotide (purchased from Promega) was added to the reaction mixture prior 
to the addition of radiolabelled probe. The reactions were usually resolved on 4-20% pre-run 
non-denaturating polyacrylamide TBE gels (BioRad premade) which were electrophoresed at 
100 V for 110 min. Gels were dried under vacuum before exposure, or exposed directly to 
Fuji  Super  RX film at –20  °C or to a FLA  3000 imaging plate at RT for the indicated 
exposure times. 
  Results  
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4.2.7  Sp1 binding to the methylated consensus binding site is diminished 
In the first experiments I determined if Sp1 binding to the consensus binding site (GC box 4) 
was influenced by DNA methylation. 2.5  µg or 5.0  µg of NE of MM6 cells shifted the 
unmethylated probe and three bands appeared (arrowheads, see Fig. 54). All three complexes 
could be competed out by the cold competitor (lanes 4 and 5). Recombinant Sp1 protein alone 
or mixed with 2.5 µg of nuclear extract produced an even more prominent band (lane 6 and 
lane 7), running on the height of the slowest migrating band, shifted with only nuclear extract. 
15 14 13 12 11 10 9 8 7 6 5 4 3 2 1
C
o
n
s
e
n
s
u
s
 
H
p
a
I
I
 
M
.
C
o
n
s
e
n
s
u
s
 
S
s
s
I
M
.
C
o
n
s
e
n
s
u
s
 
O
l
i
g
o
N
E
 
5
 
µ
g
N
E
 
2
.
5
 
µ
g
 
+
c
o
l
d
 
o
l
i
g
o
1
0
0
x
N
E
 
2
.
5
 
µ
g
N
E
 
2
.
5
 
µ
g
 
+
 
c
o
l
d
 
o
l
i
g
o
5
0
x
N
E
 
2
.
5
µ
g
N
E
 
2
.
5
µ
g
 
+
 
S
p
1
 
2
1
5
 
n
g
N
E
 
2
.
5
 
µ
g
 
+
 
 
S
p
1
 
2
1
5
 
n
g
S
p
1
 
2
1
5
 
n
g
S
p
1
 
2
1
5
 
n
g
N
E
 
2
.
5
µ
g
N
E
 
2
.
5
µ
g
 
+
 
S
p
1
 
2
1
5
 
n
g
S
p
1
 
2
1
5
 
n
g
* * *
unmethylated
HpaII methylated
SssI methylated
Sp1
Sp3
Sp3
 
Fig. 54 Gel Shifts with the unmethylated and methylated consensus oligo comprising GC box 4. 
After the labeling with 
32P-ATP and T4 Polynucleotide Kinase the unmethylated or methylated probes 
were incubated with 2.5 or 5.0 µg of nuclear extract generated from MM6 cells. For competition 
studies specific competitor in 50- or 100-fold excess was added to the incubation mixture. Binding of 
recombinant Sp1 protein to the probes was checked either in combination with nuclear extract or 
alone. 240,000 cpm of the different probes were used for the binding reactions, the gel was directly 
exposed to Fuji Super RX film at –20 °C for 2 h. * band generated with Sp1 recombinant protein. 
 
Nuclear extract shifted the consensus HpaII M. probe, methylated around the Sp1 binding 
motif, even resulting in a stronger band pattern (lanes 9-11). The slowest migrating band 
almost disappeared, the faster complexes became more evident, indicating binding of other  Results  
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proteins than Sp1. These effects were even more prominent with the consensus SssI M. probe, 
in which the Sp1 binding motif itself is methylated (lanes 13-15). Recombinant Sp1 binding 
clearly decreased with methylation.  
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Fig. 55 Gel Shifts with the unmethylated/methylated consensus oligo, comprising GC box 4, using 
nuclear extract of HeLa cells. A, B, C: After the labeling, the probes were incubated with 5.0 µg or 
10.0 µg of nuclear extract generated from HeLa cells. For competition studies specific competitor in 
50- or 100-fold excess was added to the incubation mixture. Binding of recombinant Sp1 protein to the 
probes was checked either in combination with nuclear extract or alone. 240,000 cpm of the different 
probes were used for the binding reactions, the gel was directly exposed to Fuji Super RX film at 
-20°C for 1 h. * band generated with Sp1 recombinant protein. Presented are the results from two 
different experiments, A versus B and C (B unmethylated probe, C methylated probe). 
 
The same experiment was repeated with nuclear extract from HeLa cells (see Fig. 55). The 
same bands appeared (indicated by arrowheads), which could be competed out by the specific 
Sp1/Sp3 competitor, for the unmethylated probe (A, lane 4 and 5). Again, methylation of the 
probes clearly decreased Sp1 binding (compare A, lanes 7, 11, 15), and the faster migrating 
bands were enhanced. In a second experiment (B and C), the fastest migrating band could not  Results  
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be competed out by the specific Sp1 competitor (B, lane 6), indicating protein binding other 
than any Sp1 family member, even to the non-methylated probe. Interestingly this band was 
strongly enhanced, when the probe was methylated and when competitor was added to the 
binding reaction (see fig. C). 
 
4.2.8  Sp1 binding to the non-consensus binding site increases with methylation 
Concerning the non-consensus Sp1 binding site, results from EMSA look quite different. The 
increasing amounts of nuclear extract only slightly lead to increased protein binding with the 
non-methylated probe. Only a faint shift appeared on the migration level comparable with 
recombinant Sp1 protein (indicated by the asterisk), but two strong bands on a faster level 
(indicated by arrowheads). Competition with specific unlabeled Sp1 competitor enhanced the 
middle band, instead of diminishing the signal, indicating that Sp1 is not dominating in this 
protein-DNA complex. Also the binding of recombinant Sp1 protein to the non-consensus 
probe is weak and is increased when the probe is methylated (compare lane 5 and lane 11).  
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Fig. 56 Gel Shifts with the unmethylated and methylated non-consensus oligo comprising GC box 5. 
After labeling, the probes were incubated with 2.5 µg, 5.0 µg or 10.0 µg of nuclear extract generated  Results  
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from HeLa cells. For competition studies specific competitor in 100-fold excess was added to the 
reaction mixture. Binding of recombinant Sp1 protein to the probes was checked without addition of 
nuclear extract. 250,000 cpm of the different probes were used for the binding reactions, the gel (5% 
TBE) was directly exposed to Fuji Super RX film at -20°C for 1 h. * band generated with recombinant 
Sp1. 
In a control experiment the binding of Sp1 to a shorter probe (non-consensus 20 bp), also 
containing the non-consensus motif was tested (see Fig. 57). Clearly the binding of the 
recombinant protein is more efficient to the shorter probe (compare lane  4 and lane  8), 
suggesting some hindrance of protein binding to the longer probe.  
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Fig. 57 Gel Shifts with oligonucleotides covering the non-consensus Sp1 binding site (GC-box 5). 
After end-labeling the double-stranded oligos with 
32P-ATP and T4 Polynucleotide Kinase, the probes 
were incubated at RT for 30 min either with nuclear extract from HeLa cells or with recombinant Sp1 
protein. 250,000 cpm of the different probes were used for the binding reactions, the gel (5% TBE) 
was directly exposed to Fuji Super RX film at -20°C for 1h. 
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4.2.9  Sp1 binding to the 5-fold GC box is attenuated by DNA methylation 
Finally protein binding to the 5-fold GC box was examined (see Fig. 58). With 10 µg and 
20 µg of HeLa nuclear extract three bands shifted with the non-methylated probe. Adding an 
excess of specific Sp1 competitor only competed the slowest band out (lanes 4, 5). Cold probe 
competed all bands out, excluding unspecific protein binding (lane  6). The addition of 
recombinant Sp1 protein to the binding reaction in combination with nuclear extract slightly 
enhanced the slowest migrating band (lane 7). Sp1 alone resulted in a distinct band (lane 8), 
on about the same level as the slow migrating band. Nuclear extract in combination with the 
methylated probe resulted in about five protein-DNA complexes (indicated by the 
arrowheads), the highest comparable to recombinant Sp1 binding (lane 10). The competition 
with specific Sp1 competitor enhanced the three fastest complexes (lane 12) and abrogated the 
slow migrating complexes, indicating again other protein binding than Sp1 or Sp1 family 
members. Sp1 binding itself is strongly diminished to the methylated band (lane 15). Similar 
results were achieved with MM6 extracts (data not shown). 
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Fig. 58 Sp1 binding to the 5-fold GC box. After end-labeling the double-stranded oligos with 
32P-ATP 
and T4 Polynucleotide Kinase, the probes were incubated at RT for 30 min either with nuclear extract  Results  
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from HeLa cells or with recombinant Sp1 protein. 120,000 cpm of the different probes were used for 
the binding reactions, the gel was directly exposed to a FLA 3000 imaging plate for 17 h at RT. * band 
generated with recombinant Sp1. 
To conclude from theses experiments, Sp1 binding to the methylated consensus binding site is 
attenuated, but still possible. Additionally, methylation induces the binding of an unidentified 
protein. Methylation of the 5-fold GC box results in the same effects, Sp1 binding is 
diminished and binding of an unknown protein enhanced. In case of the non-consensus 
binding site, Sp1 binding is increased upon methylation of surrounding residues, rather due to 
secondary effects, like interference with other transcription factor binding or changes in the 
secondary structure of DNA. Sadly supershift experiments with Sp1 or Sp3 antibody did not 
work. To reveal what other proteins besides Sp1 bind to the different probes, especially after 
DNA methylation, gel shift assays including supershift studies with antibodies against MBD 
proteins should be performed.  
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5  Discussion 
5.1  Regulation of 5-LO gene expression by histone deacetylation  
The 5-LO promoter lacks TATA and CCAAT boxes as well as an Inr element (Hoshiko et al. 
1990). As underlined by the presence of two CpG islands covering the proximal promoter 
area and the major transcription start site, the promoter is highly GC-rich (compare Fig. 3 
page 10). Several Sp1 binding sites, including a 5-fold tandemized Sp1/Egr1 element, convey 
basal promoter activity (In et al. 1997; Silverman et al. 1998; Dishart et al. 2005). Though 
carrying these characteristics of so-called housekeeping genes, 5-LO is tissue-specifically 
expressed, mainly in cells of myeloid origin (Steinhilber 1999). Recent results suggest that 
DNA methylation is involved in the tissue-specific expression pattern of 5-LO or at least in 
the loss of 5-LO expression in myeloid cancer cell lines HL-60TB and U937. TGFβ and 
1,25(OH)2D3 induce 5-LO expression in the monocytic cancer cell line MM6 and HL-60, but 
not in HL-60TB, a subtype of HL-60 cells characterized by the lack of 5-LO expression, or in 
U937 cells. Since in these cell lines the 5-LO promoter is heavily methylated, it seems that 
demethylation is a prerequisite for 5-LO expression and TGFβ/1,25(OH)2D3 treatment alone 
cannot induce expression (Uhl et al. 2002; Klan et al. 2003).  
DNA methylation and histone modifications of the nucleosomal core histone proteins H3 and 
H4 interact in the transcriptional shut down of genes. Methyl-CpG-binding domain proteins 
bind to methylated DNA sequences and recruit corepressor complexes including HDACs 
(Jones et al. 1998; Nan et al. 1998) or associate with histone methyltransferases (Sarraf and 
Stancheva 2004). Also direct interaction between the de novo DNA methyltransferase 
DNMT3a and HDAC1 have been reported (Fuks et al. 2001), as well as complex formation 
between DNMT1, HDAC1, Rb and E2F1 (Robertson et al. 2000) and between DNMT1 and 
HDAC2 (Rountree et al. 2000). The histone methyltransferase ESET/SETDB1 can repress 
transcription in a HMT activity-independent manner by associating with HDAC1/2 (Yang et 
al. 2003). Not only DNA methylation triggers histone modifications, such as deacetylation, 
but also histone modifications trigger DNA methylation and so far it is not clear what happens 
first. Studies in Neurospora and Arabidopsis indicate, that histone methylation directs DNA 
methylation (Tamaru and Selker 2001; Jackson et al. 2002; Tamaru et al. 2003). Methylation 
of lysine 9 of histone H3 induces DNA methylation in mice at pericentric heterochromatin 
(Lehnertz et al. 2003). After targeted gene disruption of DNA methyltransferases, the tumor 
suppressor gene p16 was reactivated after promoter demethylation in the HCT116 cell line. 
After several cell passages the gene was silenced again, independently of DNA methylation,  Discussion  
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but associated with H3K9 methylation (Bachman et al. 2003). Only in even later passages the 
gene was remethylated. Recently the interaction between the histone methyltransferase 
SETDB1 and the DNA methyltransferase DNMT3a was described (Li et al. 2006). Mutskov 
studied the events involved in the silencing of transgenes. He describes early loss of 
acetylation of H3 and H3K4 methylation, which leads to gene repression. Later H3K9 
becomes methylated followed by DNA methylation of the transgene (Mutskov and Felsenfeld 
2004). Also the promoter of the tumor supressor gene RASSF1A in human mammary 
epithelial cells is silenced after initial histone inactivation followed by DNA methylation 
(Strunnikova et al. 2005).  
These links between DNA methylation and histone modifications suggest a similar interaction 
of both pathways in the regulation of 5-LO gene expression. In the hippocampus of mice and 
in human Caco-2 cells, a colon carcinoma cell line, valproic acid and butyrate, two short 
fatty-acid histone deacetylase inhibitors, induced 5-LO mRNA expression (Wachtershauser et 
al. 2000; Yildirim et al. 2003). In MM6 and HeLa cells, the potent inhibitor trichostatin A 
induced 5-LO gene expression in reporter gene assays of non-methylated and in vitro 
methylated plasmids. Also the mRNA level of 5-LO in MM6 cells is increased after TsA 
treatment, though to a lesser extent as after differentiation with TGFβ/1,25(OH)2D3 for four 
days, (11- versus 43-fold). In order to identify the region responsible for the strong induction 
of 5-LO promoter activity in reporter gene assays, successive deletion variants of the most 
active reporter gene construct N10 were transfected into HeLa cells and the effect of TsA was 
investigated. Clearly the larger constructs N10 (-843 bp to –12 bp in relation to ATG), N11, 
N12 and N13 were induced by the HDACi TsA (4- to 6-fold) (Klan et al. 2003), whereas the 
shorter constructs N14 (-96 bp tp –12 bp) to N16 were not. Since N13 (-143 bp to –12 bp) 
already lacks the 5-fold tandemized GC box, TsA independently of this element induces 5-LO 
promoter activity. Besides in length, N13 and N14 differ in the presence of two functional 
Sp1 binding sites, termed GC4 and GC5. GC4 represents a consensus Sp1 binding site 
(5´-GGGCGGG-3´), whereas GC5 comprises the non-consensus motif (5´-GGGAGG-3´). 
Sp1 binding to both sites was verified in gel shift assays, as well as in DNase I footprints 
(Hoshiko et al. 1990; In et al. 1997; Silverman et al. 1998; Dishart et al. 2005). Furthermore 
mutations of the Sp1 binding sites caused a reduction of promoter activity in reporter gene 
assays in MM6 cells, indicating their functionality in basal promoter activity (Dishart et al. 
2005). Several reports have described the recruitment of HDAC activity by transcription 
factors, including Sp1 and Sp3. The p21 gene expression is upregulated by the HDACi 
superoylanilide hydroxamic acid in NIH3T3 cells (Xiao et al. 1999). Both Sp1 and Sp3  Discussion  
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binding to a proximal GC  site are required for this upregulation, whereas in human 
osteosarcoma cells MG63 Sp3 alone mediates the TsA response (Sowa et al. 1999). One 
proximal Sp1 binding site in the human luteinizing hormone receptor (hLHR) gene promoter 
recruits a histone deacetylase-mSin3A complex (Zhang and Dufau 2002). Often the GC site 
involved in the HDACi response, usually a proximal Sp1 binding site, also participates in the 
regulation of basal promoter activity.  
Mutational analysis in reporter gene assays indeed confirmed the involvement of Sp1/Sp3 
binding sites in the regulation of the 5-LO promoter by the histone deacetylase inhibitor TsA. 
Mutation of GC4 in the still highly inducible construct N13, attenuated the response to TsA 
comparable to the response of construct N14. Mutation of GC5 was less efficient. The double 
mutation completely eliminated the reponse to TsA, indicating an interaction between both 
sites. The fact that the mutation of GC4 without any treatment reduces promoter activity in 
HeLa cells, whereas mutation of GC5 rather activates promoter activity, suggests recruitment 
of some kind of repressor by GC5-binding factors. TsA treatment in HeLa cells reverses the 
repressing function of GC5, indicating the recruitment of HDAC activity via this binding site. 
Since the TsA response depends on GC4, it is resonable that the recruited HDAC(s) somehow 
influence GC4-binding factors. 
The influence of the particular binding sites was subsequently investigated in the larger 
promoter context of the most active reporter gene construct N10. In this promoter context the 
single GC  box mutations were relatively insufficient in suppressing the TsA effect. The 
mutation of GC4, having the strongest impact in the shorter construct N13 decreased the TsA 
triggered promoter activation only by 11%, compared to 95% in construct N13. The deletion 
of the tandem GC box (GC0) reduced the TsA response after all by 42%. The data indicate a 
cooperation for HDAC recruitment between the discrete GC  sites in the intact promoter 
context. However mutations of GC box 4, GC5 and GC1 reduce promoter activity by up to 
54%, independent of TsA treatment, thus underlining their relevance in basal 5-LO promoter 
activity.  
Successive combinatorial mutation of the separate Sp1 binding sites in construct GC0, already 
lacking the five tandemized GC box, revealed the importance and additive influence of each 
site for full promoter activity. The mutation of each site resulted in a decrease of promoter 
activity and the mutation of several sites at once enhanced this effect in an additive matter. 
Only mutation of GC5 alone did not change the promoter activity. The combined mutations of 
the proximal sites GC1, GC2, GC4, GC5 and the additional deletion of GC0 in the construct 
N9, containing parts of a second CpG island with more potential Sp1/Sp3 binding sites, were  Discussion  
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sufficient to abolish the promoter activity of this construct, giving further evidence of the 
necessity of the proximal GC sites for basal activity. The double mutation of GC4 and GC5 
introduced into GC0 strongly attenuated the inducing effect of TsA by about 82% 
emphasizing their relevance in HDAC recruitment (compare Fig. 20 page 60).  
Reporter gene analysis in MM6 cells, showed similar results. The mutation of GC4 alone, 
both in the minimal and larger promoter context, neutralized the activating effects of TsA. In 
MM6 cells both GC  box  4 and GC  box  5 revealed activating properties independently of 
HDACi treatment. Possibly HDACs and HATs are recruited at the same time to establish 
dynamic histone acetylation of promoter-bound histones. Acetylation of histone proteins is a 
dynamic process, regulated by the opposing effects of HATs and HDACs. For about 15% of 
the core histones rapid acetylation and deacetylation occurs (t1/2 = 7 min for monoacetylated 
histone H4 and t1/2 = 3-7 min for deacetylation). Other core histone proteins are acetylated 
and deacetylated at a slower rate of t1/2 = 200-300 min and t1/2 = 30 min respectively (Davie 
1997). 
In MM6 cells, the histone acetyltransferases as activating factors could overbalance HDACs, 
whereas in HeLa cells, HDACs tip the scales in the promoter regulation. As examined in 
ChIP assay the high acetylation degree of histone H4 in MM6 cells even without any TsA 
treatment supports the idea of histone acetyltransferase activity dominating over HDAC 
activity (compare Fig. 37 page 77). So far no studies exist on the histone acetylation status of 
the 5-LO gene in HeLa cells. The DNA methylation status of the 5-LO promoter in MM6 or 
HeLa cells is still unclear. However since 5-LO gene expression in MM6 cells is inducible 
with 1,25(OH)2D3 and TGFβ, but not in HeLa cells, we assume a methylation free promoter 
sequence in MM6 cells and a methylated sequence in the 5-LO negative HeLa cell line.  
In MM6 and HeLa cells the 5-LO promoter contains two negatively regulated stretches, one 
covering the sequence -5396 to –4895 and the other –914 to –779 bp in relation to the major 
TIS (Sorg et al. 2006). The second area overlaps with the more distal CpG island in the 
reporter gene construct N9. TsA treatment induces the promoter activity of N9, but does not 
completely overcome the repressive character of this promoter region. Mutation of the two 
GC boxes present in the additional promoter sequence of this construct reduces promoter 
activity, but does not relieve the response to TsA, whereas the deletion/mutation of the 
proximal sites GC0, GC1, GC2, GC4 and GC5 (see construct N9GC01245) clearly abolishes 
the effect. This finding demonstrates, that HDACs are rather recruited to the proximal than to 
the distal promoter area and further suggests involvement of other repressors in the distal 
promoter area.  Discussion  
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Since the protein levels of Sp1 and Sp3 in HeLa and MM6 cells did not change upon TsA 
treatment, the effect of their transactivation activity was investigated by cotransfection of Sp1 
and Sp3 with the 5-LO promoter mutants (Fig. 32 page 72). The cotransfection alone did not 
influence promoter activity, maybe due to already high endogenous Sp1 and Sp3 protein 
levels. Only with TsA treatment, both proteins induced the promoter activity of construct 
N13, indicating direct influence of TsA treatment on the transactivation capability of Sp1 and 
Sp3, possibly by posttranslational modifications or changing interacting protein partners. 
Interestingly neither Sp1 nor Sp3 could induce the promoter activity of N10, independently of 
TsA treatment. Sp1 and Sp3 only seem to influence the two proximal GC sites in front of the 
TIS. Regarding the different GC box mutants of N13, promoter activity was reduced after 
mutation of either GC box, but stronger activated by cotransfection than N13 itself. When 
GC4, the activating element in HeLa cells, was mutated, Sp1 cotransfection showed the 
strongest impact in relative promoter activation (11.7-fold induction). Possibly Sp1/Sp3 
compete with a repressor binding to GC box 5.  
In vitro binding of Sp1 and Sp3 to the 5-fold GC box, GC4 and GC5 was unchanged after 
HDACi treatment as investigated in DAPA. However, in vivo binding of Sp1 and Sp3 
increased upon TsA treatment, especially in the proximal promoter area, containing the 
elements investigated in DAPA. In chromatin immunoprecipitation assays the acetylation 
status of the 5-LO promoter, RNA polymerase  II binding, Sp1 and Sp3 binding were 
investigated in MM6 cells after TsA treatment. Especially in the promoter area containing all 
proximal GC sites binding of Sp1 and Sp3 is increased. Sp1 does not seem to associate with 
the more distal regions (-1049 to -318), whereas Sp3 does very well, also without HDACi 
treatment (compare Fig. 37 page 77).  
The divergence between in vitro and in vivo binding affinities of Sp1 and Sp3 to the 5-LO 
promoter after TsA treatment might be explained by changes in chromatin structure, such as 
acetylation of H3 and H4, resulting in a more relaxed chromatin structure facilitating Sp1 and 
Sp3 binding. Interestingly already in untreated Mono Mac  6 cells the examined promoter 
region contains heavily acetylated nucleosomal histone protein H4. Unlikely TsA renders the 
chromatin structure even more accessible for transcription factor binding. It has been 
demonstrated that acetylation to 46% of maximal site occupancy was sufficient to stimulate 
transcription by RNA polymerase III (Tse et al. 1998). However RNA polymerase II binding 
is clearly increased after TsA treatment and spreads to the more distal promoter parts, 
including the negatively regulated promoter area present in the reporter gene construct N9. 
The acetylation status of H3 remains to be investigated.   Discussion  
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Since the 5-LO promoter lacks TATAA or CCAAT boxes and only contains an initiator-like 
sequence, Sp1 is likely the driving force in recruiting the basal transcription machinery in this 
promoter context (Dishart et al. 2005). Increased in vivo binding of Sp1 would subsequently  
explain the increased RNA polymerase II binding and the observed rise in promoter activity 
in reporter gene assays as well as in 5-LO mRNA levels. So far it is not clear, if Sp3 is also 
able to attract the basal transcription machinery, but surely Sp3 could recruit coactivators such 
as HATs. Also the cotransfection studies, though performed in HeLa cells, suggest only 
activating functions of both Sp1 and Sp3. Sadly these ChIP data cannot discriminate protein 
binding to the single GC  boxes. ChIP assays with stably transfected mutated promoter 
constructs could help to identify specific transcription factor binding (Banchio et al. 2004).  
The high number and proximity of the different Sp1 binding sites just upstream of the major 
transcriptional start site of the 5-LO promoter suggests an interaction between the factors 
binding to these sites. Especially for Sp1 synergistic activation by oligomerization has been 
described (Mastrangelo et al. 1991). Sp1 may not only provide a platform for the basal 
transcription machinery, but also for corepressor/coactivator complexes until different stimuli 
cause transcriptional initiation. Only recently, the interaction between the zinc-finger domain 
of Sp1 and the corepressors NCoR, SMRT and BCoR has been described (Lee et al. 2005). 
Sp1 sites have also been found to be involved in tissue-specific gene expression. For example 
the expression of CD14 in monocyte/macrophages is mediated by Sp1 (Zhang et al. 1994). 
Sp1 also regulates the myeloid-restricted expression of the human haematopoietic cell kinase 
(Hauses et al. 1998). Interestingly Sp1 can loop DNA between distal and proximal promoter 
sites (Pascal and Tjian 1991; Yu et al. 2003). In MM6 cells 5-LO gene expression is strongly 
induced after differentiation of the cells to macrophages with 1,25(OH)2D3/TGFβ (mRNA 
levels increase 43-fold after 24h treatment). In reporter gene assays though, 
1,25(OH)2D3/TGFβ failed to induce 5-LO promoter activity (Klan et al. 2003). Only the 
incorporation of the 5-LO coding sequence into the reporter gene constructs alone 
(pGL-ba-cdsInJM) or together with the promoter (pN10-cdsInJM; the effect is even enhanced 
when introns J and M are included) led to a significant stimulation by 1,25(OH)2D3 and 
TGFβ, 28-fold and 14-fold respectively (unpublished data from our lab). Interestingly the 
addition of TsA to 1,25(OH)2D3/TGFβ reduced the stimulation in the reporter gene assays 
(2.3-fold and 5.5-fold respectively for pN10-cdsInJM and pGl3-ba-cdsInJM) as well as at the 
mRNA level (16-fold). On the other hand the strong induction of the promoter activity by 
TsA is abolished by the presence of the cds. However, Seuter et al. could also show that Sp1 
cotransfection, but not Sp3 cotransfection reestablished the TsA induced activity in reporter  Discussion  
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gene assays (3.2- versus 8.9-fold induction for pN10-cdsInJM without/with Sp1 
cotransfection). ChIP assays further revealed simultaneous in vivo binding of the VDR and 
RNA polymerase II to the proximal promoter area (-220 bp to +142 bp) of the 5-LO gene, 
lacking any VDRE surrounding the TIS, after 1,25(OH)2D3 stimulation (Seuter et al. 2006). 
Other studies have shown that 1,25(OH)2D3 induces complex formation between Sp1 and 
VDR at the p27 promoter and stimulates transactivation via a Sp1 consensus site within the 
promoter area (Huang et al. 2004; Cheng et al. 2006). Nevertheless the p27 promoter alone is 
1,25(OH)2D3 inducible in reporter gene studies. In experiments with the mutated proximal 
GC  boxes GC4 and GC5 of the 5-LO promoter in pN10-cdsInJM did not reduce the 
1,25(OH)2D3/TGFβ induction (data not shown), indicating no interaction between the Sp1 
sites and a possible downstream enhancer in the 5-LO cds. The possible competitive 
activation of 5-LO by TsA and 1,25(OH)2D3/TGFβ cannot simply be explained by changes in 
chromatin structure, since histone protein H4 is already heavily acetylated in untreated MM6 
cells, which do not express 5-LO (see Fig. 37 page 77). Both agents 1,25(OH)2D3 and TsA 
stimulate RNA polymerase II binding to the proximal promoter area, but this effect does not 
explain, why TsA decreases 1,25(OH)2D3/TGFβ induced 5-LO gene expression (Seuter et al. 
2006).  
A possible link between the TsA and TGFβ/1,25(OH)2D3 mediated induction of 5-LO 
expression could be the regulation of Smad 7 by acetylation/deacetylation. TGFβ signaling is 
mediated through the Smad family of transcription factors. Acetylation of the inhibitory 
Smad  7 by p300 leads to increased protein stability by preventing the ubiquitination of 
overlapping lysines and subsequent protein degradation (Gronroos et al. 2002). After TGFβ 
stimulation Smad 7 translocates to the activated TGFβ receptors at the plasma membrane 
together with the Smurf E3-ubiquitin ligase. The Smurf-Smad  7 complex blocks the 
interaction between the receptor-activated Smads and the receptor, thus blocking TGFβ 
induction. HDAC1 and HDAC3 strongly bind to Smad 7, HDAC2 weakly (Simonsson et al. 
2005). Deacetylation by HDACs increases the degradation of Smad  7. Hence HDACi 
treatment would possibly counteract TGFβ induction, explaining why the combination of TsA 
and 1,25(OH)2D3/TGFβ results in a lower 5-LO gene expression than 1,25(OH)2D3/TGFβ 
alone. 
HDACi as well as 1,25(OH)2D3 induce cell differentiation. Differentiation of monocytes to 
macrophages is accompanied by an upregulation of 5-LO activity and protein expression. 
Also the platelet-activating factor acetylhydrolase gene is upregulated during the maturation 
of primary human monocytes into macrophages, a process, which is associated with an  Discussion  
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increase of Sp1 and Sp3 DNA-binding activity to the promoter (Wu et al. 2003). Sp1 and Sp3 
also activate the expression of the myeloid-restricted integrin genes CD11b and CD11c in 
differentiating monocytes (Chen et al. 1993; Noti et al. 1996; Noti 1997).  
In HL-60 and MM6 cells, a differentiation inducer, such as 1,25(OH)2D3, is necessary to 
upregulate 5-LO expression (Brungs et al. 1994; 1995). In MM6 cells the maximal 
upregulation of 5-LO primary transcripts already occurs after 8 h of treatment. For this, both 
agents are required and protein expression induced by TGFβ is involved (Harle et al. 1998). 
In order to achieve increased 5-LO protein activity at least 48 h treatment is necessary. In vivo 
binding of Sp1 and Sp3 to the 5-LO promoter is already induced after 6 h of TsA treatment in 
MM6 cells. Also the reporter gene data suggest an early activation of the promoter (compare 
Fig. 29 page 68). After 4 h of TsA treatment N10 is activated 3.9-fold. However TsA does not 
change the protein levels of Sp1, Sp3, HDAC1 or HDAC2 (Fig. 31 page 71). If 
1,25(OH)2D3/TGFβ would exert their activating effect simply by increasing Sp1/Sp3 binding 
to the proximal 5-LO promoter, the treatment would also increase promoter activity in 
reporter gene assays, which is not the case. In a study performed by Dishart, Sp1/Sp3 protein 
levels and their DNA binding affinity in MM6 cells did not alter after 1,25(OH)2D3/TGFβ 
treatment (Dishart et al. 2005). 
Factors binding to GC4 and GC5, likely Sp1 as well as Sp3, recruit HDAC activity towards 
the 5-LO promoter as demonstrated in reporter gene assays. In order to identify the HDACs 
recruited to the promoter, the effects of another HDACi were investigated. VPA preferentially 
inhibits class I HDACs, at least HDAC2 is 5-fold more efficiently inhibited than HDAC5 and 
HDAC6 (Gottlicher et al. 2001). In contrast to TsA, VPA also induces the proteasomal 
degradation of HDAC2 (Kramer et al. 2003). In the reporter gene study with the 5-LO 
construct N10 VPA evoked similar effects as TsA. Maybe due to the lower specificity of VPA 
in comparison to TsA (IC50 ∼1 mM versus 37 nM, unpublished data and (Klan et al. 2003)) 
the promoter activation was less pronounced. Clearly nicotinamide, a class  III HDAC 
inihibitor did not influence 5-LO promoter activity.  
Most likely rather HDAC1, 2 or 3 are recruited to the 5-LO promoter than class II HDACs. 
All class I HDACs, except for HDAC8 are involved in transcriptional regulation. Several 
reports describe the interaction between Sp1 and HDAC1 or HDAC2 and their recruitment to 
different promoters (Sowa et al. 1997; Sowa et al. 1999; Xiao et al. 1999; Hou et al. 2002). 
HDAC1 association with the p21 (Gui et al. 2004) and metallothionein I promoter (Ghoshal et 
al. 2002) is inhibited by HDACi. A new study could show that in human colon cancer cells 
the p21 promoter is regulated by multiple HDACs including HDAC1, 2 and 3 (Wilson et al.  Discussion  
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2006). The TsA inducible gdf11 promoter on the other hand is exclusivley regulated by 
HDAC3 (Zhang et al. 2004). For catalytic activity HDAC3 exists in a complex with the 
nuclear receptor corepressors NCoR/SMRT (Guenther et al. 2001). HDAC1 and HDAC2 
together form the catalytic core of mSin3a, Mi2/NuRD/NRD and CoREST complexes (Cress 
and Seto 2000; Ng and Bird 2000; Grozinger and Schreiber 2002).  
In cotransfection studies with the different class I HDACs, HDAC1, 2, 3 and 8, the potential 
repressors rather activated the promoter construct N13 (Fig. 38 page 79). Similarly in 
cotransfection studies with the human gdf11 promoter, also performed in HeLa cells, all 
cotransfected histone deacetylases induced promoter activity, except for HDAC3, later 
identified as the recruited corepressor of gdf11 promoter activity (Zhang et al. 2004). There 
are cases, where HDACs appear to be required for gene activation. For example, TsA 
decreases CD9 expression in macrophages (Wang et al. 2002) or expression of Hmga2 protein 
in HeLa, NIH3T3 and F9 cells (Ferguson et al. 2003). Thus indirect effects may account for 
the activating function of HDACs in these cotransfection experiments. 
TsA treatment relieved the activition by HDAC1, 2 and 3. As in the experiments before, 
HDACi treatment induced transactivation by Sp1. Interestingly cotransfection of HDAC2 and 
HDAC8 enhanced this effect. It is hard to draw any conclusion from this experiment. The 
expression pattern of HDAC8, which was so far only detected in smooth muscle cells, and its 
potential role in regulation of smooth muscle cytoskeletal proteins rather excludes this protein 
as a potential regulator of 5-LO promoter activity (Waltregny et al. 2004; Waltregny et al. 
2005). In concomitant Western blot analysis HDAC8 could not be detected in HeLa cells, 
whereas all other class I HDACs were expressed.  
Sadly HDAC1 recruitment could not be demonstrated in DNA affinity purification assays, 
neither with HeLa nor MM6 cell extracts. Though HDAC2 binding to GC4 and GC5 was 
detected, the conditions used to screen for Sp1/Sp3 binding were not strict enough to show 
distinct association of HDAC2 to the separate probes. Instead HDAC2 already showed 
affinity to the beads only. HDAC3 and HDAC8 could not be detected at all. siRNA in 
combination with reporter gene assays would be a nice approach to investigate the 
recruitment of HDACs to the proximal Sp1 binding sites. Subsequently in ChIP experiments 
in vivo binding should be examined.  
Histone acetyltransferases and histone deacetylases usually function in an equilibrium. Often 
HATs and HDACs are recruited simultaneously. HDACi treatment in these cases shifts the 
balance towards enhanced HAT activity. As known for HDACs, HATs not only target histone 
proteins but also transcription factors, including Sp1 and Sp3. Since TsA induced in vivo  Discussion  
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binding of Sp1 and Sp3, posttranslational modifications might play a role in the increased 
binding and/or transactivation activity. Acetylation of Sp1/Sp3 or phosphorylation of Sp1 
after TsA treatment has been described. In case of the IGFBP-3 promoter TsA treament 
released Sp3 and HDAC1 from a protein complex consisting of Sp1/Sp3/HDAC1/p300. TsA 
treatment furthermore induced phosphorylation of Sp1 and Sp1 binding was enhanced in gel 
shifts (Choi et al. 2002). However it was not shown, that phospho-Sp1 binding itself is 
increased or how TsA triggers phosphorylation. At the TGFβ type II receptor, TsA leads to 
the release of HDAC1 from a NF-Y/Sp1/HDAC1 protein complex with subsequent 
recruitment of p300 and PCAF with concomitant acetylation of Sp1 depending on PCAF 
acetyltransferase activity (Huang et al. 2005). HDAC1 is also released from the p21 and 
metallothionein  I promoter after TsA treatment (Ghoshal et al. 2002; Gui et al. 2004). 
HDAC1 directly interacts with the zinc-finger DNA binding domains of Sp1 and interferes 
with the recognition of GC-boxes (Kang et al. 2005). Similarly p300 interaction with the 
DNA binding domain of the transcription factor Sp1 has been described. Despite acetylation 
of Sp1 by the acetyltransferase domain of p300 the pure physical interaction with p300 
stimulated the DNA binding activity of Sp1 (Suzuki et al. 2000). DNA binding of Sp1 on the 
other hand inhibited the p300 interaction. Also the interaction between the inhibitory domain 
and DNA binding domain of Sp1 with the nuclear corepressors SMRT, NCoR and BCoR has 
previously been described. The same group also suggests a modulation of this interaction by 
MEK (Lee et al. 2005), but by phosphorylation of the corepressor molecules. 
Many hematopoietic transcription factors are reversible acetylated. Acetylation can influence 
DNA binding, transcription activation, repressor activity, protein-protein interactions and 
protein stability (reviewed in (Glozak et al. 2005). The regulation of transcription factors by 
acetylation/deacetylation may influence tissue-specific and lineage-specific gene expression. 
Sadly the binding of acetylated Sp1 or Sp3 in DNA affinity purification assays could not be 
demonstrated. Possibly the affected protein amounts are not detectable in this assay.  
Immunoprecipitation studies performed in our lab to identify increased acetylation of Sp1 or 
Sp3 did not produce repeatable results. This may be due to too low specificity of the 
acetyl-lysine antibody. Furthermore the antibody may just not recognize the acetylated lysine 
in our context.  
In summary, TsA treatment induces 5-LO promoter activity and 5-LO mRNA levels. The data 
so far available suggest that increased in vivo binding of Sp1 and Sp3 to the proximal 
promoter with subsequent or concomitant RNA polymerase II binding are responsible for the 
upregulated gene transcription. Recruitment of HDACs or HATs via the Sp1 binding sites  Discussion  
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GC4 or GC5 could not be demonstrated. Therefore it was not possible to show TsA induced 
variances in recruited protein complexes. We could not demonstrate TsA induced post-
translational modifications of Sp1 or Sp3 either, such as acetylation. However increased 
acetylation of histone H4 protein, resulting in a transcriptional more accessible chromatin 
structure at least in MM6 cells does not seem the reason for increased Sp1/Sp3 binding as 
indicated by the already high basal acetylation status of H4 protein surrounding the 5-LO 
promoter. TsA does not alter the expression levels of Sp1/Sp3 either.  
In future studies HDAC and HAT recruitment, as well as the association of corepressor 
complexes, such as NCoR, mSin3A, SMRT and BCoR should be studied. It would be of 
interest to improve the DAPA conditions in order to show specific HDAC2 recruitment. With 
re-ChIP analysis also the in-vivo interaction between Sp1 and i.e. HDACs or possible VDR 
and Smads could be investigated. 1,25(OH)2D3/TGFβ effects on Sp1 and Sp3 in vivo binding 
should be investigated, to rule out or proof interacting pathways in 5-LO regulation. 
 
5.2  Regulation of the 5-LO promoter by DNA methylation 
As already outlined in the first part of the discussion 5-LO gene transcription is regulated by 
DNA methylation and the recruitment of histone deacetylases. Uhl and Klan could show that 
treatment of the 5-LO negative cell lines HL-60TB and U937 with the DNA 
methyltransferase inhibitor 5-aza-2`-deoxcytidine (AdC) demethylated the 5-LO promoter 
and induced 5-LO gene expression (Uhl et al. 2002). Concurrently in vitro methylation of 
5-LO reporter gene plasmids strongly reduced the promoter activity in MM6 and HeLa cells 
(Klan et al. 2003). TsA treatment partially reversed the methylation dependent promoter 
repression, but the promoter activity never reached the level of the unmethylated plasmids.  
These first experiments demonstrated a role of DNA methylation in the regulation of 5-LO, 
but did not further investigate the DNA sequences or proteins involved in this mechanism, 
such as methyl-CpG-binding proteins (MBDs), DNA methyltransferases (DNMTs) or histone 
modifying enzymes such as HDACs. 
In the further study we focused on identifying relevant DNA sequences in the regulation by 
DNA methylation within the core promoter, comprising the sequence -778 bp to +53 bp in 
relation to the major TIS, present in the most active reporter gene construct N10, and its 
successive deletion variants N11 to N16. The data indicate that the more sites become 
methylated, the lower is the promoter activity of the reporter gene constructs. Complete 
methylation by in vitro methylation with SssI methylase abolishes promoter activity, partial 
methylation by M. HpaII or M. HhaI recognizing more distinct methylation sites, –CCGG-  Discussion  
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and  -CGCG- respectively, strongly reduced promoter activity (about 12-fold, 5-fold after 
HpaII and HhaI methylation, respectively and 51-fold after SssI methylation). It seems, that in 
the shorter deletion variants N14 to N16 the different methylation patterns have similar 
impacts on promoter activity, either due to the adjusting ratio of methylation sites or the 
special relevance of particular sites within this proximal promoter area. However, since the 
promoter activity was only significantly decreased in the larger deletion variants N10 to N13, 
it remains speculative to assume special sites within the promoter region of N14. Also the 
plasmid backbone may influence the promoter activity, indicated by the methylation effects of 
M. HpaII on the control plasmid pGl3Prom, lacking any recognition site for this methylase 
within the sequence of the SV40 promoter, but showing a strong reduction in promoter 
activity (about 17-fold). MBDs binding to distal plasmid parts outside of the promoter area 
could influence promoter activity. Regulation from about 3  kb far distal sites have been 
described for MBD1 (Fujita et al. 2003). Also mutation of a putative MBD1 binding site in an 
FGF2-luciferase reporter construct did not relieve the repressing effect (Jorgensen et al. 
2004), suggesting that other CpGs may instead attract the MBD1 protein. 
Since DNA methylation often involves HDAC recruitment, we tested TsA treatment on in 
vitro methylated plasmids. Clearly, the treatment cannot reverse the repressing effect of the 
methylation on the promoter activity, indicating additional repressing mechanisms besides 
HDAC recruitment, i.e subsequent chromatin condensation, histone H3K9 methylation and 
HP1 binding (compare Fig. 45 C page 87). Studies with transiently and stably transfected 
promoter constructs did not show differences in HDAC recruitment, suggesting the formation 
of some kind of minichromatin of the transfected plasmids (Ishizuka and Lazar 2003; Zhang 
et al. 2004). However after HpaII and HhaI methylation the induction by TsA is enhanced 
compared to the unmethylated plasmids (for example 17-fold versus 68–fold for N10 after 
HpaII methylation), suggesting increased HDAC recruitment. The complete methylation by 
M. SssI abolishes promoter activity and inducibility by TsA. DNA methylation at this stage 
dominates over histone acetylation/deacetylation. 
In a cotransfection study with murine Mbd1, Mbd2, Mbd3 and rat MeCP2, only Mbd1 further 
reduced 5-LO promoter activity, most effectively after HpaII methylation, both in N10 and 
the shorter deletion variant N13. TsA did not relieve the repressing effects, indicating other 
repressive mechanisms involved besides histone deacetylation. Repression by the TRD of 
MBD proteins is variably sensitive to TsA, indicating that HDAC activity is not consistently 
involved in the regulation by MBDs (Ng et al. 2000; Fujita et al. 2003). Whereas 
MBD2/MBD3, as well as MeCP2 are associated with HDAC activity in the corepressor  Discussion  
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complexes mSin3a and Mi2-NuRD (Nan et al. 1998; Ng et al. 1999), MBD1 does not 
coimmunoprecipitate with HDAC1. MBD1 is capable of binding to both methylated and 
unmethylated promoters (Fujita et al. 2000; Ng et al. 2000). In gel shifts MBD1 binds to a 
single symmetrically methylated CpG site, containing a –CCGG- site, equivalent to the motif 
recognized by HpaII methylase (Hendrich and Bird 1998). An other study demonstrated that 
MBD1 preferentially binds to densely methylated DNA fragments (Fujita et al. 1999). The 
interaction with non-methylated DNA depends on a third zinc-coordinating CXXC domain, 
which is not present in all MBD1 splice variants (Fujita et al. 1999; Jorgensen et al. 2004), 
whereas interaction with methylated DNA is mediated by the methyl-CpG-binding domain 
alone. Interestingly MBD1 can repress promoter activity from far distances (Fujita et al. 
2003), eventually making it difficult to identify specific DNA sequences within in vitro 
methylated plasmids. Recently the interaction between MBD1 and MCAF1 has been 
described (Fujita et al. 2003). In the absence of MBD1 MCAF1 acts as an transcriptional 
activator, which interacts with Sp1. MBD1 inhibits this interaction and interferes with the 
Sp1-mediated transactivation. Furthermore the MBD1-MCAF1 complex associates with 
SETDB1, a histone methyltransferase, facilitating the formation of heterochromatin (Sarraf 
and Stancheva 2004; Ichimura et al. 2005). Sp1-activated transcription of methylated p16 and 
SNRPN promoters was inhibited by all MBD1 isoforms. The isoforms MBD1v1 and 
MBD1v2 carrying the CXXC3 domain also reduced Sp1-activated transcription from the 
unmethylated promoters (Fujita et al. 1999).  
According to these reports MBD1 seems as the ideal candidate to initiate transcriptional 
repression of the 5-LO promoter. Interacting with MCAF1, MBD1 would interfere with Sp1 
induced promoter activity. Subsequent recruitment of the histone methyltransferase SETDB1 
may induce DNA methylation and heterochromatin formation by HP1 binding (Ichimura et al. 
2005). Also the presence of the MCAF1-Sp1 complex in HeLa cells has been demonstrated 
by Fujita (Fujita et al. 2003).  
Mbd1 reduces the promoter activity in both reporter gene constructs N10 and N13, especially 
after in vitro methylation. Only in combination with TsA treatment the unmethylated 
constructs are influenced by Mbd1. However, also the murine isoform Mbd1a, which was 
cotransfected, binds to unmethylated DNA (Jorgensen et al. 2004). Maybe HDAC recruitment 
by Sp1 via GC box 4 interferes with Mbd1 binding. The strong reduction in promoter activity 
by Mbd1 cotransfection after HpaII methylation suggests a special relevance of the 
recognition motif –CCGG-. Since the effect occurred within the shorter deletion variant N13, 
further mutational study of the potential CpG sites of this promoter part was performed. If  Discussion  
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possible, CpGs were mutated to TpG, thus preventing methylation of the cytosine (see Tab. 1 
at page 47 for the exact primer sequences).  
Unexpectedly the point mutation within the inverted repeat structure beside the 5-fold 
GC-box (N13MutInvRep1), indeed containing a –CCGG- methylation site, strongly reduced 
the promoter activity of N13 already in an unmethylated state. Apart from this mutation, only 
the elimination of the GC box 5 flanking methylation sites in N13MutMethII, including a 
HhaI methylation site, significantly reduced the promoter activity of the unmethylated 
construct. In the context of increased Sp1 binding in gel shifts after methylation of exactly 
these adjacent CpG sites (compare Fig. 56 page 105), it is reasonable that the same sites are of 
relevance for promoter activity in an unmethylated state. The impact of the point mutation in 
N13Rep1 remains unexplainable. So far, the role of the inverted repeat structure in the 5-LO 
promoter is unknown and the sequence does not contain a known putative response element 
for any transcription factor. However the intact structure of this element seems to be 
important for full promoter activity. None of the mutations changed the TsA response in the 
unmethylated state, underlining the role of GC4 in recruiting HDAC activity (compare Fig. 50 
page 92).  
Other  HpaII methylation sites were mutated within construct N13MutMethIII and 
N13MutMethInvRep2. After in vitro methylation with M. HpaII the methylation triggered 
reduction of promoter activity was relieved in construct N13Rep1 and N13MMII. Since both 
constructs already displayed impaired promoter activity in an unmethylated state, the reduced 
impact of DNA methylation on their activity may just reflect their already low basal activity, 
but does not completely exclude a potential role in DNA methylation. Only the mutation of 
the HpaII methylation sites in N13MMIII significantly relieved the methylation triggered 
repression, but only after HhaI methylation, which should not be affected by the mutation of 
an HpaII site (compare Fig. 51 B page 93).  
The additional cotransfection of Mbd1 further reduced the promoter activity of the mutants, 
but was not significantly changed by any mutation. Possibly Mbd1 alternatively from sites 
outside the promoter region represses the promoter activity, as described by Fujita (Fujita et 
al. 2003). Under these circumstances it is hard to draw any conclusion from the mutational 
analysis. Also the endogenous expression of MBD proteins may interfere with the 
overexpression of Mbd1 and conceal cotransfection effects. 
N13 also contains a potential MIZF (MBD2-interacting zinc finger) recognition sequence 
-CGGAC- (at position +7 to +11  bp in relation to TIS), which is mutated in construct 
N13MMI (Sekimata et al. 2001; Sekimata and Homma 2004). MIZF recruits MBD2 and  Discussion  
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potentially the HDAC containing Mi2-NuRD complex to specific target genes and allows 
sequence-dependent repression by MBD2. However, the mutation of this motif to  -TGGAC- 
has no impact on the methylation effect, nor on the TsA response. The two so far known 
recognition sites for Kaiso, -CGCGCCCAAACG- serves as a recognition motif in a 
methylated state and –CTGCNA- in an unmethylated state, are not present in N13. However 
the minimal recognition motif  -CTGCNA- is present in the 5-LO promoter sequence at 
-418 bp to –423 bp in relation to the TIS (also comprised in construct N10) and has to be 
considered in further studies. Apart from Kaiso, ZBTB4 and ZBTB38, two other members of 
the BTB/POZ transcription factor family, have been identified as CpG binding proteins. Both 
zinc-finger containing proteins can bind to a single methylated CpG residue. ZBTB4 
recognizes the extended Kaiso binding site –TCCTGCNA-, whereas ZBTB38 binds to the E-
box -CACCTG- (Filion et al. 2006). The ZBTB4 motif is not detectable within the 5-LO 
promoter region, but the E-box element is found at several positions (+26 to +31, -3031 to 
-3026, -3777 to -3772 on the direct strand and on the complementary strand at –3174 to 
-3169,  -1039 to –1034 in relation to the 5-LO TIS). 
The cotransfection study and mutational analysis present some evidence that MBDs, possibly 
MBD1, could be recruited to the proximal 5-LO promoter. However, no direct interaction in 
gel shifts or even in ChIP assays has so far been presented. The gel shifts performed with in 
vitro methylated probes (discussed below) clearly indicate additional protein binding to the 
methylated probes, especially when HpaII recognition sites are methylated. Unfortunately 
supershift studies have not been performed yet to eventually identify MBD1 recruitment. Also 
DNA affinity purification assays failed to proof any MBD recruitment to the in vitro 
methylated promoter sequence of N13, probably due to the experimental conditions and low 
MBD protein abundance in HeLa cells. Even with nuclear extracts Western blot analysis 
revealed only faint protein bands.  
Since the basal and TsA induced promoter activity depends on Sp1/Sp3 binding, the influence 
of DNA methylation on Sp1 binding was investigated. The experiments as in the methylation 
study focused on the proximal promoter area, which contains three functional Sp1 binding 
sites. At least in vitro Sp1 binding to the 5-fold GC box, GC box 4 and GC box 5 has been 
shown in gel shifts and/or DNase I footprints (In et al. 1997; Silverman et al. 1998; Dishart et 
al. 2005). In vivo binding of Sp1 and Sp3 covering the same promoter area was demonstrated 
in ChIP assays (compare Fig. 37 page 77 ).  
Concerning Sp1-binding controversial studies exist, describing either impaired association 
with DNA after methylation or no influence of the DNA modification (Holler et al. 1988;  Discussion  
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Clark et al. 1997; Fujita et al. 2000; Zhu et al. 2003). For example, in reporter gene assays 
with p16 and SNRPN promoter constructs the cotransfection of Sp1 even enhanced the 
promoter activity after in vitro methylation (Fujita et al. 2000). However complete 
methylation of 5-LO promoter constructs with SssI methylase abolishes promoter activity 
(Uhl et al. 2002; Klan et al. 2003), suggesting that Sp1/Sp3 binding and transactivation is 
inhibited. 
The gel shifts performed with nuclear extracts from HeLa and MM6 cells and the three 
different 5-LO promoter probes indicate differential binding characteristics of Sp1 depending 
on the surrounding promoter context and the complexity of the GC box. Clearly Sp1 binding 
to the 5-fold GC  box and the consensus motif GC4 is impaired, when surrounding 
methylation sites are methylated, and almost abolished, when the GC  box itself becomes 
methylated (compare Fig. 54 lanes 6, 10 and 14 and Fig. 58 lane 8 and 15). The slowest 
migrating band appears to be formed by Sp1 binding, since recombinant Sp1 protein shows 
the same migration height (compare Fig. 54 lane 3 and lane 6). Sadly supershift experiments 
did not work, thus it was not possible to identify the two faster migrating bands. Presumably 
these bands consist of the different Sp3 isoforms, since in other studies with HeLa cells the 
same gel shift patterns are produced and the bands disappear, when specific competitor is 
added (Zhu et al. 2003). Also Sp1 and Sp3 binding to all three sites has been demonstrated in 
DAPA. Both, methylation around GC4 (equivalent to in vitro HpaII methylation) and 
methylation of the site itself, lead to recruitment of an unidentified protein or protein 
complex. Mutation of the same sites in the reporter gene study (compare Fig. 51, construct 
N13MMIII) did not alter promoter activity after in vitro methylation.  
Looking at the 5-fold GC box, the recombinant Sp1 shift completely disappears when the 
probe is methylated (compare lane 8 and lane 15 in Fig. 58 page 101). However the Sp1 band 
produced with nuclear extract is hardly recognizable. The specific competitor does not 
completely prevent protein binding to this site, indicating some kind of competition between 
DNA binding proteins. In this case it is reasonable that Egr1 competes with Sp1 binding. Egr1 
binding to the 5-fold GC box has been demonstrated before (Silverman et al. 1998). No other 
Egr1 binding site within the proximal 5-LO promoter was identified in the same study. Since 
the consensus binding site for Egr1 is –GCGGGGGCG- the specific competitor used in our 
gel shift experiments would not reduce Egr1 binding. The addition of the specific competitor 
even produces a more distinct band, when the probe is methylated. However only a supershift 
would help to identify the new band. So far it is unclear if Egr1 binding is influenced by DNA  Discussion  
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methylation. If the slower migrating bands are really produced by Sp3 binding, Sp3 seems to 
bind better to the 5-fold GC box than to the consensus motif GC4.  
Interestingly, Sp1 binding to the non-consensus motif is increased after methylation of the 
surrounding CpG sites (see Fig. 56 and Fig. 57). However to both the unmethylated and 
methylated probe rather Sp3 seems to bind than Sp1. Also other than Sp protein binding to 
this site is demonstrated, since the competitor does not relieve the signal of the faster 
migrating bands.  
From these data it is clear, that DNA methylation, depending on its degree, at least reduces 
(HpaII and HhaI methylation) if not abolishes promoter activity (SssI methylation). At least 
during the establishment of complete DNA methylation HDAC activity is involved, indicated 
by the increased effects of the histone deacetylase inhibitor TsA on promoter activity after 
partial methylation by HpaII and HhaI. Later or after complete methylation TsA does not 
reverse the repressing effect of DNA methylation anymore, being in line with the idea, that 
DNA methylation is the final step in transcriptional shut down.  
The gel shifts demonstrate, that DNA methylation interferes with Sp1 binding to the 
activating binding sites GC4 and the 5-fold GC box. Additionally so far unidentified protein 
binding is enhanced after methylation most prominently to GC4. The methylation around 
GC5 induces Sp1 binding to this site, but Sp1 does not seem to be the major factor binding to 
this site.  
The cotransfection study suggests an involvement of MBD1 in the regulation of the 5-LO 
promoter. However the data do not provide clear evidence of a specific binding site. 
Supershift studies in combination with ChIP assays also proving in vivo binding should be 
performed in the future.  
  Summary  
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6  Summary 
5-LO is the key enzyme in the biosynthesis of proinflammatory leukotrienes, converting 
arachidonic acid to 5-HPETE, and in a second step 5-HPETE to leukotriene A4. Apart from 
the multiple regulation mechanisms on the enzyme level, also regulation of 5-LO gene 
expression is far more complex than originally expected. Although the 5-LO promoter 
possesses characteristics of so-called housekeeping genes, such as lack of TATA/CCAAT 
boxes and existence of several Sp1 binding sites, the 5-LO gene is tissue-specifically 
expressed in primarily immune competent cells of myeloid origin including granulocytes, 
monocytes, macrophages, mast cells and B-lymphocytes. So far two major mechanisms of 
5-LO gene regulation have been identified, but are far from understood. 5-LO gene expression 
in MM6 and HL-60 cells is strongly induced after differentiation of the cells with TGFβ and 
1,25(OH)2D3. Up to now, it is unclear how both agents exactly stimulate expression. It seems 
that improved transcript elongation and maturation are involved. In some monocytic cancer 
cell lines, such as HL-60-TB and U937, TGFβ and 1,25(OH)2D3 treatment are not able to 
activate 5-LO gene transcription. It was demonstrated, that in these cell lines the 5-LO core 
promoter is heavily methylated and that only demethylation by the DNA methyltransferase 
inhibitor 5-aza-2`-deoxycytidine (Adc) upregulated the 5-LO mRNA levels. It was also 
shown that the histone deacetylase inhibitor TsA could induce 5-LO mRNA levels, but only 
in 1,25(OH)2D3/TGFβ inducible MM6 cells. Interestingly the 1,25(OH)2D3/TGFβ effect on 
5-LO expression is reduced, when combined with TsA. Already from these previous data one 
can assume multiple regulatory mechanisms on the transcriptional level of 5-LO, from the 
complete shut down of 5-LO gene expression by DNA methylation to facultative and to 
induced 5-LO gene transcription involving epigenetic mechanisms and 
differentiation-induced upregulation by 1,25(OH)2D3/TGFβ. The work presented here focused 
on the regulation of the 5-LO promoter by DNA methylation and histone deacetylation.  
In the first part of my studies, the upregulation of 5-LO mRNA levels by the histone 
deacetylase inhibitor TsA was investigated. Reporter gene assays revealed that 5-LO 
promoter activity is strongly induced after 24 h treatment with 330 nM TsA (construct N10 up 
to 35-fold in HeLa cells). The effect is dependent on the presence of the proximal Sp1 binding 
site GC4 (-53 bp to –48 bp in relation to the major TIS) in both HeLa and MM6 cells. In vitro 
binding of the transcription factor Sp1 to this site has been demonstrated in gel shift assays 
and DNase I footprints. Mutation of the binding site resulted in a loss of basal promoter 
activity in both 5-LO negative HeLa cells and in 5-LO positive MM6 cells, as well as in the  Summary  
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loss of TsA inducibility. The mutational study of different Sp1 binding sites in a larger 
promoter context revealed the interaction or respectively the additive effect of the multiple 
Sp1 binding sites of the 5-LO promoter on basal as well as on TsA upregulated promoter 
activity. However, GC4 seems to be of special relevance for both the basal promoter activity, 
possibly recruiting the basal transcription machinery, as well as for the TsA induced 
upregulation of 5-LO promoter activity. TsA does not alter the protein expression levels of 
Sp1 and Sp3 as investigated in Western blot analysis, neither in HeLa nor in MM6 cells. DNA 
affinity purification assays revealed that TsA had no effect on the DNA affinity of Sp1 or 
Sp3. In vitro binding of both Sp1 and Sp3 to the 5-fold GC  box, GC4 and GC5 was 
demonstrated by DAPA analysis, but histone deacetylase inhibition did not change the 
associated protein amounts. Finally, in vivo binding of Sp1 and Sp3 was investigated in 
chromatin immunoprecipitation assay (ChIP) in MM6 cells. TsA clearly induced the 
association of both proteins to the promoter area surrounding the TIS. Upon TsA treatment 
also RNA polymerase  II binding to the area surrounding the TIS (-318 to +52  bp) was 
increased and even initiated in the more distal promoter parts –1049 to –292 bp, which are 
negatively regulated in reporter gene assays. Interestingly histone H4 is already highly 
acetylated without TsA treatment and the acetylation status of H4 remains unchanged after 
histone deacetylase inhibition, indicating an open chromatin structure of the 5-LO gene in 
MM6 cells. In a cotransfection study with Sp1 and Sp3, the transactivating potential of factors 
was investigated and in accordance with the ChIP data, Sp1 and Sp3 increased the promoter 
activity, but only after TsA treatment. 
Since alterations in chromatin structure do not seem to be the reason for increased Sp1/Sp3 
binding to the 5-LO promoter, we assumed that TsA might trigger post-translational 
modifications of the transcription factors, such as acetylation, which in some cases facilitated 
DNA binding or transactivation. However in DNA affinity purification assays, I could not 
show increased binding of acetylated Sp1 or Sp3, not even identify the acetylation at all. 
Immunoprecipitation studies in our lab so far could not demonstrate an increase in Sp1 or Sp3 
acetylation either. 
In order to identify the HDAC activity recruited by the Sp1/Sp3 binding sites, we also 
performed DAPA, HDAC2 association was detected, but unspecifically. No other HDAC 
recruitment could be demonstrated, nor association of the histone acetyltransferases p300 or 
PCAF. At least in immunoprecipitation studies performed in our lab interaction between Sp1 
and HDAC1 as well with HDAC2 was demonstrated. TsA did not alter the association 
though.   Summary  
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In gel shift assays, the influence of DNA methylation on Sp1 binding was investigated. The 
results indicate different roles for the three proximal promoter sites. Whereas Sp1 binding to 
the 5-fold GC  box and GC4 is impaired by DNA methylation, binding to GC5 is even 
increased. The data also indicate, that possibly rather Sp3 than Sp1 is recruited to this 
non-consensus binding site independent of the methylation state. However, so far no 
supershift experiments were performed to prove Sp3 binding. Interestingly, DNA methylation 
not only decreases Sp1 binding to GC4 and the tandemized GC  box, but also leads to 
prominent association of so far unidentified protein to thess promoter regions. A 
cotransfection study with methylated 5-LO promoter constructs and the murine 
methyl-CpG-binding proteins suggest MBD1 involvement in the regulation of the 5-LO 
promoter. A following mutational analysis of the different methylation sites within the 
proximal promoter area (-78 bp to +53 bp in relation to TIS) could not relieve the repressive 
effect of Mbd1 cotransfection. Thus it was not possible to identify a specific binding site for 
Mbd1. The reporter gene assays with in vitro methylated promoter constructs demonstrated 
increased HDAC recruitment after partial promoter methylation and complete loss of 
promoter activtiy after complete methylation. Since in gel shifts Sp1 binding is inhibited by 
DNA methylation, at least to the 5-fold GC box and the activating element GC4, and similarly 
the mutation/deletion of the same sites strongly reduces or inhibits promoter activity, it is 
likely to assume, that the loss of promoter activity after in vitro methylation is in the first 
place due to impaired Sp1/Sp3 binding. In future studies it would be of strong interest to 
investigate Sp1/Sp3 in vivo binding in a methylated 5-LO promoter area. Together the data 
underline the importance and complexity of Sp1/Sp3 binding to the GC-rich sites in the 
regulation of 5-LO promoter activity in response to the histone deacetylase inhibitor TsA as 
well as in respect to DNA methylation.  
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7  Zusammenfassung 
Die 5-Lipoxygenase ist das Schlüsselenzym in der Leukotrienbiosynthese. Sie katalysiert den 
Einbau von molekularem Sauerstoff in Arachidonsäure zur 5-HPETE (5(S)-Hydroxyperoxy-
6-trans-8, 11, 14-cis-eicosatetraensäure) und in einer weiteren Reaktion den Umbau der 
5-HPETE zum instabilen Epoxid Leukotrien A4 (LTA4). Neben den vielfältigen 
Regulationswegen auf Enzymebene, gestaltet sich auch die Regulation der 
5-LO-Genexpression weit komplexer als zunächst erwartet. Obwohl der 5-LO-Promotor 
einige Eigenschaften von sogenannten Haushaltsgenen aufweist, wie das Fehlen einer TATA- 
oder CCAAT-Box und das Vorhandensein zahlreicher Sp1-Bindungsstellen, wird die 
5-Lipoxygenase zelltyp-spezifisch exprimiert, vorwiegend in immunkompetenten Zellen wie 
Granulozyten, Monozyten, Makrophagen, Mastzellen und B-Lymphozyten. Bisher konnten 
zwei wichtige Mechanismen der 5-LO-Genregulation beschrieben werden, die induzierte 
Genexpression nach Vitamin D3- und TGFβ-Behandlung, sowie die epigenetische Regulation 
durch DNA-Methylierung.  
In den beiden Krebszelllinien, MM6 und HL-60, nimmt die 5-LO-mRNA-Menge nach 
Differenzierung der Zellen mit 1,25(OH)2D3 (Vitamin D3) und TGFβ dramatisch zu (43-fach 
nach 24-stündiger Behandlung in MM6-Zellen). Bisher ist allerdings unklar, wie die beiden 
Agenzien die Expression stimulieren. Zumindest scheinen sowohl die Transkriptions-
elongation als auch die mRNA-Reifung involviert zu sein.  
In anderen monozytären Krebszelllinien dagegen, U937 und HL-60TB, konnten TGFβ und 
1,25(OH)2D3 die 5-LO-Transkription nicht aktivieren. Im gleichen Zusammenhang konnte 
gezeigt werden, dass die DNA des 5-LO-Kernpromotors in diesen 5-LO negativen Zelllinien 
stark methyliert vorliegt. Nur nach einer Demethylierung des Promotors mit 
5-Azadeoxycytidin konnte die 5-LO-mRNA-Menge durch 1,25(OH)2D3/TGFβ gesteigert 
werden.  
Auch die Behandlung mit dem Histondeacetylase-Hemmer Trichostatin A (TsA) erhöht die 
5-LO-mRNA-Menge (11-fach), allerdings nur in 1,25(OH)2D3/TGFβ-induzierbaren 
MM6-Zellen. Unerwarteter weise führt die Kombination von TsA und 1,25(OH)2D3/TGFβ im 
Vergleich zu 1,25(OH)2D3/TGFβ alleine zu einer verringerten 5-LO-Expression (17-fach 
versus 43-fach).  
Diese Daten zeigen, wie vielfältig die 5-LO-Transkription reguliert wird, ausgehend von der 
völligen Stilllegung des Gens, über eine fakultative bis hin zur induzierbaren Genaktivierung, 
die sowohl epigenetische Mechanismen als auch eine 1,25(OH)2D3/TGFβ-abhängige  Zusammenfassung  
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Induktion einschließen. Die hier präsentierte Arbeit legt ihren Schwerpunkt auf die 
Untersuchung der Regulation des 5-LO-Promotors durch DNA-Methylierung und 
Histondeacetylierung.  
Der erste Teil befasst sich mit dem Einfluss des Histondeacetylase-Hemmers TsA auf die 
5-LO-Genexpression. In Reportergenstudien zeigte sich, dass die 5-LO-Promotoraktivität 
nach einer 24-stündigen Behandlung mit TsA stark induziert wurde, 35-fach für das 
Promotorkonstrukt N10 ( -778 bp bis +53 bp in Bezug auf den Haupttranskriptionsstart der 
5-LO) in 5-LO-negativen HeLa-Zellen, 6-fach in 5-LO-exprimierenden MM6-Zellen. Auch 
die 5´-Promotordeletionsvarianten N11, N12 und N13 zeigen eine erhöhte Promotoraktivität 
im Reportergenassay nach TsA-Behandlung. Erst das Minimalkonstrukt N14 (-31  bp bis 
+53  bp in Relation zum Transkriptionsstart) reagiert nicht mehr auf eine Hemmung der 
Histondeacetylierung. Im Unterschied zum Reportergenplasmid N14, enthält N13 (-78 bp bis 
53 bp) eine weitere Sp1-Bindungsstelle, die GC-Box 4 (-53 bp bis –48 bp in Relation zum 
Transkriptionsstart). 
In-vitro wurde die Bindung des Transkriptionsfaktors Sp1 an dieses Element bereits in 
EMSAs und DNase  I-Footprints gezeigt. Die Mutation der Bindungsstelle im 
Promotorkonstrukt N13 führt sowohl zum Verlust der basalen Promoteraktivität als auch der 
TsA-Induzierbarkeit sowohl in 5-LO-negativen HeLa-Zellen als auch in 5-LO-positiven 
MM6-Zellen. Eine Mutationsanalyse in einem größeren Promotorkontext verdeutlicht sowohl 
bei der Regulation der basalen als auch der TsA-induzierten Aktivität das Zusammenspiel 
bzw. den additiven Effekt der einzelnen Sp1-Bindungsstellen im 5-LO-Promotor. Außer der 
GC-Box  4 enthält der 5-LO-Promotor im Bereich –294  bp bis +53  bp weitere acht 
Sp1-Bindungsmotive, darunter eine 5-fach GC-Box. Die additive Mutation/Deletion dieser 
proximalen GC-Boxen GC1, GC2, GC4, GC5 und der 5-fach GC-Box im sonst aktivsten 
Promotorkonstrukt N10 heben die Promotoraktivität völlig auf. Allerdings haben die 
einzelnen Mutationen der Sp1-Bindungsstellen bei intakter 5-fach GC-Box im Konstrukt N10 
deutlich weniger Einfluss auf die basale Promotoraktivität und Induzierbarkeit durch TsA, als 
bei Deletion der 5-fach GC-box in dem Konstrukt GC0, was auf ein Zusammenspiel der 
einzelnen Elemente hindeutet. Trotzdem zeigt gerade die GC-Box  4 auch im größeren 
Promotorkontext einen besonderen Stellenwert sowohl für die basale Aktivität, 
möglicherweise durch die Rekrutierung der basalen Transkriptionsmaschinerie, als auch für 
die TsA-induzierte Hochregulation der 5-LO Promotoraktivität.  
TsA zeigt weder in HeLa- noch in MM6-Zellen einen Einfluss auf die Proteinexpression von 
Sp1 und Sp3. Mittels einem „DNA Affinitäts- und Aufreinigungsassay” (DAPA) wurde die  Zusammenfassung  
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in-vitro Bindung von Sp1 und Sp3 an die verschiedenen proximalen Sp1-Bindungsstellen im 
5-LO Promotor, die 5-fach GC-Box, die GC-Box 4 und GC-Box 5 nachgewiesen. TsA zeigte 
in diesen Versuchen keinen Einfluss auf die Bindungsaffinitäten von Sp1 und Sp3.  
Wenn Sp1 und Sp3 mit den N13-GC-Mutanten im Reportergenassay kotransfiziert wurden, 
zeigte sich nur unter TsA-Behandlung eine Steigerung der 5-LO-Promotoraktivität, besonders 
wenn GC-Box 4 oder GC-Box 5 alleine mutiert waren (jeweils 11,7-fach und 4,5-fach), was 
auf eine Interaktion der beiden Bindungsstellen hindeutet. Der unmutierte Minimalpromotor 
in N13 wird durch Sp1 nur 3-fach induziert. Die Sp3-Expression zeigte keine nennenswerten 
Effekte, führte aber auch zu keiner Erniedrigung der Sp1-induzierten Promotoraktivität durch 
eine mögliche Kompetition, wenn beide Expressionsplasmide kombiniert wurden.  
Schließlich wurde die in-vivo Bindung von Sp1 und Sp3 in Chromatin-
Immunopräzipitationsstudien in Abhängigkeit von TsA untersucht. TsA induzierte deutlich 
die Sp1- und die Sp3-Bindung in den untersuchten MM6-Zellen, besonders im proximalen 
Promotorbereich von –318  bp bis +52  bp, der alle proximalen GC-Boxen und den 
Transkriptionsstart umfasst. Neben einer Zunahme der Sp1 und Sp3- Bindung induziert TsA 
auch die Rekrutierung der RNA-Polymerase  II, auffälligerweise auch in den distalen 
Promoterarealen, die sich im Reportergenassay als negativ regulierte Bereiche erwiesen haben 
(-1049 bp  bis  –292 bp).  Interessanterweise  zeigt TsA keinen Einfluss auf den 
Histonacetylierungsgrad des 5-LO-Promotors. Selbst in unbehandelten MM6-Zellen zeigt sich 
bereits eine prägnante Acetylierung von Histon H4. 
Es ist daher anzunehmen, dass in dieser Zelllinie die Chromatinstruktur auch ohne 
TsA-Behandlung weitgehend offen und daher leicht zugänglich für Transkriptionsfaktoren 
und die RNA-Polymerase  II ist. Im Reportergenassay aktivieren Sp1 und Sp3 den 
5-LO-Promotor, allerdings nur nach einer TsA-Behandlung der transfizierten Zellen. Da im 
ChIP-Versuch die Sp1/Sp3-Bindung unter TsA zunimmt, liegt die Vermutung nahe, dass TsA 
die Promoter-Aktivität durch eine Verbesserung der Sp1/Sp3-Bindung induziert.  
Da Veränderungen der Chromatinstruktur, zumindest bzgl. der Histonacetylierung, nicht der 
Grund für eine verstärkte Sp1/Sp3-Bindung zu sein scheinen, nahmen wir mögliche 
posttranslationale Veränderungen von Sp1 und/oder Sp3, wie z. B. eine Acetylierung an, die 
in einigen Fällen die DNA-Affinität oder die Transaktivierung dieser Transkriptionsfaktoren 
erhöht. Leider konnte diese Annahme nicht bestätigt werden. Im DAPA ließ sich keine 
Bindung von acetyliertem Sp1 oder Sp3 nachweisen. Mit Hilfe der Immunpräzipitation 
konnte zwar eine Acetylierung von beiden Transkriptionsfaktoren gezeigt werden, aber keine 
Zunahme von acetyliertem Sp1 oder Sp3 nach TsA-Behandlung der Zellen.   Zusammenfassung  
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Die TsA-vermittelte Induktion der 5-LO-Promotoraktivität und Genexpression deutet auf eine 
Rekrutierung von Histondeacetylasen hin. Die Daten der Mutationsanalyse im 
Reportergenassay zeigen, dass TsA seinen Effekt vorwiegend über die GC-Box 4 ausübt. 
Mittels DAPA sollte festgestellt werden, welche Histondeacetylase über diese 
Sp1-Bindungsstelle rekrutiert wird. Außerdem wurde eine mögliche Bindung an die 5-fach 
GC-Box und an GC-Box 5 untersucht. Sp1 und Sp3 binden an alle drei proximalen 
GC-Boxen etwa gleich stark, unabhängig von einer TsA-Behandlung. Leider konnte keine 
spezifische Rekrutierung von Klasse  I-HDACs (HDAC1, 2, 3 und 8) gezeigt werden. 
HDAC1, 3 und 8 ließen sich nicht nachweisen und HDAC2 assoziert mit allen Proben, auch 
der Negativkontrolle ohne DNA-Sonde. Auch die Detektion der Histonacetyltransferasen 
p300 und PCAF scheiterte in diesen Versuchen. Leider zeigte auch die Kotransfektion von 
HDAC1, 2, 3 und 8 nicht die erwartete Abnahme der 5-LO-Promotoraktivität im 
Reportergenassay unabhängig von einer TsA-Behandlung sowie einer Sp1-Kotransfektion.  
Aus den bisherigen Daten lässt sich zusammenfassend sagen, dass die TsA-vermittelte 
Erhöhung der 5-LO-mRNA Menge sowie die gesteigerte Promotoraktivität in MM6-Zellen 
wohl durch eine verbesserte in-vivo Bindung des Transkriptionsfaktors Sp1, sowie eine 
vermehrte Rekrutierung der RNA Polymerase II vermittelt wird. Leider konnte bisher nicht 
direkt nachgewiesen werden, ob und welche Histondeacetylasen oder auch 
Histoneacetyltransferasen vom 5-LO-Promotor rekrutiert werden.  
Im zweiten Teil der Arbeit sollten Promotorsequenzen im 5-LO-Promotor ausfindig gemacht 
werden, die eine Rolle in der Regulation der 5-LO-Transkription durch DNA-Methylierung 
spielen. Die mögliche Rekrutierung von Methyl-CpG-bindenden Proteinen, sowie der 
Einfluss der DNA-Methylierung auf die Sp1-Bindung sollten näher beleuchtet werden. 
In Reportergenstudien wurde zunächst der Effekt einer in-vitro Methylierung auf die 
Promotoraktivität verschiedener 5-LO-Reportergenplasmide untersucht. Dabei zeigte sich, 
dass eine Methylierung aller CpG-Stellen des hochaktiven Reportergenkonstruktes N10 zu 
einer totalen Aufhebung der Promotoraktivität führt (51-fache Reduktion der 
Promotoraktivität). Auch eine partielle Methylierung des Promotors durch Methylasen mit 
spezifischerem Erkennungsmotiv senkt die Promotoraktivität signifikant (12-fach bzw. 
5-fach). Die Reduktion der Promotoraktivität korreliert mit der Anzahl der methylierten 
CpG-Stellen, wie sich auch bei einer Methylierung der Deletionsvarianten N11, N12 und N13 
zeigt.  
Die Reportergenassays zeigten auch eine verstärkte Rekrutierung von HDAC-Aktivität 
zumindest bei partieller Methylierung des Promotors und einen totalen Verlust an  Zusammenfassung  
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Induzierbarkeit durch den Histonedeacetylase-Inhibitor TsA bei Methylierung aller 
CpG-Dinukleotide. Da DNA-Methylierung und Histondeacetylierung in der Regel Hand in 
Hand gehen, ist eine verstärkte Rekrutierung von HDACs wahrscheinlich. Nach vollständiger 
Methylierung des Promotors kann TsA durch eine Änderung des Histonacetylierungsgrades 
aber anscheinend die Promotoraktivität nicht mehr induzieren. 
In EMSAs wurde der Einfluss der DNA-Methylierung auf die Sp1-Bindung untersucht. Die 
Ergebnisse deuten auf verschiedene Funktionen der drei proximalen Bindungsstellen im 
Zusammenhang mit einer DNA-Methylierung. Während die Sp1-Bindung an die 5-fach 
GC-Box und GC-Box 4 infolge der DNA-Methylierung abnimmt, stimuliert die Methylierung 
benachbarter CpG-Stellen die Bindung von Sp1 an GC-Box 5. Interessanterweise verhindert 
die DNA-Methylierung nicht nur die Sp1-Bindung an GC4 und die Tandem-GC-Box, sondern 
fördert deutlich die Proteinbindung eines bisher unidentifizierten Proteins. Die 
Kotransfektionsstudie mit in-vitro methylierten 5-LO-Promotorkonstrukten und den murinen 
Methyl-CpG-Bindungsproteinen weist auf eine Rekrutierung von MBD1 hin. Allerdings 
konnte in Mutationsstudien keine direkte Bindungsstelle für MBD1 ausgemacht werden und 
die durch die Mbd1-Kotransfektion vermittelte Reduktion der Promoteraktivität nicht 
aufgehoben werden. Durch Supershiftexperimente im EMSA und ChIP-Versuche sollte die 
mögliche MBD1-Bindung nachgeprüft werden.  
Da in den EMSAs die Sp1-Bindung durch DNA-Methylierung verhindert wird, zumindest an 
die aktivierenden Elemente, die 5-fach-GC-Box und die GC-Box-4, und eine Mutation bzw. 
Deletion der gleichen Sp1-Bindungsstellen im Reportergenassay zu einem Verlust der 
Promotoraktivität führt, ist es wahrscheinlich, dass die in-vitro Methylierung schon durch die 
verhinderte Sp1/Sp3-Bindung zu einer Senkung der Promotoraktivität führt. Es wäre von 
Interesse in der Zukunft die in-vivo-Bindung von Sp1/Sp3 am methylierten 5-LO-Promotor 
zu untersuchen.  
Zusammenfassend unterstreichen die Daten, wie wichtig und komplex die Sp1/Sp3-Bindung 
an die verschiedenen GC-reichen Sequenzen des 5-LO Promotors ist, sowohl in Bezug auf die 
Regulation durch den Histondeacetylase-Hemmer TsA, als auch in Bezug auf die Regulation 
durch DNA-Methylierung. 
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8  Abbreviations 
14-3-3   14-3-3 protein recognition site 
1,25(OH)2D3  1,25-dihydroxyvitamin D3 (calcitriol/1,25-dihydroxycholecalciferol) 
AA   arachidonic  acid 
aa   amino  acid 
AD   activation  domain 
AdC   5-aza-2`-deoxycytidine 
AIA   aspirin-induced  asthma 
ALXR   lipoxin A4 receptor 
AP-1/2   activating  protein-1/2 
AR   androgen receptor 
ATA   aspirin-tolerant  asthma 
ATF   activating  transcription factor, also CREB 
ATG    translational start codon 
ATL   aspirin-triggered  lipoxins 
ATP   adenosine  triphosphate 
B   beads 
bp   base  pair(s) 
BCL6   B-cell CLL/lymphoma 6 zinc finger protein 
BLT   leukotriene  B4 receptor 
BTB    broad complex, tramtrack and bric-a-bric domain, also POZ domain 
BxPC-3  pancreatic carcinoma cell line 
Caco-2  human Caucasian colon adenocarcinoma cells 
CAT   chloramphenicol  acetyl transferase assay 
CBP    CREB binding protein 
cDNA   copy DNA 
cds    coding sequence  
ChIP    chromatin immunoprecipitation assay 
CK2    casein kinase 2 
CLP   coactosin-like  protein 
CMV   cytomegalie  virus 
COX   cyclooxygenase 
COUP-TFII  chicken ovalbumin upstream promoter transcription factor-II 
cPLA2  cytosolic  phospholipase  A2 
CREB   cAMP regulatory element-binding protein/cAMP-regulated enhancer 
binding protein 
CRSP   cofactors required for Sp1 activation 
CtBP    C-terminal binding protein 
CTCF   CCCTC-binding factor, zinc finger protein 
Cys   cysteine 
CysLT    cysteinyl leukotriene  
DAPA   DNA affinity purification assay 
DBD   DNA-binding  domain 
DMSO dimethylsulfoxide 
DNA   desoxyribonucleic  acid 
DNase I desoxyribonuclease  I 
DNMT DNA  methyltransferase 
DRIP    vitamin D receptor interacting proteins 
DTT   dithiothreitol   
EGFR   epidermal growth factor receptor  Abbrevations  
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Egr1   early-growth response factor-1 
EKLF   erythroid Kruppel-like factor 
EMSA   electrophoretic mobility shift assays 
ER   estrogen  receptor 
ER   endoplasmic  reticulum 
ERK    extracellular signal-regulated kinase 
FCS   fetal calf serum 
FEV    forced expiratory volume 
FLAP   5-lipoxygenase activating protein 
GATA   transcription factor binding to (A/T)GATA(A/G) 
GCN5   histone acetyltransferase, general control of amino-acid synthesis 5 
GM-CSF  granulocyte macrophage colony stimulating factor 
GPCR   G protein coupled receptor 
GPx   glutathione  peroxidase 
GR   glucocorticoid  receptor 
Grb-2   growth factor receptor-bound protein 2 
GRIP-1 glucocorticoid  receptor-interacting protein-1 
GSH   glutathione 
GST   glutathione  S-transferase 
H   histone 
H3K9   histone 3 lysine 9 
HAT   histone acetyl transferase 
HCT116  human colon carcinoma cell line 
HDAC   histone  deacetylase 
HDACi HDAC  inhibitor 
HeLa cells  epithelial cells derived from a cervix carcinoma 
HepG2  human hepatoma cell line 
Hep3B    human hepatoma cell line 
His   histidine 
HL-60 cells  human promyeloic leukemic cell line 
HL-60TB  HL-60 cells negative for 5-LO 
hLHR   human lueinizing hormone receptor 
HMT   histone  methyltransferase 
HNF-4    hepatocyte nuclear factor 4 
HP1    heterochromatin-associated protein 1 
H(P)ETE hydro(peroxy)eicosatetraenoic  acid 
HpODE hydroperoxyoctadecaenoic  acid 
Hsp    heat shock protein 
HTERT  human telomerase reverse transcriptase 
HUB    HDAC6-, USP3-, BRAP2-related finger 
HUVEC  human umbilical vein endothelial cells 
IC50    half maximal inhibitory concentration 
ID   inhibitory  domain 
IGFBP3 Insulin-like  growth  factor binding protein-3 
IL   interleukin 
Ile   isoleucine 
InvRep  inverted repeat 
JNK   c-jun NH2-terminal kinase 
K   lysine 
kb   kilobase 
kDa   kilo  Dalton  Abbrevations  
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KLF    Kruppel like factor 
KO   knock out 
L   leucine 
LBD    ligand binding domain 
LDL   low-density  binding  protein 
LO   lipoxygenase 
LRD   ligand  recognition  domain 
LT(R)   leukotriene (receptor) 
LTA4H leukotriene  A4 hydrolase 
LTC4S leukotriene  C4 synthase 
LX(R)   lipoxin (receptor) 
Lys   lysine 
MAPK  mitogen-activated protein kinase 
MBD(P)  methyl-cytosine-binding domain (protein) 
MCAF  MBD1-containing chromatin-associated factor 
MCF-7  human mammary gland epithelial cells 
mcs   multiple  cloning  site 
MeCP   methyl-CpG-binding protein 
MEF2   myocyte enhancer factor-2 
MEK   MAPK  kinase 
MG63   human osteoblast-like cell line 
Mi2    SWI2/SNF2 type helicase 
MIA PaCa-2 pancreatic carcinoma cell line 
MIZF   MBD2-interacting zinc finger  
MM6 cells  Mono Mac 6 cells 
mRNA messenger  RNA 
NA   nicotinamide 
NCoR   nuclear receptor corepressor 
NE   nuclear  extract 
NES    nuclear export signal 
NF-1    nuclear factor 1 
NFAT   nuclear factor of activated T-cells 
NF-Y    nuclear factor Y or CCAAT-binding protien 
NFκB   nuclear factor of κ-light polypeptide gene enhancer in B cells 
NIH3T3  mouse fibroblast cell line 
NLS    nuclear localization sequence 
NO   nitric oxide 
NR   nuclear  receptor 
NSAID  non-steroidal anti-inflammatory drug 
NuRD   nucleosome remodeling histone deacetylase complex 
Oct-1    octamer binding transcription factor 
oxoETE oxoeicosatetraenoic  acid 
PAF   platelet-activating  factor 
PBS    phosphate buffered saline 
PC   phosphatidylcholine 
PCAF   p300/CBP-associated factor 
PCNA   proliferating cell nuclear antigen 
PCR    polymerase chain reaction 
PG   prostaglandin 
PI 3-K   phosphatidylinositol 3-kinase 
PK   protein kinase   Abbrevations  
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PL   phospholipase 
PLAT   Polycystin-1, Lipoxygenase, α-Toxin 
PMA   phorbol-12-myristate-13-acetate 
PML   promyelocytic  leukemia 
PMT   posttranslational  histone  modification 
PMNL   polymorphonuclear  leukocyte 
PMSF   phenylmethansulfonylfluoride 
POZ    poxvirus and zinc finger domain, also BTB domain 
PPAR   peroxisome proliferator activated receptor 
PR   progesterone  receptor 
pre-mRNA precursor-mRNA 
RA   retinoic acid 
RAR    retinoic acid receptor 
Rb   retinoblastoma  protein 
RBCE   retinoblastoma control element 
RE   response  element 
REST   repressor element 1 silencing transcription factor 
RLU   relative  light  unit 
RNA   ribonucleic  acid 
RNAi   RNA  interference 
ROR    retinoid orphan receptor 
ROS    reactive oxygen species 
RT-PCR reverse  transcription-polymerase chain reaction 
RXRα   retinoid X receptor alpha 
RZR    retinoid Z receptor 
S   serine 
SAH   S-adenosylhomocysteine 
SAM   S-adenosylmethionine 
SBE    Smad binding element 
SE   standard  error 
SE14   Ser-Glu-containing  tetradecapeptide  repeat 
SEAP   secreted alkaline phosphatase 
Ser   serine 
SF-1   steroidgenic  factor-1 
SH3   src-homology 
Sin3   SWI  independent 
SIR    silent information regulator 
siRNA   small interfering RNA 
Ski   Sloan-Kettering  Institute oncoprotein 
SKIP   Ski-interacting protein 
SL2    macrophage-like drosophila melanogaster cells 
Smad    Sma and Mad related protein 
SMRT   silencing mediator for retinoic acid and thyroid hormone receptors 
SMURF Smad  ubiquitylation  regulatory factor 
SNF   sucrose  non-fermenter 
SNRNP  small nuclear ribonucleoprotein polypetide N 
Sp1   serum  protein1/specific  protein1/selective promoter factor1 
sPLA2  secretory  phospholipase  A2 
SRC-1   steroid receptor coactivator-1 
STAT   signal transducers and activators of transcription 
STI    soybean trypsin inhibitor  Abbrevations  
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SUMO  sumoylation signal 
SV-40   simian virus-40 
SW620  human colon carcinoma cell line 
SWI    mating type switch 
TAFII   TATA-binding protein associated factor II 
TBP   TATA-binding  protein 
TF   transcription  factor 
TFIIB   transcription factor IIB 
TGFβ   transforming growth factor beta 
TGFβR TGFβ receptor 
TNFα   tumor necrosis factor alpha 
TGFβRE TGFβ responsive element 
TIS    transcription initiation site 
TRD    transcriptional repression domain 
Trp   tryptophane 
TsA   Trichostatin  A 
TSS    translation start site 
U937 cells  human lymphoma cell line 
UK Pan-1  pancreatic adenocarcinoma cell line 
UTR   untranslated  region 
VDR    vitamin D receptor 
VDRE   vitamin D response element 
VPA   valproic  acid 
w/o   without 
YY1   Yin-Yan-1 
ZBZB   zinc finger and BTB containing factor 
ZE   cell  extract 
ZF   zinc  finger 
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